BioMedLib Search Engine
[ goto HOMEPAGE ]
Save time; Find better answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
acute biphenotypic leukemia morphologic abnormality 2005:2010[pubdate] *count=100
134 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
acute biphenotypic leukemia morphologic abnormality
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 134
1.
Bosch FJ, Badenhorst L, Le Roux JA, Louw VJ:
Successful treatment of Chromobacterium violaceum sepsis in South Africa.
J Med Microbiol
; 2008 Oct;57(Pt 10):1293-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
As far as could be ascertained, this infection has never been reported in a patient with
leukaemia
.
We describe what we believe to be the first such case of C. violaceum sepsis, in a 16-year-old female patient with
acute biphenotypic
leukaemia
, which developed during the neutropenic phase after intensive chemotherapy.
[MeSH-minor]
Adolescent. Antifungal Agents / pharmacology. Candidiasis / complications. Candidiasis / drug therapy. Female. Humans.
Leukemia
/ complications. Neutropenia / complications. South Africa / epidemiology. Treatment Outcome
MedlinePlus Health Information.
consumer health - Antibiotics
.
MedlinePlus Health Information.
consumer health - Sepsis
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18809561.001).
[ISSN]
0022-2615
[Journal-full-title]
Journal of medical microbiology
[ISO-abbreviation]
J. Med. Microbiol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Anti-Bacterial Agents; 0 / Antifungal Agents
2.
Fujiwara S, Yamashita Y, Choi YL, Watanabe H, Kurashina K, Soda M, Enomoto M, Hatanaka H, Takada S, Ozawa K, Mano H:
Transforming activity of purinergic receptor P2Y, G protein coupled, 8 revealed by retroviral expression screening.
Leuk Lymphoma
; 2007 May;48(5):978-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Biphenotypic acute leukemia
(BAL) is a relatively rare subtype of
acute leukemia
characterized by the presence of both
myeloid and lymphoid cell
surface antigens.
A variety of luciferase-based reporter assays revealed that P2RY8 increased both the trans-activation activities of CREB and Elk-1 as well as the transcriptional activities of the serum response element and enhancer-promoter fragments of the c-Fos
and c
-Myc genes.
Quantitation of P2RY8 mRNA in CD34(+) cells of bone marrow showed that P2RY8 expression is frequently increased in
leukemia
patients, especially in those with refractory
disease
.
Our data thus reveal an abundant expression of P2RY8 in leukemic cells and its unexpected role in the pathogenesis of
acute leukemia
.
[MeSH-major]
Gene Expression Regulation, Leukemic.
Leukemia
/ genetics.
Leukemia
/ metabolism. Receptors, Purinergic / physiology. Receptors, Purinergic P2 / metabolism. Receptors, Purinergic P2Y / metabolism. Receptors, Purinergic P2Y / physiology. Retroviridae / metabolism
[MeSH-minor]
3T3 Cells. Animals. Antigens, CD34 / biosynthesis. Bone Marrow Cells / metabolism.
Cell
Line, Tumor. DNA, Complementary / genetics. Gene Library. Humans. Mice. Mice, Nude. Transcription, Genetic
MedlinePlus Health Information.
consumer health - Leukemia
.
Guide to Pharmacology.
gene/protein/disease-specific - P2RY8 - data and references
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17487742.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD34; 0 / DNA, Complementary; 0 / P2RY8 protein, human; 0 / P2RY9 receptor, human; 0 / P2RY9 receptor, mouse; 0 / Receptors, Purinergic; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2Y
3.
Amakawa R, Hiramoto N, Kawano S, Hyo A, Nakamichi N, Tajima K, Ito T, Mori S, Kishimoto Y, Fukuhara S:
Dic (17;20) (p11;q11) preceded MLL gene amplification in a patient with de novo mixed-lineage leukemia.
J Clin Exp Hematop
; 2010;50(1):51-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dic (17;20) (p11;q11) preceded MLL gene amplification in a patient with
de
novo
mixed
-
lineage
leukemia
.
We report a case of
acute
mixed
-
lineage
leukemia
, as seen in a 65 year-old female with MLL gene amplification and biallelic loss of wild type p53 gene.
The
diagnosis
was based on the findings that her bone marrow (BM) blasts expressed cytoplasmic CD3 (cyCD3), B-
lineage
antigens
and myeloid
antigens accompanied by clonal rearrangements of IgH gene.
Add (11q23)
abnormality
was found in sideline karyotypes as well as the stemline
abnormality
of dic(17;20) (p11;q11).
[MeSH-major]
Gene Amplification.
Leukemia
,
Biphenotypic
,
Acute
/ genetics. Translocation, Genetic
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20505276.001).
[ISSN]
1880-9952
[Journal-full-title]
Journal of clinical and experimental hematopathology : JCEH
[ISO-abbreviation]
J Clin Exp Hematop
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
Advertisement
4.
Nakagawa Y, Hasegawa M, Kurata M, Yamamoto K, Abe S, Inoue M, Takemura T, Hirokawa K, Suzuki K, Kitagawa M:
Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL).
Am J Hematol
; 2005 Mar;78(3):173-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of IAP-family proteins in adult
acute
mixed lineage
leukemia
(AMLL).
To determine the apoptosis-resistant mechanism in adult
acute
mixed lineage
leukemia
(AMLL) with
biphenotypic
blasts responsible for resistance against chemotherapy, the expression levels of IAP-family proteins in AMLL bone marrow cells were analyzed by quantitative RT-PCR.
These findings suggest that higher expression of various IAPs is associated with the chemotherapy-resistant nature of this specific type of
leukemia
.
[MeSH-major]
Apoptosis. Biomarkers, Tumor / metabolism. Bone Marrow Cells / metabolism.
Leukemia
,
Biphenotypic
,
Acute
/ metabolism. Proteins / metabolism
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Flow Cytometry. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Inhibitor of Apoptosis Proteins.
Leukemia
, Monocytic,
Acute
/ drug therapy.
Leukemia
, Monocytic,
Acute
/ metabolism.
Leukemia
, Monocytic,
Acute
/ pathology. Male. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Proteins. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / drug therapy. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / metabolism. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / pathology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15726601.001).
[ISSN]
0361-8609
[Journal-full-title]
American journal of hematology
[ISO-abbreviation]
Am. J. Hematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proteins; 0 / RNA, Messenger
5.
Pérez-Campos-Mayoral L, Ruiz-Argüelles A, Pérez-Romano B, Zenteno E, Hernández-Cruz P, Martínez-Cruz R, Martínez-Cruz M, Pina-Canseco S, Pérez-Campos E:
Potential use of the Macrobrachium rosenbergii lectin for diagnosis of T-cell acute lymphoblastic leukemia.
Tohoku J Exp Med
; 2008 Jan;214(1):11-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Potential use of the Macrobrachium rosenbergii lectin for
diagnosis
of T-
cell
acute
lymphoblastic
leukemia
.
T-
cell
acute
lymphoblastic
leukemia
is the most common form of cancer in children.
Lectins are proteins or glycoproteins from plants or animals that recognize oligossacharides on the
cell
surface and have been used to characterize the structural changes of oligosaccharides in
leukemias
.
In this study, we used the lectin from the freshwater prawn Macrobrachium (M. rosenbergii), specific for acetyl groups in sialylated glycans, because increased sialylation of glycoproteins and glycolipids has been identified in
lymphoblastic leukemias
.
We compared the specificity of the M. rosenbergii lectin for
lymphoblastic leukemias
with the specificities of the lectins from Triticum vulgaris, Solanum tuberosum, Arachis hipogaea, and Phytolacca americana.
By
morphologic
and phenotype characterization with a panel of monoclonal antibodies, we identified four types of
leukemias
from 106
leukemia
patients: 11 cases of T-
cell
acute
lymphoblastic
leukemia
, 61 cases of B-
cell
acute
lymphoblastic
leukemia
, 24 cases of
acute
myeloblastic
leukemia
, and 10 cases of
acute biphenotypic leukemia
.
As determined by cytofluorometric assays, nine of the eleven cases with T-
cell
acute
lymphoblastic
leukemia
(8 +/- 3 years old) were specifically identified with the lectin from M. rosenbergii.
In contrast, only six cases of B-
cell
leukemia
, one case of myeloblastic
leukemia
, and 2 cases of
biphenotypic leukemia
were identified with this M. rosenbergii lectin.
The other lectins tested showed no capacity to differentiate, in a significant manner, any of the four types of
leukemias
tested.
Thus, the lectin from M. rosenbergii could be considered a useful tool for the
diagnosis and
study of T-
cell
acute
lymphoblastic
leukemia
.
[MeSH-major]
Lectins.
Leukemia
,
Biphenotypic
,
Acute
/
diagnosis
. Palaemonidae / chemistry
[MeSH-minor]
Animals. Antibodies, Monoclonal. Antigens, CD45 / analysis. Antigens, Neoplasm / immunology. Child.
Diagnosis
, Differential. Flow Cytometry. Humans. Lymphocytes / drug effects. Lymphocytes / metabolism. Phenotype
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18212483.001).
[ISSN]
0040-8727
[Journal-full-title]
The Tohoku journal of experimental medicine
[ISO-abbreviation]
Tohoku J. Exp. Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Lectins; EC 3.1.3.48 / Antigens, CD45
6.
Haouas H, Haouas S, Uzan G, Hafsia A:
Identification of new markers discriminating between myeloid and lymphoid acute leukemia.
Hematology
; 2010 Aug;15(4):193-203
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of new markers discriminating between
myeloid and lymphoid
acute leukemia
.
BACKGROUND: The heterogeneity of
acute
myeloid
leukemia
(AML) with respect to biology and clinical course resides in the fact that patients belonging to the same group show marked differences in their response to chemotherapy, necessitating a refinement of AML classification.
RESULTS: We have shown that two downregulated genes in AML, those encoding guanine nucleotide-binding protein gamma11 (GNG11) and amphiregulin (AREG), are also downregulated in B-
lineage
acute
lymphoblastic
leukemia
(B-ALL)
and T
-
lineage
acute
lymphoblastic
leukemia
(T-ALL) patients.
A second gene, that encoding ceruloplasmin (CP), is upregulated in AML but not in B-ALL
and T
-ALL.
Our study is the first to analyze these genes in AML, B-ALL, T-ALL and chronic
leukemia
(
myeloid and lymphoid
) patients by RT-PCR.
This rapid and sensitive method could be used to screen these genes in different types of
leukemia
.
[MeSH-major]
Biomarkers, Tumor / metabolism. Gene Expression Regulation, Leukemic.
Leukemia
,
Myeloid
,
Acute
/
diagnosis
.
Leukemia
,
Myeloid
,
Acute
/ genetics. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma /
diagnosis
. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics
[MeSH-minor]
Adolescent. Adult. Aged. Amphiregulin.
Cell
Line, Tumor. Ceruloplasmin / genetics. Ceruloplasmin / metabolism.
Diagnosis
, Differential. EGF Family of Proteins. Female. GTP-Binding Protein alpha Subunits, Gq-G11 / genetics. GTP-Binding Protein alpha Subunits, Gq-G11 / metabolism. Gene Expression Profiling. Glycoproteins / genetics. Glycoproteins / metabolism. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Precursor B-
Cell Lymphoblastic
Leukemia
-Lymphoma / blood. Precursor B-
Cell Lymphoblastic
Leukemia
-Lymphoma /
diagnosis
. Precursor B-
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics. Precursor T-
Cell Lymphoblastic
Leukemia
-Lymphoma / blood. Precursor T-
Cell Lymphoblastic
Leukemia
-Lymphoma /
diagnosis
. Precursor T-
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20670477.001).
[ISSN]
1607-8454
[Journal-full-title]
Hematology (Amsterdam, Netherlands)
[ISO-abbreviation]
Hematology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / AREG protein, human; 0 / Amphiregulin; 0 / Biomarkers, Tumor; 0 / EGF Family of Proteins; 0 / Glycoproteins; 0 / Intercellular Signaling Peptides and Proteins; EC 1.16.3.1 / Ceruloplasmin; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gq-G11
7.
Davis CC, Marti LC, Sempowski GD, Jeyaraj DA, Szabolcs P:
Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.
Cancer Res
; 2010 Jul 1;70(13):5249-58
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Donor leukocyte infusions (DLI) in the allogeneic hematopoietic transplant setting can provide a clinically relevant boost of immunity to reduce opportunistic infections and to increase graft-versus-
leukemia
activity.
However, significant apoptosis occurs in proliferating T cells, diminishing the yield and skewing the CD4/CD8 ratio in the T-
cell
population, jeopardizing the potential efficacy of DLI.
Recognizing that infused T lymphocytes will need to meet microbial antigens in secondary
lymphoid
organs to generate effectors, we also show that expansion with IL-7 promotes the preservation of a polyclonal broad T-
cell
receptor repertoire
and a
surface phenotype that favors lymph node homing.
Expanded lymphocytes lack alloreactivity against recipient and other allogeneic cells, indicating a favorable safety profile from graft-versus-host
disease
.
Nevertheless, expanded T cells can be primed subsequently against
lymphoid and myeloid
leukemia
cells to generate tumor-specific cytotoxic T cells.
Genetic Alliance.
consumer health - Transplantation
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 AACR.
[Cites]
Bone Marrow Transplant. 1999 Dec;24(11):1229-33
[
10642813.001
]
[Cites]
Blood. 2009 Mar 26;113(13):2999-3007
[
19008454.001
]
[Cites]
Blood. 2001 Mar 1;97(5):1491-7
[
11222398.001
]
[Cites]
Nat Immunol. 2000 Nov;1(5):426-32
[
11062503.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8732-7
[
11447288.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9277-82
[
11470908.001
]
[Cites]
Biol Blood Marrow Transplant. 2001;7(8):454-66
[
11569891.001
]
[Cites]
Blood. 2001 Oct 1;98(7):2256-65
[
11568014.001
]
[Cites]
Scand J Immunol. 2001 Nov;54(5):501-5
[
11696202.001
]
[Cites]
Nat Med. 2002 Jan;8(1):47-53
[
11786906.001
]
[Cites]
Blood. 2002 Oct 1;100(7):2642-9
[
12239180.001
]
[Cites]
Stem Cells. 2003;21(3):296-303
[
12743324.001
]
[Cites]
J Immunol. 2003 Jul 1;171(1):61-8
[
12816983.001
]
[Cites]
Exp Hematol. 2003 Aug;31(8):708-14
[
12901976.001
]
[Cites]
Blood. 2003 Sep 15;102(6):2004-13
[
12763934.001
]
[Cites]
J Clin Invest. 2003 Oct;112(7):1095-107
[
14523046.001
]
[Cites]
J Virol. 2004 Sep;78(18):9740-9
[
15331707.001
]
[Cites]
Biol Blood Marrow Transplant. 2004 Nov;10(11):772-83
[
15505608.001
]
[Cites]
Immunol Today. 1990 Jun;11(6):211-6
[
2162180.001
]
[Cites]
Bone Marrow Transplant. 1994 Oct;14(4):545-53
[
7858529.001
]
[Cites]
Eur J Immunol. 1997 Mar;27(3):633-40
[
9079802.001
]
[Cites]
Immunol Lett. 1997 Oct;59(1):21-8
[
9334853.001
]
[Cites]
Blood. 1998 Jul 1;92(1):11-8
[
9639493.001
]
[Cites]
J Immunol. 1998 Dec 1;161(11):5909-17
[
9834071.001
]
[Cites]
Am J Reprod Immunol. 1998 Nov;40(5):319-25
[
9870074.001
]
[Cites]
Bone Marrow Transplant. 1999 Apr;23(8):783-8
[
10231140.001
]
[Cites]
Immunology. 1999 Jan;96(1):35-47
[
10233676.001
]
[Cites]
Nat Rev Immunol. 2004 Nov;4(11):856-67
[
15516965.001
]
[Cites]
Clin Immunol. 2005 Jan;114(1):30-41
[
15596407.001
]
[Cites]
Immunology. 2005 Mar;114(3):322-35
[
15720434.001
]
[Cites]
Clin Exp Immunol. 2005 Jul;141(1):10-8
[
15958064.001
]
[Cites]
Bioinformatics. 2005 Aug 15;21(16):3394-400
[
15955781.001
]
[Cites]
Blood. 2006 Feb 15;107(4):1325-31
[
16269610.001
]
[Cites]
Cytotherapy. 2006;8(2):149-57
[
16698688.001
]
[Cites]
J Immunother. 2006 May-Jun;29(3):313-9
[
16699374.001
]
[Cites]
Immunol Rev. 2006 Jun;211:154-63
[
16824125.001
]
[Cites]
Biol Blood Marrow Transplant. 2006 Sep;12(9):919-27
[
16920557.001
]
[Cites]
Leuk Lymphoma. 2006 Jul;47(7):1222-8
[
16923550.001
]
[Cites]
Blood. 2006 Sep 1;108(5):1770-3
[
16675712.001
]
[Cites]
Cytotherapy. 2007;9(2):111-22
[
17453963.001
]
[Cites]
Biol Blood Marrow Transplant. 2007 Oct;13(10):1135-44
[
17889349.001
]
[Cites]
Blood. 2007 Oct 15;110(8):2803-10
[
17595335.001
]
[Cites]
Blood. 2007 Dec 15;110(13):4543-51
[
17671230.001
]
[Cites]
Biol Blood Marrow Transplant. 2008 Jan;14(1):16-27
[
18158957.001
]
[Cites]
Bone Marrow Transplant. 2008 Jan;41(2):193-8
[
17982497.001
]
[Cites]
J Exp Med. 2008 Jul 7;205(7):1701-14
[
18573906.001
]
[Cites]
Biol Blood Marrow Transplant. 2008 Oct;14(10):1190-6
[
18804050.001
]
[Cites]
Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):162-8
[
19147099.001
]
[Cites]
Blood. 2000 Aug 1;96(3):885-93
[
10910901.001
]
(PMID = 20530666.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
ENG
[Grant]
United States / NHLBI NIH HHS / HL / R01 HL091749; United States / NHLBI NIH HHS / HL / 7R01HL091749; United States / NCI NIH HHS / CA / R01 CA132110; United States / NIAID NIH HHS / AI / UC6 AI058607; United States / NIAID NIH HHS / AI / P30 AI051445; United States / NHLBI NIH HHS / HL / R01 HL091749-04; United States / NCI NIH HHS / CA / R01-CA132110; United States / NCI NIH HHS / CA / R01 CA132110-03; United States / NCI NIH HHS / CA / CA132110-03; United States / NIAID NIH HHS / AI / UC6 AI58607; United States / NIAID NIH HHS / AI / P30 AI51445
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD137; 0 / Antigens, CD28; 0 / Antigens, CD3; 0 / Interleukin-7; 0 / Receptors, Antigen, T-Cell, alpha-beta; 126465-35-8 / Perforin; 147205-72-9 / CD40 Ligand
[Other-IDs]
NLM/ NIHMS203765; NLM/ PMC2896454
8.
Pagano L, Caira M, Nosari A, Rossi G, Locatelli F, Viale P, Aversa F, Hema E-Chart Group Italy:
Hema e-Chart: Italian Registry for prospective analysis of epidemiology, management and outcome of febrile events in patients with hematological malignancies.
J Chemother
; 2010 Feb;22(1):20-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A systematic approach that starts from the registration of new
diagnosis and
complete follow-up can be of help for the study of treatment and evolution of these complications.
Its aim is to improve the speed, quality and integration of information related to subjects with febrile event, ultimately resulting in improving patients' care.Patients included adults and children with
acute
and chronic
myeloid
or
lymphoid
leukemia
, Hodgkin's and non-Hodgkin's lymphoma, myelodysplastic syndrome, or multiple myeloma.
The registry also included data regarding event onset in hematopoietic stem
cell
transplants (HSCTs).
[MeSH-minor]
Hematopoietic Stem
Cell
Transplantation. Humans. Incidence. Italy. Prospective Studies
MedlinePlus Health Information.
consumer health - Fever
.
MedlinePlus Health Information.
consumer health - Fungal Infections
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20227988.001).
[ISSN]
1973-9478
[Journal-full-title]
Journal of chemotherapy (Florence, Italy)
[ISO-abbreviation]
J Chemother
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Investigator]
Levis A; Leoni P; Liso V; Baccarani M; Cortellazzo S; Rossi G; Russo D; La Nasa G; Storti S; Giustolisi R; Morabito F; Cuneo A; Bosi A; Capalbo SF; Cascavilla N; Ghio R; Carella A; Brugiatelli M; Ciceri F; Martinelli G; Morra E; Pogliani E; Mettivier V; Carli M; Abbadessa V; Musso M; Aricò M; Lazzarino M; Visani G; Fioritoni G; Di Bartolomeo P; Vallisa D; Petrini M; Favre C; Olivieri A; Gugliotta L; Leone G; Amadori S; De Rossi G; De Fabritiis P; Majolino I; D'Arco A; Lauria F; Mazza P; Fagioli F; Gherlinzoni F; Chesesi T; Rodeghiero F
9.
Kiyomizu K, Yagi T, Yoshida H, Minami R, Tanimura A, Karasuno T, Hiraoka A:
Fulminant septicemia of Bacillus cereus resistant to carbapenem in a patient with biphenotypic acute leukemia.
J Infect Chemother
; 2008 Oct;14(5):361-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fulminant septicemia of Bacillus cereus resistant to carbapenem in a patient with
biphenotypic acute leukemia
.
A 33-year-old man was suffering from febrile neutropenia (FN) on day 15 after the start of remission-induction therapy for
biphenotypic acute leukemia
under gut decontamination with polymyxin
B and
nystatin.
If B. cereus resistant to carbapem increases, our method of gut decontamination with polymyxin
B and
nystatin may have to be changed to one containing a new quinolone for the prevention of septicemia.
[MeSH-major]
Bacillus cereus / drug effects. Bacteremia / microbiology. Carbapenems / therapeutic use.
Leukemia
,
Biphenotypic
,
Acute
/ complications
[MeSH-minor]
Adult. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Stem / microbiology. Brain Stem / pathology. Fever / drug therapy. Gram-Positive Bacterial Infections / complications. Gram-Positive Bacterial Infections /
diagnosis
. Gram-Positive Bacterial Infections / drug therapy. Gram-Positive Bacterial Infections / pathology. Humans. Liver / microbiology. Liver / ultrastructure. Lung / microbiology. Lung / ultrastructure. Male. Microbial Sensitivity Tests. Neutropenia / drug therapy. Remission Induction. beta-Lactam Resistance
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18936889.001).
[ISSN]
1341-321X
[Journal-full-title]
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
[ISO-abbreviation]
J. Infect. Chemother.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
0 / Anti-Bacterial Agents; 0 / Carbapenems
10.
Dixon N, Kishnani PS, Zimmerman S:
Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome.
Am J Med Genet C Semin Med Genet
; 2006 Aug 15;142C(3):149-57
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Increased erythrocyte mean corpuscular volume (MCV) is frequently found among DS infants and remains elevated throughout life in two-thirds of patients, making interpretation of red
cell
indices for
diagnosis
of nutritional anemias or bone marrow failure disorders more challenging.
Transient myeloproliferative
disorder
(TMD) associated with pancytopenia, hepatosplenomegaly, and circulating immature WBCs, is found almost exclusively in DS infants with an incidence of approximately 10%.
Despite the high rate of spontaneous regression, TMD can be a preleukemic
disorder
in 20-30% of children with DS.
There is an increased risk of
leukemia
with an equal incidence of
lymphoid and myeloid
leukemia
.
Acute
megakaryocytic
leukemia
(AMKL) subtype is the most common form of
acute
myeloid
leukemia
(AML) in this setting, and is uncommon in children without DS.
Children with DS and
leukemia
are more sensitive to some chemotherapeutic agents such as methotrexate than other children which requires careful monitoring for toxicity.
Although the risk for
leukemia
is higher in individuals with DS, these patients have a lower risk of developing solid tumors, with the exception of germ
cell
tumors, and perhaps retinoblastoma and lymphoma.
[MeSH-major]
Down Syndrome / complications. Hematologic Diseases /
diagnosis
. Hematologic Diseases / etiology. Neoplasms /
diagnosis
. Neoplasms / etiology
[MeSH-minor]
Child. Female. Humans. Infant.
Leukemia
/
diagnosis
.
Leukemia
/ etiology. Male. Myeloproliferative Disorders /
diagnosis
. Myeloproliferative Disorders / etiology
Genetic Alliance.
consumer health - Down Syndrome
.
MedlinePlus Health Information.
consumer health - Blood Disorders
.
MedlinePlus Health Information.
consumer health - Cancer in Children
.
MedlinePlus Health Information.
consumer health - Down Syndrome
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17048354.001).
[ISSN]
1552-4868
[Journal-full-title]
American journal of medical genetics. Part C, Seminars in medical genetics
[ISO-abbreviation]
Am J Med Genet C Semin Med Genet
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 2T32 CA 09307
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Number-of-references]
72
11.
Ning BT, Tang YM, Chen YH, Shen HQ, Qian BQ:
Comparison between CD19 and CD20 expression patterns on acute leukemic cells.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 2005 Dec;13(6):943-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison between CD19 and CD20 expression patterns on
acute
leukemic cells.
In order to provide the evidences for CD19 as a better antibody targeting molecule for
B lineage
acute
leukemias
than CD20 through the multi-parameter flow-cytometry analysis of
leukemia
cells, the samples from 321 patients with
acute leukemia
(AL) were immunophenotyped by multi-color flow cytometry and CD45/SSC gating strategy followed by the analysis of CD19 and CD20 expression.
The results showed that the positive rate of CD19 (115/116, 99.1%) in 116 cases with
B lineage
acute
lymphoblastic
leukemia
(
B lineage
ALL) was significantly higher than that of CD20 (33/116, 28.4%) (P < 0.01); in 17 patients with
B lineage
/
Myeloid
(B/My)
acute
mixed lineage
leukemia
(AMLL), the former positive rate (17/17, 100%) was also higher than the latter (5/17, 29.4%) (P < 0.01).
Both of the two antigens were negative in 29 patients with
acute
T lymphoblastic
leukemia
and 7 patients with T/My AMLL.
The positive rates of CD19 and CD20 in 152 patients with
acute
myeloid
leukemia
(AML) were 7.2% and 2.0%, respectively.
The difference of the fluorescence intensity between the two antigens on the cells from each patient with
B lineage
ALL or B/My AMLL was statistically significant (t = 20.68, P < 0.001).
The specificity of CD19 and CD20 in
B lymphocytic lineage
was 92.3% (132/143) and 92.7% (38/41), respectively, while the sensitivity was 99.2% (132/133) and 28.6% (38/133), respectively, the former sensitivity was significantly higher than the latter (chi(2) = 144.018, P = 0.001).
It is concluded that CD19 continuously and steadily express on almost all subtypes of
B lineage
leukemic cells with homogeneous pattern while only a small number of
leukemias
express CD20.
These indicate that CD19 may be a better antibody targeting molecule than CD20 for patients with B-
lineage
acute leukemia
.
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16403255.001).
[ISSN]
1009-2137
[Journal-full-title]
Zhongguo shi yan xue ye xue za zhi
[ISO-abbreviation]
Zhongguo Shi Yan Xue Ye Xue Za Zhi
[Language]
ENG
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Antigens, CD19; 0 / Antigens, CD20
12.
Wang L, Lin D, Zhang X, Chen S, Wang M, Wang J:
Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients.
Leuk Res
; 2005 Dec;29(12):1393-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese
acute leukemia
patients.
Genomic aberrations of Fms-like tyrosine kinase 3 (FLT3), including internal tandem duplication (ITD) and point mutations, have been demonstrated in 25-30% of adults
acute
myeloid
leukemia
(AML) and are markers of poor prognosis.
FLT3/ITD and D835 mutations were analyzed in 194 Chinese patients with
acute leukemia
and myelodysplastic syndromes (MDS) by polymerase chain reaction (PCR).
However, neither aberrations was found in 25 patients with
acute
lymphoblastic
leukemia
(ALL), 2
acute
hybrid
leukemia
, 17 MDS and 7 chronic
myeloid
leukemia
in blast crisis (CML-BC).
[MeSH-major]
Leukemia
/ genetics. Mutation, Missense. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics
[MeSH-minor]
Acute
Disease
. Adolescent. Adult. Amino Acid Sequence. Asian Continental Ancestry Group / genetics. DNA Mutational Analysis. Female. Humans. Leukocytosis. Male. Middle Aged. Molecular Sequence Data. Myelodysplastic Syndromes / genetics. Prognosis. Remission Induction
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15996732.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
13.
Sárová I, Brezinová J, Zemanová Z, Izáková S, Lizcová L, Malinová E, Berková A, Cermák J, Maaloufová J, Nováková L, Michalová K:
Cytogenetic manifestation of chromosome 11 duplication/amplification in acute myeloid leukemia.
Cancer Genet Cytogenet
; 2010 Jun;199(2):121-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytogenetic manifestation of chromosome 11 duplication/amplification in
acute
myeloid
leukemia
.
Gene amplification is a frequent genetic
abnormality
in solid tumors, and many oncogenes are activated in this way.
In
acute
myeloid
leukemia
(AML), a frequent target of gene amplification is chromosome 11, particularly chromosome region 11q23, including the MLL (
myeloid
/
lymphoid
leukemia
) gene.
[MeSH-major]
Chromosomes, Human, Pair 11 / genetics. Gene Amplification. Gene Duplication.
Leukemia
,
Myeloid
,
Acute
/ genetics. Trisomy
Genetic Alliance.
consumer health - Chromosome 11
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Inc. All rights reserved.
(PMID = 20471515.001).
[ISSN]
1873-4456
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
14.
Schimmer AD:
Induction of apoptosis in lymphoid and myeloid leukemia.
Curr Oncol Rep
; 2006 Nov;8(6):430-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Induction of apoptosis in
lymphoid and myeloid
leukemia
.
Defects in the core machinery of the apoptosis pathway contribute to chemoresistance and poor outcomes in patients with
acute leukemia
.
This review highlights compounds that target the mitochondrial, death receptor, and convergence pathways of caspase activation that are being developed for the treatment of
acute leukemia
.
[MeSH-major]
Apoptosis / physiology.
Leukemia
,
Lymphoid
/ therapy.
Leukemia
,
Myeloid
/ therapy
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Chronic Lymphocytic Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 1998 Mar 20;273(12):6916-20
[
9506996.001
]
[Cites]
J Med Chem. 2003 Sep 25;46(20):4259-64
[
13678404.001
]
[Cites]
Cancer Res. 2003 Nov 15;63(22):7724-32
[
14633697.001
]
[Cites]
J Med Chem. 2004 Aug 12;47(17):4147-50
[
15293984.001
]
[Cites]
Cancer Cell. 2005 May;7(5):457-68
[
15894266.001
]
[Cites]
Nature. 1999 Oct 21;401(6755):818-22
[
10548111.001
]
[Cites]
Curr Treat Options Oncol. 2003 Jun;4(3):211-8
[
12718798.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1252-6
[
9990010.001
]
[Cites]
Cancer Res. 2004 Oct 15;64(20):7183-90
[
15492230.001
]
[Cites]
EMBO J. 2005 Feb 9;24(3):645-55
[
15650747.001
]
[Cites]
Haematologica. 2004 Mar;89(3):363-4
[
15020280.001
]
[Cites]
Cancer Res. 1999 Jan 15;59(2):336-41
[
9927043.001
]
[Cites]
Cell Death Differ. 2002 Sep;9(9):881-92
[
12181739.001
]
[Cites]
Science. 1998 Aug 28;281(5381):1312-6
[
9721091.001
]
[Cites]
J Mol Biol. 2000 Sep 8;302(1):171-88
[
10964568.001
]
[Cites]
Chem Biol. 2003 Aug;10(8):759-67
[
12954335.001
]
[Cites]
Blood. 2005 May 15;105(10):4043-50
[
15687241.001
]
[Cites]
Leukemia. 2003 Nov;17(11):2122-9
[
12931220.001
]
[Cites]
Mol Cell. 2003 Feb;11(2):519-27
[
12620238.001
]
[Cites]
Cell. 2001 Mar 9;104(5):781-90
[
11257231.001
]
[Cites]
Cell. 2001 Mar 9;104(5):769-80
[
11257230.001
]
[Cites]
EMBO J. 1999 Oct 1;18(19):5242-51
[
10508158.001
]
[Cites]
J Biol Chem. 1999 Jun 18;274(25):17941-5
[
10364241.001
]
[Cites]
Science. 2004 Sep 3;305(5689):1471-4
[
15353805.001
]
[Cites]
Cell. 2001 Mar 9;104(5):791-800
[
11257232.001
]
[Cites]
Leukemia. 1995 Jan;9(1):131-8
[
7845007.001
]
[Cites]
J Am Chem Soc. 2004 Dec 29;126(51):16686-7
[
15612682.001
]
[Cites]
Science. 1997 Feb 21;275(5303):1132-6
[
9027315.001
]
[Cites]
Cancer Cell. 2004 Jan;5(1):25-35
[
14749124.001
]
[Cites]
Nature. 1998 Dec 10;396(6711):580-4
[
9859993.001
]
[Cites]
Br J Haematol. 2003 Jun;121(5):730-8
[
12780787.001
]
[Cites]
Blood. 2001 Dec 15;98(13):3541-53
[
11739155.001
]
[Cites]
J Biol Chem. 2000 Oct 27;275(43):33777-81
[
10934209.001
]
[Cites]
Cell Death Differ. 2004 Apr;11(4):372-80
[
14765132.001
]
[Cites]
Cancer Gene Ther. 2005 May;12(5):509-14
[
15706355.001
]
[Cites]
Cancer Res. 2004 Nov 1;64(21):7927-35
[
15520199.001
]
[Cites]
J Biol Chem. 1999 Apr 23;274(17):11549-56
[
10206961.001
]
[Cites]
Cell. 1997 Nov 14;91(4):443-6
[
9390553.001
]
[Cites]
J Med Chem. 2004 Aug 26;47(18):4417-26
[
15317454.001
]
[Cites]
Br J Haematol. 2001 Mar;112(3):706-13
[
11260076.001
]
[Cites]
Leukemia. 1999 Oct;13(10):1574-80
[
10516759.001
]
[Cites]
Mol Cell Biol. 2000 Jun;20(11):3781-94
[
10805722.001
]
[Cites]
J Biol Chem. 2002 Jun 21;277(25):22320-9
[
11940602.001
]
[Cites]
J Med Chem. 2004 May 6;47(10):2430-40
[
15115387.001
]
[Cites]
Trends Neurosci. 2000 May;23(5):222-9
[
10782128.001
]
[Cites]
Clin Cancer Res. 2003 Jul;9(7):2826-36
[
12855663.001
]
[Cites]
Science. 2004 Sep 3;305(5689):1466-70
[
15353804.001
]
[Cites]
Cell Growth Differ. 2000 May;11(5):261-7
[
10845427.001
]
[Cites]
Nat Med. 1999 Feb;5(2):157-63
[
9930862.001
]
[Cites]
Mol Cell Biol. 2004 Aug;24(16):7003-14
[
15282301.001
]
[Cites]
Leuk Res. 1998 Jan;22(1):81-7
[
9585084.001
]
[Cites]
Leukemia. 2002 Jan;16(1):67-73
[
11840265.001
]
[Cites]
Cancer Res. 2004 Oct 15;64(20):7570-8
[
15492284.001
]
[Cites]
J Biol Chem. 1998 Oct 16;273(42):27084-90
[
9765224.001
]
[Cites]
Ann N Y Acad Sci. 2005 Nov;1058:215-34
[
16394139.001
]
[Cites]
Nature. 2005 Jun 2;435(7042):677-81
[
15902208.001
]
[Cites]
Leukemia. 1997 Dec;11(12):2075-8
[
9447823.001
]
[Cites]
Cancer Res. 2002 May 1;62(9):2462-7
[
11980633.001
]
[Cites]
EMBO J. 1999 Jul 1;18(13):3586-95
[
10393175.001
]
[Cites]
Nat Med. 2000 May;6(5):564-7
[
10802713.001
]
[Cites]
J Biol Chem. 1999 Jan 29;274(5):3189-98
[
9915859.001
]
[Cites]
Cancer Res. 2005 Mar 15;65(6):2378-86
[
15781653.001
]
[Cites]
Genes Dev. 1998 Jun 1;12(11):1551-70
[
9620844.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9
[
10860979.001
]
[Cites]
Cell Death Differ. 2006 Feb;13(2):179-88
[
16322751.001
]
[Cites]
Mol Biol Cell. 2003 Jan;14(1):78-92
[
12529428.001
]
[Cites]
Br J Haematol. 2000 Jul;110(1):154-60
[
10930993.001
]
(PMID = 17040621.001).
[ISSN]
1523-3790
[Journal-full-title]
Current oncology reports
[ISO-abbreviation]
Curr Oncol Rep
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Apoptosis Regulatory Proteins; 0 / Receptors, Death Domain; EC 3.4.22.- / Caspases
[Number-of-references]
68
15.
Kobayashi K, Ogasawara M, Kiyama Y, Miyazono T, Kagawa K, Imai K, Hirano T, Kobayashi N, Tanimoto M, Kasai M:
Successful voriconazole treatment of invasive pulmonary aspergillosis in a patient with acute biphenotypic leukemia.
Acta Med Okayama
; 2009 Aug;63(4):213-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Successful voriconazole treatment of invasive pulmonary aspergillosis in a patient with
acute biphenotypic leukemia
.
A 23-year old woman with
acute biphenotypic leukemia
(ABL) complained of chest pain with cough, high fever and hemoptysis during induction chemotherapy, although she had been treated with anti-biotics and micafungin.
We made a clinical
diagnosis
of invasive pulmonary aspergillosis (IPA) based on a consolidation in the right upper lung field on a chest radiograph as well as a high level of serum beta-D-glucan (with no evidence of tuberculosis and candidiasis).
Later, we discovered an air-crescent sign by CT scan that supported the
diagnosis
of IPA.
Serological tests and CT findings can aid in early
diagnosis
of IPA, which, along with treatment for IPA, will improve clinical outcomes.
[MeSH-major]
Antifungal Agents / therapeutic use. Invasive Pulmonary Aspergillosis / drug therapy.
Leukemia
,
Biphenotypic
,
Acute
/ complications. Pyrimidines / therapeutic use. Triazoles / therapeutic use
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
Genetic Alliance.
consumer health - Aspergillosis
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19727206.001).
[ISSN]
0386-300X
[Journal-full-title]
Acta medica Okayama
[ISO-abbreviation]
Acta Med. Okayama
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
16.
He GS, Zhang X, Wu DP, Sun AN, Jin ZM, Qiu HY, Miao M, Tang XW, Fu ZZ, Han Y:
Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients.
Chin Med Sci J
; 2009 Sep;24(3):178-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcomes of CAG regimen for refractory
biphenotypic acute leukemia
patients.
OBJECTIVE: To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor (CAG) regimen for refractory
biphenotypic acute leukemia
(BAL).
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19848320.001).
[ISSN]
1001-9294
[Journal-full-title]
Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
[ISO-abbreviation]
Chin. Med. Sci. J.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin
17.
Gozzetti A, Calabrese S, Raspadori D, Crupi R, Tassi M, Bocchia M, Fabbri A, Lauria F:
Concomitant t(4;11) and t(1;19) in a patient with biphenotypic acute leukemia.
Cancer Genet Cytogenet
; 2007 Aug;177(1):81-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Concomitant t(4;11)
and t
(1;19) in a patient with
biphenotypic acute leukemia
.
[MeSH-major]
Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 4 / genetics.
Leukemia
,
Myeloid
,
Acute
/ genetics. Translocation, Genetic
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17693199.001).
[ISSN]
0165-4608
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
United States
18.
Yao PJ, Petralia RS, Bushlin I, Wang Y, Furukawa K:
Synaptic distribution of the endocytic accessory proteins AP180 and CALM.
J Comp Neurol
; 2005 Jan 3;481(1):58-69
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
AP180 and clathrin assembly
lymphoid myeloid
leukemia
protein (CALM) are clathrin accessory proteins that promote the formation of clathrin-coated vesicles.
COS Scholar Universe.
author profiles
.
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15558718.001).
[ISSN]
0021-9967
[Journal-full-title]
The Journal of comparative neurology
[ISO-abbreviation]
J. Comp. Neurol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Monomeric Clathrin Assembly Proteins; 0 / Picalm protein, rat; 0 / clathrin assembly protein AP180
19.
Mikulic M, Batinic D, Sucic M, Davidovic-Mrsic S, Dubravcic K, Nemet D, Serventi-Seiwerth R, Sertic D, Labar B:
Biological features and outcome of biphenotypic acute leukemia: a case series.
Hematol Oncol Stem Cell Ther
; 2008 Oct-Dec;1(4):225-30
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biological features and outcome of
biphenotypic acute leukemia
: a case series.
BACKGROUND:
Biphenotypic acute leukemia
(BAL) is a distinct entity that is immunophenotypically defined by the European Group for the Immunological Classification of
Leukemia
(EGIL) scoring system and accounts for less than 5% of all
acute leukemia
cases.
Since it is a rare and heterogeneous form of
acute leukemia
with an allegedly poor outcome, there is no consensus on the best treatment approach in these patients.
PATIENTS AND METHODS: Using the EGIL system, we identified 21 cases (3.9%) of BAL from 535 newly diagnosed
acute leukemia
patients in an 11-year period.
RESULTS: There were ten cases of
myeloid
+B-
lymphoid
leukemia
, eight cases of
myeloid
+T-
lymphoid
, one case of B+T-
lymphoid and
two cases of trilineage (
myeloid
+B+T-
lymphoid
leukemia
).
Patients that received
acute
lymphoblastic
leukemia
-oriented chemotherapy had a higher CR rate compared with those who received
acute
myeloid
leukemia
-oriented chemotherapy (100% vs. 60%, P = .007).
The white blood
cell
count at
diagnosis
was found to have statistically significant impact on survival.
CONCLUSION: Despite the progress in the treatment of
acute leukemia
, the prognosis of BAL remains poor and treatment protocols devised explicitly for this entity should be investigated in prospective collaborative studies.
[MeSH-major]
Leukemia
,
Biphenotypic
,
Acute
/ pathology.
Leukemia
,
Biphenotypic
,
Acute
/ therapy
[MeSH-minor]
Acute
Disease
. Adolescent. Adult. Aged.
Disease
-Free Survival. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Stem
Cell
Transplantation. Treatment Outcome. Young Adult
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20058478.001).
[ISSN]
1658-3876
[Journal-full-title]
Hematology/oncology and stem cell therapy
[ISO-abbreviation]
Hematol Oncol Stem Cell Ther
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
20.
Thavaraj V, Seth R:
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate.
World J Pediatr
; 2008 May;4(2):145-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prophylaxis of central nervous system
leukemia
: a case of chronic
myeloid
leukemia
with
lymphoid
blast crisis treated with imatinib mesylate.
BACKGROUND: Chronic
myeloid
leukemia
(CML) in blast crisis has a dismal prognosis.
METHODS: A child with CML in
lymphoid
blast crisis was diagnosed by complete hematological and bone marrow examination.
There was no central nervous system (CNS)
leukemia
at presentation.
Results of cerebrospinal fluid taken for cytopathology showed CNS
leukemia
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / drug therapy. Central Nervous System Neoplasms / prevention & control. Piperazines / administration & dosage. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / drug therapy. Pyrimidines / administration & dosage
[MeSH-minor]
Anti-Inflammatory Agents / administration & dosage. Benzamides. Blood
Cell
Count. Chemoprevention / methods. Child. Clinical Protocols. Cytarabine / administration & dosage. Drug Therapy, Combination. Female. Humans. Hydrocortisone / administration & dosage. Imatinib Mesylate. Injections, Spinal. Methotrexate / therapeutic use. Remission Induction
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
Hazardous Substances Data Bank.
HYDROCORTISONE
.
Hazardous Substances Data Bank.
METHOTREXATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 2003 Oct 15;9(13):4674-81
[
14581336.001
]
[Cites]
Blood. 1983 Jan;61(1):85-91
[
6571717.001
]
[Cites]
Ann Hematol. 2004 Jun;83(6):401-2
[
14673623.001
]
[Cites]
Am J Med. 1993 Jan;94(1):69-74
[
8420302.001
]
[Cites]
N Engl J Med. 2001 Apr 5;344(14):1038-42
[
11287973.001
]
[Cites]
Leuk Lymphoma. 2004 Apr;45(4):695-8
[
15160941.001
]
[Cites]
Blood. 2004 Nov 1;104(9):2655-60
[
15231574.001
]
[Cites]
FDA Consum. 2001 Jul-Aug;35(4):6
[
11692893.001
]
[Cites]
N Engl J Med. 2002 Feb 28;346(9):645-52
[
11870241.001
]
[Cites]
N Engl J Med. 1983 Oct 6;309(14):826-31
[
6412140.001
]
(PMID = 18661773.001).
[ISSN]
1708-8569
[Journal-full-title]
World journal of pediatrics : WJP
[ISO-abbreviation]
World J Pediatr
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Anti-Inflammatory Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 8A1O1M485B / Imatinib Mesylate; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
21.
Marques-Salles Tde J, Barros JE, Soares-Ventura EM, Cartaxo Muniz MT, Santos N, Ferreira da Silva E, Silva ML, Liehr T, Mkrtchyan H:
Unusual childhood biphenotypic acute leukemia with a yet unreported t(3;13)(p25.1;q13).
Leuk Res
; 2010 Aug;34(8):e206-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Unusual childhood
biphenotypic acute leukemia
with a yet unreported t(3;13)(p25.1;q13).
[MeSH-major]
Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 3 / genetics. Killer Cells, Natural / pathology.
Leukemia
,
Myeloid
,
Acute
/ pathology. Precursor T-
Cell Lymphoblastic
Leukemia
-Lymphoma / pathology. Translocation, Genetic / genetics
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20338638.001).
[ISSN]
1873-5835
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
22.
Zhao XF, Gojo I, York T, Ning Y, Baer MR:
Diagnosis of biphenotypic acute leukemia: a paradigmatic approach.
Int J Clin Exp Pathol
; 2009;3(1):75-86
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnosis
of
biphenotypic acute leukemia
: a paradigmatic approach.
Biphenotypic acute leukemia
(BAL), or
acute leukemia
with a single population of blasts coexpressing markers of two different lineages, is a rare clinical entity.
To define BAL, a scoring system was proposed by the European Group of Immunological Markers for
Leukemias
(EGIL) in 1995.
However, increasing evidence suggests that this system has limitations, as acknowledged by the 2008 World Health Organization (WHO) Classification of Tumors of Hematopoietic
and Lymphoid
Tissues.
We propose a new paradigmatic approach to defining BAL based on recent clinical studies of BAL and advances in immunologic marker definition and cytogenetics, and applied our new approach to 8 cases of "BAL" among a cohort of 742 new
acute
leukemias
in our Cancer Center.
By our new criteria, 6 cases were reclassified as
acute
lymphoblastic
leukemia
(ALL), while only 2 were still classified as BAL.
[MeSH-major]
Leukemia
,
Biphenotypic
,
Acute
/
diagnosis
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Arch Pathol Lab Med. 2001 Jul;125(7):948-50
[
11419984.001
]
[Cites]
Am J Clin Pathol. 1998 Feb;109(2):211-20
[
9583894.001
]
[Cites]
Am J Hematol. 2001 Oct;68(2):69-74
[
11559944.001
]
[Cites]
Exp Hematol. 2002 Mar;30(3):205-11
[
11882357.001
]
[Cites]
Br J Haematol. 2003 Dec;123(5):842-9
[
14632775.001
]
[Cites]
Cancer Res. 2004 Oct 15;64(20):7399-404
[
15492262.001
]
[Cites]
Nature. 1975 Dec 4;258(5534):454-6
[
1059878.001
]
[Cites]
Br J Haematol. 1976 Aug;33(4):451-8
[
188440.001
]
[Cites]
Blood. 1981 Sep;58(3):648-52
[
6973348.001
]
[Cites]
Blood. 1983 Apr;61(4):718-25
[
6572534.001
]
[Cites]
Blood. 1983 Jun;61(6):1138-45
[
6404327.001
]
[Cites]
Hum Pathol. 1998 May;29(5):498-504
[
9596274.001
]
[Cites]
Am J Hematol. 1998 Jul;58(3):241-3
[
9662278.001
]
[Cites]
Cytometry. 1998 Aug 15;34(4):198-202
[
9725460.001
]
[Cites]
Haematologica. 1999 Aug;84(8):699-706
[
10457405.001
]
[Cites]
Cancer. 2004 Dec 15;101(12):2788-801
[
15481055.001
]
[Cites]
Exp Mol Pathol. 2005 Aug;79(1):39-41
[
16005710.001
]
[Cites]
Cancer Genet Cytogenet. 2005 Nov;163(1):62-7
[
16271957.001
]
[Cites]
Blood. 2007 May 1;109(9):3697-705
[
17218387.001
]
[Cites]
Exp Mol Pathol. 2007 Aug;83(1):138-41
[
17434163.001
]
[Cites]
Br J Haematol. 2007 Jul;138(2):213-6
[
17593028.001
]
[Cites]
Exp Mol Pathol. 2007 Dec;83(3):471-3
[
17963747.001
]
[Cites]
Trends Biochem Sci. 2008 Feb;33(2):51-7
[
18201888.001
]
[Cites]
Int J Hematol. 2008 Mar;87(2):132-6
[
18288568.001
]
[Cites]
Leuk Lymphoma. 2008 Apr;49(4):700-9
[
18398737.001
]
[Cites]
Cancer Genet Cytogenet. 2008 Aug;185(1):28-31
[
18656690.001
]
[Cites]
Blood. 2009 May 21;113(21):5083-9
[
19131545.001
]
[Cites]
J Biol Chem. 2000 Mar 24;275(12):8633-40
[
10722703.001
]
[Cites]
Am J Clin Pathol. 2000 Jun;113(6):823-30
[
10874883.001
]
[Cites]
J Chin Med Assoc. 2007 Jul;70(7):269-73
[
17631462.001
]
[Cites]
Leukemia. 2007 Nov;21(11):2264-70
[
17611554.001
]
[Cites]
Pathology. 1986 Jan;18(1):99-110
[
3014425.001
]
[Cites]
EMBO J. 1988 Nov;7(11):3457-64
[
2463161.001
]
[Cites]
Leukemia. 1989 Mar;3(3):170-81
[
2465463.001
]
[Cites]
Br J Haematol. 1990 Jun;75(2):202-7
[
2372506.001
]
[Cites]
Blood. 1990 Aug 15;76(4):808-13
[
2166608.001
]
[Cites]
Blood. 1992 Jul 15;80(2):470-7
[
1378322.001
]
[Cites]
J Immunol. 1992 Oct 1;149(7):2281-5
[
1382094.001
]
[Cites]
Leukemia. 1993 Apr;7(4):489-98
[
7681917.001
]
[Cites]
Blood. 1993 Aug 1;82(3):853-7
[
8338949.001
]
[Cites]
J Exp Med. 1993 Sep 1;178(3):1049-55
[
7688784.001
]
[Cites]
Blood. 1993 Sep 1;82(5):1599-607
[
8395912.001
]
[Cites]
J Pathol. 1993 Oct;171(2):99-104
[
7506772.001
]
[Cites]
Am J Clin Pathol. 1994 Mar;101(3):296-9
[
7510927.001
]
[Cites]
Br J Haematol. 1994 Jun;87(2):273-81
[
7947267.001
]
[Cites]
Leukemia. 1995 Oct;9(10):1783-6
[
7564526.001
]
[Cites]
Am J Clin Pathol. 1996 Jun;105(6):761-8
[
8659452.001
]
[Cites]
Am J Clin Pathol. 1996 Aug;106(2):185-91
[
8712171.001
]
[Cites]
Br J Haematol. 1997 Oct;99(1):101-6
[
9359509.001
]
[Cites]
Br J Haematol. 1998 Jan;100(1):147-55
[
9450804.001
]
[Cites]
Am J Clin Pathol. 2001 Jul;116(1):25-33
[
11447748.001
]
(PMID = 19918331.001).
[ISSN]
1936-2625
[Journal-full-title]
International journal of clinical and experimental pathology
[ISO-abbreviation]
Int J Clin Exp Pathol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
[Other-IDs]
NLM/ PMC2776262
[Keywords]
NOTNLM ; ALL / AML / Biphenotypic acute leukemia / EGIL / classification
23.
Ru YX, Wang HJ, Yang BX, Liu JH, Li ZQ, Li CW, Wang JX, Mi YC:
The ultrastructure of hybrid acute leukemia: a study of 15 cases.
Ultrastruct Pathol
; 2005 Sep-Oct;29(5):341-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The ultrastructure of
hybrid
acute leukemia
: a study of 15 cases.
The objective of this study was to investigate the ultrastructural characteristics of
hybrid
acute leukemia
(HAL).
By TEM, 5 out 15 cases of HAL were consistent with immunophenotyping (3 cases of
biphenotypic
type, and 2 cases of biclonal type with granulocytes and lymphocytes); 2 cases were suspected as HAL.
Most of the blast cells of
biphenotypic
HAL showed
lymphoid
features, except some cases containing MPO positive granules in blasts, while a few cases exhibited monocytic or nonspecific features.
TEM offers advantages in the
diagnosis
of biclonal type HAL and
biphenotypic
HAL positive for MPO.
However, it is difficult to differentiate MPO-negative cases of
biphenotypic
HAL from ALL
and a
few cases may be misinterpreted as M5 by TEM.
[MeSH-major]
Granulocyte Precursor Cells / ultrastructure.
Leukemia
,
Myeloid
,
Acute
/
diagnosis
. Lymphocytes / ultrastructure. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma /
diagnosis
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16257860.001).
[ISSN]
0191-3123
[Journal-full-title]
Ultrastructural pathology
[ISO-abbreviation]
Ultrastruct Pathol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
EC 1.11.1.7 / Peroxidase
24.
Kiratli H, Balci KE, Himmetoğlu C, Uner A:
Isolated extraocular muscle involvement as the ophthalmic manifestation of leukaemia.
Clin Exp Ophthalmol
; 2009 Aug;37(6):609-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Isolated extraocular muscle involvement as the ophthalmic manifestation of
leukaemia
.
BACKGROUND: Clinical and imaging features of patients with orbital
leukaemia
primarily involving extraocular muscles were evaluated.
METHODS: This retrospective case series includes patients with
leukaemia
whose only ophthalmic manifestation was extraocular muscle enlargement.
Demographic data, clinical information on the systemic
disease
, prominent ocular signs and symptoms, computed tomography and magnetic resonance imaging characteristics, treatments applied and the outcomes were collected.
Acute
myeloid leukaemia
was the
diagnosis
in two patients, and chronic
lymphocytic leukaemia
, chronic
myeloid leukaemia
and
biphenotypic acute
leukaemia
were found in one patient each, respectively.
Restricted ocular motility was the most common
finding
.
In one patient who had no prior history of
leukaemia
, an incisional biopsy established the
diagnosis
.
CONCLUSIONS: Leukaemic infiltration of extraocular muscles is a rare and late manifestation of the advanced
disease
associated with relapse and there seems to be a predilection for the lateral rectus muscle.
[MeSH-major]
Leukemia
,
Lymphocytic
, Chronic, B-
Cell
/
diagnosis
.
Leukemia
, Myelogenous, Chronic, BCR-ABL Positive /
diagnosis
.
Leukemia
,
Myeloid
,
Acute
/
diagnosis
. Leukemic Infiltration. Oculomotor Muscles / pathology. Orbital Neoplasms /
diagnosis
[MeSH-minor]
Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Ocular Motility Disorders /
diagnosis
. Prognosis. Retrospective Studies. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Clin Exp Ophthalmol. 2010 Aug;38(6):651
[
20553299.001
]
(PMID = 19702712.001).
[ISSN]
1442-9071
[Journal-full-title]
Clinical & experimental ophthalmology
[ISO-abbreviation]
Clin. Experiment. Ophthalmol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
25.
Shankar DB, Cheng JC, Sakamoto KM:
Role of cyclic AMP response element binding protein in human leukemias.
Cancer
; 2005 Nov 1;104(9):1819-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Role of cyclic AMP response element binding protein in human
leukemias
.
Acute
myeloid
leukemia
(AML) in adults has a 20% 5-year
disease
-free survival despite treatment with aggressive cytotoxic chemotherapy.
Previous work from our laboratory demonstrated that the majority of patients with
acute
lymphoid and myeloid
leukemia
overexpress CREB in the bone marrow.
CREB overexpression is associated with poor initial outcome of clinical
disease
in AML patients.
CREB is a transcription factor that functions in glucose homeostasis, growth-factor-dependent
cell
survival, and memory.
To study its role in hematopoiesis, we overexpressed CREB in
leukemia
cell
lines and in mice.
CREB overexpression resulted in increased survival and proliferation of
myeloid
cells and blast-transformation of bone marrow progenitor cells from transgenic mice expressing CREB in the
myeloid lineage
.
CREB transgenic mice also develop myeloproliferative
disease
after 1 year.
Thus, CREB acts as a protooncogene to regulate hematopoiesis and contributes to the
leukemia
phenotype.
Our results suggest that CREB-dependent pathways may serve as targets for directed therapies in
leukemia
in the future.
[MeSH-major]
Cyclic AMP Response Element-Binding Protein / genetics.
Leukemia
/ metabolism
[MeSH-minor]
Acute
Disease
. Animals.
Cell
Line, Tumor.
Cell
Survival.
Disease
-Free Survival. Hematopoiesis / genetics. Humans. Mice. Mice, Transgenic. Mutation. Transcription Factors / genetics. Up-Regulation
MedlinePlus Health Information.
consumer health - Leukemia
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2005 American Cancer Society.
(PMID = 16196046.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA16042; United States / NCI NIH HHS / CA / CA68221
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Cyclic AMP Response Element-Binding Protein; 0 / Transcription Factors
[Number-of-references]
30
26.
Strick R, Zhang Y, Emmanuel N, Strissel PL:
Common chromatin structures at breakpoint cluster regions may lead to chromosomal translocations found in chronic and acute leukemias.
Hum Genet
; 2006 Jun;119(5):479-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Common chromatin structures at breakpoint cluster regions may lead to chromosomal translocations found in chronic and
acute
leukemias
.
The t(9;22) BCR/ABL fusion is associated with over 90% of chronic myelogenous and 25% of
acute
lymphocytic
leukemia
.
Chromosome 11q23 translocations in
acute
myeloid and lymphoid
leukemia
cells demonstrate
myeloid lymphoid
leukemia
(MLL) fusions with over 40 gene partners, like AF9 and AF4 on chromosomes 9 and 4, respectively.
Therapy-related
leukemia
is associated with the above gene rearrangements following the treatment with topoisomerase II (topo II) inhibitors.
In this report, using
cell
lines and primary cells, chromatin structural elements were analyzed in BCR, ABL and AF4 and, for comparison, in MLL2, which is a homolog to MLL, but not associated with chromosome translocations.
Although MLL2 was expressed in all
cell
lines tested, except for the presence of one DNAse I site in the promoter, no other structural elements were found in MLL2.
A NHR model presented demonstrates the importance of chromatin structure in chromosome translocations involved with
leukemia
.
[MeSH-major]
Chromatin / chemistry. Chromosome Breakage. Chromosomes, Human / genetics.
Leukemia
/ genetics.
Leukemia
/ metabolism. Translocation, Genetic
[MeSH-minor]
Acute
Disease
.
Cell
Line, Tumor. Cells, Cultured. Chronic
Disease
. Humans. K562 Cells. Proto-Oncogene Proteins c-bcr / chemistry. Proto-Oncogene Proteins c-bcr / genetics. Recombination, Genetic
MedlinePlus Health Information.
consumer health - Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biochemistry. 1997 May 20;36(20):5934-9
[
9166762.001
]
[Cites]
Cell. 1985 May;41(1):127-32
[
2986841.001
]
[Cites]
Gene. 2002 May 29;291(1-2):251-7
[
12095698.001
]
[Cites]
EMBO J. 1990 Apr;9(4):1319-27
[
2323342.001
]
[Cites]
Science. 1994 Jan 28;263(5146):515-8
[
8290959.001
]
[Cites]
Curr Biol. 2000 Jul 27-Aug 10;10(15):923-6
[
10959840.001
]
[Cites]
Leukemia. 1996 Feb;10(2):372-7
[
8637251.001
]
[Cites]
J Cell Biochem. 2001;82(2):299-309
[
11527155.001
]
[Cites]
Genomics. 1995 May 1;27(1):67-82
[
7665185.001
]
[Cites]
Annu Rev Biochem. 1989;58:351-75
[
2549853.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6236-9
[
8016145.001
]
[Cites]
Oncogene. 1989 May;4(5):559-67
[
2657572.001
]
[Cites]
Oncogene. 1990 Nov;5(11):1669-73
[
2267134.001
]
[Cites]
Oncogene. 2001 May 24;20(23):2900-7
[
11420702.001
]
[Cites]
J Cell Biol. 2001 Dec 10;155(6):899-910
[
11739403.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Apr;33(4):331-45
[
11921269.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4790-5
[
10758153.001
]
[Cites]
EMBO J. 2002 Oct 1;21(19):5269-80
[
12356743.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Oct;32(2):144-54
[
11550282.001
]
[Cites]
Genes Chromosomes Cancer. 2003 Apr;36(4):393-401
[
12619163.001
]
[Cites]
Proc Natl Acad Sci U S A. 1988 Apr;85(7):2076-80
[
2832845.001
]
[Cites]
Nucleic Acids Res. 1997 Feb 1;25(3):511-7
[
9016589.001
]
[Cites]
Cancer Res. 1999 Jul 15;59(14 ):3357-62
[
10416593.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Aug 14;98 (17 ):9802-7
[
11493704.001
]
[Cites]
Oncogene. 1998 Dec 3;17(22):2921-31
[
9879998.001
]
[Cites]
J Cell Sci. 2004 Sep 1;117(Pt 19):4583-90
[
15331666.001
]
[Cites]
Nucleic Acids Res. 1988 Jun 24;16(12):5533-56
[
2838820.001
]
[Cites]
Proc Natl Acad Sci U S A. 1989 Jul;86(14):5497-501
[
2546156.001
]
[Cites]
Cell. 1995 Dec 29;83(7):1137-48
[
8548801.001
]
[Cites]
J Cell Biochem Suppl. 2000;Suppl 35:3-22
[
11389527.001
]
[Cites]
Hum Mol Genet. 1998 May;7(5):767-76
[
9536079.001
]
[Cites]
Hum Mol Genet. 2000 Jul 1;9(11):1671-9
[
10861294.001
]
[Cites]
Mol Cell Biol. 1991 Oct;11(10):4973-84
[
1656219.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14535-40
[
10588740.001
]
[Cites]
Cell Mol Life Sci. 2002 Feb;59(2):373-85
[
11915950.001
]
[Cites]
Mol Cell Biol. 1997 Jul;17(7):4070-9
[
9199342.001
]
[Cites]
Biochem J. 1994 Nov 1;303 ( Pt 3):681-95
[
7980433.001
]
[Cites]
Blood. 1996 Apr 1;87(7):2649-58
[
8639880.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 May 15;90(10 ):4631-5
[
8506309.001
]
[Cites]
Hum Mol Genet. 2002 Jun 1;11(12):1391-7
[
12023981.001
]
[Cites]
J Biol Chem. 2002 Jun 14;277(24):21458-67
[
11940566.001
]
[Cites]
Hum Mutat. 2003 Sep;22(3):229-44
[
12938088.001
]
[Cites]
Cell. 1992 Nov 13;71(4):701-8
[
1423625.001
]
[Cites]
Oncogene. 1998 Dec 10;17 (23 ):3035-44
[
9881706.001
]
[Cites]
Genomics. 1999 Jul 15;59(2):187-92
[
10409430.001
]
[Cites]
Leuk Res. 2002 Aug;26(8):713-20
[
12191565.001
]
[Cites]
Br J Haematol. 1999 Apr;105(1):256-64
[
10233389.001
]
[Cites]
Blood. 2000 Feb 1;95(3):738-43
[
10648381.001
]
[Cites]
Oncogene. 1999 Dec 23;18(56):7975-84
[
10637508.001
]
[Cites]
Cancer Res. 1995 Jan 1;55(1):34-8
[
7805037.001
]
[Cites]
Cancer Res. 1996 Apr 15;56(8):1855-62
[
8620504.001
]
[Cites]
Blood. 1996 Mar 1;87(5):1912-22
[
8634439.001
]
[Cites]
Nature. 2001 Sep 27;413(6854):435-8
[
11574892.001
]
[Cites]
Cancer Lett. 2003 Apr 10;193(1):1-9
[
12691817.001
]
[Cites]
Leukemia. 1997 Sep;11(9):1571-4
[
9305614.001
]
[Cites]
Chromosoma. 1996 Aug;105(2):122-33
[
8753702.001
]
[Cites]
Leukemia. 1999 Dec;13(12):2107-13
[
10602437.001
]
[Cites]
Cancer Res. 1993 Oct 1;53(19):4489-92
[
8402620.001
]
[Cites]
Mol Cell Biol. 1999 Apr;19(4):2986-97
[
10082566.001
]
[Cites]
Hum Genet. 2003 Jul;113(1):80-91
[
12665971.001
]
[Cites]
Blood. 1998 Nov 15;92(10):3793-803
[
9808573.001
]
[Cites]
Genomics. 1998 Jan 15;47(2):217-29
[
9479494.001
]
[Cites]
Blood. 2001 Dec 15;98(13):3778-83
[
11739186.001
]
[Cites]
Genes Dev. 2001 Dec 15;15(24):3237-42
[
11751629.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Sep;35(1):92-6
[
12203795.001
]
[Cites]
Cancer Res. 2001 Jun 1;61(11):4550-5
[
11389089.001
]
[Cites]
Blood. 1990 Aug 1;76(3):597-601
[
2198962.001
]
[Cites]
Genetics. 2002 Apr;160(4):1363-73
[
11973293.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9882-7
[
12114534.001
]
[Cites]
Genes Chromosomes Cancer. 2004 Nov;41(3):257-65
[
15334549.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3
[
10781030.001
]
[Cites]
FASEB J. 2004 Jan;18(1):173-5
[
14630694.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Apr;33(4):362-78
[
11921271.001
]
[Cites]
Mol Pharmacol. 1998 Jul;54(1):78-85
[
9658192.001
]
[Cites]
Cancer Res. 2004 Apr 15;64(8):2656-62
[
15087374.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3070-5
[
11867721.001
]
[Cites]
Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72
[
10595755.001
]
[Cites]
Chromosoma. 1991 Feb;100(2):97-102
[
1849068.001
]
[Cites]
Leukemia. 1998 Mar;12(3):346-52
[
9529129.001
]
[Cites]
Leukemia. 1995 Aug;9(8):1305-12
[
7643617.001
]
(PMID = 16572268.001).
[ISSN]
0340-6717
[Journal-full-title]
Human genetics
[ISO-abbreviation]
Hum. Genet.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
[Publication-country]
Germany
[Chemical-registry-number]
0 / Chromatin; EC 2.7.11.1 / BCR protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
27.
Scolnik MP, Aranguren PN, Cuello MT, Palacios MF, Sanjurjo J, Giunta M, Bracco MM, Acevedo S:
Biphenotypic acute leukemia with t(15;17).
Leuk Lymphoma
; 2005 Apr;46(4):607-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biphenotypic acute leukemia
with t(15;17).
Biphenotypic acute
leukemias
(BAL) represent 5% of all
acute
leukemias
.
Immunophenotype revealed the compromise of
myeloid and
B-
lymphoid
lineages.
This report describes a BAL case with an unfrequent cytogenetic
abnormality
, and highlights the importance of correlating the results of multiple diagnostic methods in order to establish a correct
diagnosis and
treatment in BAL patients.
[MeSH-major]
Chromosome Inversion. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics.
Leukemia
/ genetics
[MeSH-minor]
Acute
Disease
. Child. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Female. Flow Cytometry / methods. Gene Rearrangement. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence / methods. Neoplasm, Residual /
diagnosis
. Neoplasm, Residual / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Trisomy
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16019491.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
28.
Wang LH, Wang M, Zhou CL, Chen S, Zhang XW, Xing HY, Wang JX:
[Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi
; 2005 Jun;26(6):335-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Detection of point mutation at second tyrosine kinase domain of FLT3 gene in
acute
myeloid
leukemia
].
OBJECTIVE: To evaluate the prevalence of a novel FLT3 activating mutation in tyrosine kinase domain (TDK) in
acute leukemia
patients and its clinical implication.
METHODS: Genomic DNA from bone marrow mononuclear cells of 143 cases of
acute
myeloid
leukemia
(AML), 25
acute
lymphocytic
leukemia
(ALL), 2
acute
hybrid
leukemia
(AHL), 17 myelodysplastic syndromes (MDS) and 7 chronic myelogenous
leukemia
in blast crisis (CML-BC) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3-TKD point mutations.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ genetics. fms-Like Tyrosine Kinase 3 / genetics
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16185475.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
29.
Buckley O, Reardon M:
A young male with bone pain.
Eur J Intern Med
; 2005 Sep;16(5):366-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Bone marrow biopsy and peripheral blood film confirmed the
diagnosis
of an
acute biphenotypic
leukaemia
.
This case report highlights the fact that bone pain associated with a normal peripheral blood count may be the presentation of an
acute
haematological
disorder
in both adults and children.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16137555.001).
[ISSN]
0953-6205
[Journal-full-title]
European journal of internal medicine
[ISO-abbreviation]
Eur. J. Intern. Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
30.
Rubnitz JE, Onciu M, Pounds S, Shurtleff S, Cao X, Raimondi SC, Behm FG, Campana D, Razzouk BI, Ribeiro RC, Downing JR, Pui CH:
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital.
Blood
; 2009 May 21;113(21):5083-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acute
mixed lineage
leukemia
in children: the experience of St Jude Children's Research Hospital.
To characterize the biology and optimal therapy of
acute
mixed
-
lineage
leukemia
in children, we reviewed the pathologic and clinical features, including response to therapy, of 35 patients with
mixed
-
lineage
leukemia
.
The majority of cases (91%) had blasts cells that simultaneously expressed either T-
lineage
plus
myeloid
markers (T/
myeloid
, n = 20) or B-
lineage
plus
myeloid
markers (B/
myeloid
, n = 12).
Overall survival rates for the B/
myeloid and
T/
myeloid
subgroups were not significantly different from each other or from the rate for
acute
myeloid
leukemia
(AML) but were inferior to the outcome in children with
acute
lymphoblastic
leukemia
(ALL).
Analysis of gene-expression patterns identified a subset of
biphenotypic
leukemias
that did not cluster with T-
cell
ALL, B-progenitor ALL, or AML.
We propose that treatment for
biphenotypic leukemia
begin with one course of AML-type induction therapy, with a provision for a switch to
lymphoid
-type induction therapy with a glucocorticoid, vincristine, and L-asparaginase if the patient responds poorly.
We also suggest that hematopoietic stem
cell
transplantation is often not required for cure of these patients.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Immunol Methods. 2000 Sep 21;243(1-2):59-75
[
10986407.001
]
[Cites]
Leukemia. 2000 Dec;14(12):2286-94
[
11187920.001
]
[Cites]
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
[
11752295.001
]
[Cites]
Cancer Cell. 2002 Mar;1(2):133-43
[
12086872.001
]
[Cites]
J Clin Oncol. 2002 Oct 15;20(20):4217-24
[
12377965.001
]
[Cites]
J Clin Oncol. 2003 Aug 15;21(16):3084-91
[
12915598.001
]
[Cites]
Br J Haematol. 2003 Dec;123(5):842-9
[
14632775.001
]
[Cites]
Cancer. 2003 Dec 15;98(12):2715-22
[
14669294.001
]
[Cites]
Br J Haematol. 2004 Jun;125(6):814-5
[
15180872.001
]
[Cites]
Br J Cancer. 1977 Jan;35(1):1-39
[
831755.001
]
[Cites]
Blood. 1985 Nov;66(5):1115-23
[
3931724.001
]
[Cites]
Blood. 1990 Jan 1;75(1):198-202
[
2294988.001
]
[Cites]
Leukemia. 1990 Feb;4(2):121-6
[
2137547.001
]
[Cites]
N Engl J Med. 1991 Mar 21;324(12):800-8
[
1997852.001
]
[Cites]
Blood. 1991 Sep 1;78(5):1327-37
[
1878594.001
]
[Cites]
J Clin Oncol. 1992 Sep;10(9):1419-29
[
1517785.001
]
[Cites]
Leukemia. 1995 Oct;9(10):1783-6
[
7564526.001
]
[Cites]
Blood. 1995 Oct 15;86(8):3097-108
[
7579404.001
]
[Cites]
Leukemia. 1996 Aug;10(8):1283-7
[
8709632.001
]
[Cites]
Haematologica. 1997 Jan-Feb;82(1):64-6
[
9107085.001
]
[Cites]
Blood. 1997 Jul 1;90(1):28-35
[
9207434.001
]
[Cites]
Br J Haematol. 1998 Jan;100(1):147-55
[
9450804.001
]
[Cites]
Leukemia. 1998 Dec;12(12):2038
[
9844938.001
]
[Cites]
J Clin Oncol. 1998 Dec;16(12):3768-73
[
9850020.001
]
[Cites]
Haematologica. 1999 Aug;84(8):699-706
[
10457405.001
]
[Cites]
Blood. 2004 Dec 1;104(12):3679-87
[
15226186.001
]
[Cites]
Leukemia. 2005 Dec;19(12):2125-9
[
16281077.001
]
[Cites]
N Engl J Med. 2006 Jan 12;354(2):166-78
[
16407512.001
]
[Cites]
Bioinformatics. 2006 Aug 15;22(16):1979-87
[
16777905.001
]
[Cites]
Br J Haematol. 2007 Jul;138(2):213-6
[
17593028.001
]
[Cites]
Blood. 2007 Aug 15;110(4):1271-7
[
17456722.001
]
[Cites]
Leukemia. 2007 Nov;21(11):2264-70
[
17611554.001
]
[CommentIn]
Blood. 2009 May 21;113(21):5036
[
19470432.001
]
(PMID = 19131545.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA-21765
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2686179
31.
Ara AI, Xia M, Ramani K, Mato JM, Lu SC:
S-adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation.
Hepatology
; 2008 May;47(5):1655-66
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We previously showed that S-adenosylmethionine (SAMe) and its metabolite methylthioadenosine (MTA) blocked lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNFalpha) expression in RAW (murine macrophage
cell
line) and Kupffer cells at the transcriptional level without affecting nuclear factor kappa B nuclear binding.
LPS increased the binding of histone methyltransferases Set1
and myeloid
/
lymphoid
leukemia
to these promoters, which was unaffected by SAMe or MTA.
Exogenous SAMe is unstable and converts spontaneously to MTA, which is stable
and cell
-permeant.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Annu Rev Med. 1994;45:491-503
[
8198398.001
]
[Cites]
J Immunol. 1991 Sep 1;147(5):1694-700
[
1715367.001
]
[Cites]
Immunology. 1996 Dec;89(4):558-62
[
9014821.001
]
[Cites]
Biochem Biophys Res Commun. 1997 Jul 30;236(3):655-60
[
9245708.001
]
[Cites]
Am J Physiol. 1999 May;276(5 Pt 1):G1069-73
[
10329995.001
]
[Cites]
J Hepatol. 1999 Jun;30(6):1081-9
[
10406187.001
]
[Cites]
Biochem J. 1999 Aug 15;342 ( Pt 1):21-5
[
10432295.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8603-8
[
15941828.001
]
[Cites]
J Biol Chem. 2005 Jul 1;280(26):24824-38
[
15870070.001
]
[Cites]
J Biol Chem. 2006 Jun 23;281(25):17180-8
[
16613853.001
]
[Cites]
Biochem J. 2007 Jan 1;401(1):87-96
[
16953798.001
]
[Cites]
Cell. 2007 Mar 9;128(5):889-900
[
17320163.001
]
[Cites]
Cell. 2007 Mar 23;128(6):1077-88
[
17320160.001
]
[Cites]
Hepatology. 2007 May;45(5):1306-12
[
17464973.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10835-40
[
17578910.001
]
[Cites]
Cell. 2007 Jul 13;130(1):77-88
[
17632057.001
]
[Cites]
Gastroenterology. 2007 Jul;133(1):207-18
[
17631143.001
]
[Cites]
Nature. 2001 Mar 1;410(6824):116-20
[
11242053.001
]
[Cites]
Science. 2001 Aug 10;293(5532):1074-80
[
11498575.001
]
[Cites]
Mol Cell Biol. 2001 Oct;21(20):7065-77
[
11564889.001
]
[Cites]
J Hepatol. 2001 Dec;35(6):692-9
[
11738094.001
]
[Cites]
Mol Cell. 2001 Dec;8(6):1207-17
[
11779497.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G256-65
[
12121871.001
]
[Cites]
J Clin Invest. 2002 Sep;110(5):643-50
[
12208865.001
]
[Cites]
Nature. 2002 Sep 26;419(6905):407-11
[
12353038.001
]
[Cites]
Mol Cell Biol. 2003 Jan;23(2):526-33
[
12509451.001
]
[Cites]
Nat Neurosci. 2004 Mar;7(3):229-35
[
14770186.001
]
[Cites]
Hepatology. 2004 Apr;39(4):1088-98
[
15057913.001
]
[Cites]
Cell. 2004 Jun 11;117(6):721-33
[
15186774.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G352-62
[
15064230.001
]
[Cites]
J Virol. 2004 Nov;78(22):12308-19
[
15507618.001
]
[Cites]
Biochem Biophys Res Commun. 1981 May 29;100(2):523-31
[
6791639.001
]
[Cites]
Nucleic Acids Res. 1983 Mar 11;11(5):1475-89
[
6828386.001
]
[Cites]
J Exp Med. 1990 Jan 1;171(1):35-47
[
2104921.001
]
[Cites]
Mol Cell Biol. 1990 Apr;10(4):1498-506
[
2181276.001
]
[Cites]
Cell. 1995 May 19;81(4):641-50
[
7538909.001
]
(PMID = 18393372.001).
[ISSN]
1527-3350
[Journal-full-title]
Hepatology (Baltimore, Md.)
[ISO-abbreviation]
Hepatology
[Language]
ENG
[Grant]
United States / NIAAA NIH HHS / AA / T32 AA007578; None / None / / R01 AT001576-05; United States / NCCIH NIH HHS / AT / R01 AT001576-05; United States / NIAAA NIH HHS / AA / AA007578-07; United States / NIAAA NIH HHS / AA / AA12677; United States / NIDDK NIH HHS / DK / R01 DK051719-11; United States / NCCIH NIH HHS / AT / R01 AT001576; United States / NIDDK NIH HHS / DK / DK048522-139003; United States / NIDDK NIH HHS / DK / R01 DK051719; United States / NIAAA NIH HHS / AA / T32 AA07578; United States / NCCIH NIH HHS / AT / AT1576; United States / NIAAA NIH HHS / AA / T32 AA007578-07; United States / NIDDK NIH HHS / DK / DK48522; United States / NIAAA NIH HHS / AA / R01 AA013847; United States / NIAAA NIH HHS / AA / R01 AA012677; United States / NIDDK NIH HHS / DK / DK051719-11; United States / NIAAA NIH HHS / AA / R01 AA012677-05; United States / NIDDK NIH HHS / DK / DK51719; United States / NIAAA NIH HHS / AA / R01 AA013847-05; United States / NIDDK NIH HHS / DK / P30 DK048522; United States / NIAAA NIH HHS / AA / AA13847; United States / NIDDK NIH HHS / DK / P30 DK048522-139003; United States / NIAAA NIH HHS / AA / AA012677-05; United States / NIAAA NIH HHS / AA / AA013847-05
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Chromatin; 0 / DNA Primers; 0 / Histones; 0 / Lipopolysaccharides; 0 / Tumor Necrosis Factor-alpha; 63231-63-0 / RNA; 7LP2MPO46S / S-Adenosylmethionine
[Other-IDs]
NLM/ NIHMS49821; NLM/ PMC2408693
32.
Coche D, Bergues B, Harrivel V, Guillaume N:
[Biphenotypic acute leukaemia with Burkitt-like cytology].
Ann Biol Clin (Paris)
; 2009 Jul-Aug;67(4):437-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Biphenotypic acute
leukaemia
with Burkitt-like cytology].
[Transliterated title]
Leucémie aiguë biphénotypique avec aspect cytologique
de
type Burkitt.
Biphenotypic acute
leukaemia
(BAL) represents about 5% of adult
acute
leukaemia
.
Based on a previously described scoring system, the European Group for Immunologic Classification of
Leukaemia
(EGIL) proposed a set of diagnostic criteria for BAL.
This scoring system is based on the number and degree of the specificity of several markers for
myeloid
or T/
B lymphoid
blasts.
Here, we report the case of a BAL with Burkitt-like cytology, corresponding to "the
acute
lymphoblastic leukaemia
, Burkitt type" L3 for the FAB classification.
By flow cytometry, the blasts showed a positivity for
B lymphoid
cytoplasmic (CD79a and mu) and membrane (CD19, CD22, CD24, IgM) markers
AND a
positivity for the
myeloid
(CD13, CD33, CD65, CD15) markers.
[MeSH-major]
Leukemia
,
Biphenotypic
,
Acute
/ genetics
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19654084.001).
[ISSN]
0003-3898
[Journal-full-title]
Annales de biologie clinique
[ISO-abbreviation]
Ann. Biol. Clin. (Paris)
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
33.
Murase K, Iyama S, Sato T, Takimoto R, Kobune M, Kato J:
[Therapeutic results in patients with biphenotypic acute leukemia at Sapporo Medical University Hospital].
Gan To Kagaku Ryoho
; 2010 Oct;37(10):2011-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Therapeutic results in patients with
biphenotypic acute leukemia
at Sapporo Medical University Hospital].
We reviewed the results of 6 patients with
biphenotypic acute leukemia
(BAL) which the diagnostic standard of the European Group for the Immunological Characterization of
Leukemia
(EGIL) at Sapporo Medical University Hospital between 2006 and 2008.
Among them, 4 were
B lymphoid and myeloid
, 2 were
T lymphoid and myeloid
, and one was T/
B lymphoid
.
Two of 4 patients did not attain complete remission, and two relapsed after first treatment with
acute
myeloblastic
leukemia
(AML) protocol.
On the other hand, two showed complete remission after the
acute
lymphoblastic
leukemia
(ALL) protocol.
One of 4 patients survived who had been treated with hematopoietic stem
cell
transplantation as a post-remission therapy.
[MeSH-major]
Leukemia
,
Biphenotypic
,
Acute
/ drug therapy
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20948276.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
34.
Naghashpour M, Lancet J, Moscinski L, Zhang L:
Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report.
Am J Hematol
; 2010 Jun;85(6):451-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mixed
phenotype
acute leukemia
with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-
lymphoid
type: A first case report.
The majority of cases of
acute leukemia
belong to a specific
lineage
origin, either
lymphoid
or
myeloid
, and therefore are classified as
acute
lymphoblastic
leukemia
(ALL) or
acute
myelogenous
leukemia
(AML), based on
morphologic
features and cytochemical and immunophenotypic profile of the blast cells.
A minority of
acute
leukemias
however, show no clear evidence of differentiation along a single
lineage
.
These are now classified under
acute
leukemias
of ambiguous
lineage
by the most recent WHO classification and account for <4% of all cases of
acute leukemia
[1].
They include
leukemias
with no
lineage
specific antigens (
acute
undifferentiated
leukemias
) and those with blasts that express antigens of more than one
lineage
to such degree that it is not possible to assign the
leukemia
to any one particular
lineage
with certainty (
mixed
phenotype
acute
leukemias
).
The latter can either be
leukemias
with two distinct populations of blasts, each expressing antigens of a different
lineage
(historically referred to as "bilineal"
leukemias
) or a single blast population expressing antigens of multiple lineages (historically referred to as "
biphenotypic
"
acute
leukemias
) [2].
Acute
leukemias
of ambiguous
lineage
may harbor a variety of genetic lesions.
Those with t(9;22)(q34;q11) or translocations associated with
mixed lineage leukemias
(MLL) gene, i.e., t(11;V)(q23;V), occur frequently enough and are associated with distinct features, that are considered as separate entities according to the recent WHO classification.
Co-expression of
myeloid and
B-
lymphoid
antigens is most common in
mixed
phenotype
acute leukemia
(MPAL), followed by co-expression of
myeloid and
T-
lymphoid
antigens, accounting for 66-70% and 23-24% of MLLs, respectively.
Coexpression of B-
and T
-
lineage
associated antigens or antigens of all three lineages is exceedingly rare, accounting for <5% of MLLs [3,4].
The requirements for assigning more than one
lineage
to a single blast population has been established by current WHO classification [1].
[MeSH-major]
Antigens, Neoplasm / blood. Chromosomes, Human, Pair 11 / ultrastructure. Chromosomes, Human, Pair 19 / ultrastructure. Immunophenotyping.
Leukemia
/ classification.
Myeloid
-
Lymphoid
Leukemia
Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
[MeSH-minor]
Acute
Disease
. Adult. Antigens, CD / analysis. Bone Marrow / pathology.
Cell Lineage
. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Transcription Factors / genetics
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20513125.001).
[ISSN]
1096-8652
[Journal-full-title]
American journal of hematology
[ISO-abbreviation]
Am. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / MLL-ENL oncoprotein, human; 0 / MLLT1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
35.
Mohan AV, Ramnath VR, Patalas E, Attar EC:
Non-specific interstitial pneumonia as the initial presentation of biphenotypic acute leukemia: a case report.
Cases J
; 2009;2:8217
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Non-specific interstitial pneumonia as the initial presentation of
biphenotypic acute leukemia
: a case report.
We present a 46-year-old woman with recent-onset rheumatologic illness who developed pulmonary symptoms as the presenting feature of
biphenotypic acute
leukaemia
.
Corticosteroid therapy resulted in resolution of both her pulmonary and rheumatologic symptoms, and her pulmonary symptoms did not recur following treatment of her
leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leuk Lymphoma. 2002 Nov;43(11):2083-92
[
12533032.001
]
[Cites]
J Am Acad Dermatol. 2001 Mar;44(3):530-1
[
11209130.001
]
[Cites]
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1338-47
[
18388353.001
]
[Cites]
Crit Rev Oncol Hematol. 2007 Aug;63(2):100-10
[
17391977.001
]
[Cites]
Intern Med. 2004 Aug;43(8):721-6
[
15468974.001
]
[Cites]
Semin Respir Crit Care Med. 2006 Dec;27(6):652-8
[
17195141.001
]
[Cites]
Respiration. 2005 Jan-Feb;72(1):39-45
[
15753633.001
]
[Cites]
Haematologica. 1997 Jan-Feb;82(1):64-6
[
9107085.001
]
[Cites]
Br J Haematol. 2007 Jul;138(2):213-6
[
17593028.001
]
(PMID = 19918465.001).
[ISSN]
1757-1626
[Journal-full-title]
Cases journal
[ISO-abbreviation]
Cases J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2769415
36.
Choi HW, Shin MG, Kim HJ, Lee IK, Yun JH, Kim HR, Kim YK, Yun HK, Cho D, Kee SJ, Shin JH, Suh SP, Ryang DW:
[Biphenotypic Acute Leukemia with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.].
Korean J Lab Med
; 2006 Aug;26(4):249-54
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Biphenotypic Acute Leukemia
with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.].
Biphenotypic acute leukemia
(BAL) is a subtype of
leukemia
of ambiguous
lineage
in the World Health Organization classification system.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18156734.001).
[ISSN]
1598-6535
[Journal-full-title]
The Korean journal of laboratory medicine
[ISO-abbreviation]
Korean J Lab Med
[Language]
kor
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Korea (South)
37.
Huh JY, Chung S, Oh D, Kang MS, Eom HS, Cho EH, Han MH, Kong SY:
Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature.
Korean J Lab Med
; 2010 Apr;30(2):117-21
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clathrin assembly
lymphoid myeloid
leukemia
-AF10-positive
acute
leukemias
: a report of 2 cases with a review of the literature.
The translocation t(10;11)(p13;q14q21) has been found to be recurrent in
acute
lymphoblastic and myeloid leukemias
, and results in the fusion of the clathrin assembly
lymphoid myeloid
leukemia
(CALM) gene with the AF10 gene; these genes are present on chromosomes 11 and 10, respectively.
Because the CALM-AF10 rearrangement is a rare chromosomal
abnormality
, it is not included in routine molecular tests for
acute leukemia
.
The first patient (case 1) was diagnosed with T-
cell
ALL, and the second patient (case 2) was diagnosed with AML.
Both patient samples showed expression of the homeobox A gene cluster and the histone methyltransferase hDOT1L, which suggests that they mediate leukemic transformation in CALM-AF10-positive
and mixed
-
lineage
leukemia
-AF10-positive
leukemias
.
The first patient (case 1) relapsed after double-unit cord blood transplantation; there was no evidence of relapse in the second patient (case 2) after allogenic peripheral blood stem
cell
transplantation.
Since CALM-AF10- positive
leukemias
have been shown to have poor prognosis with conventional therapy, molecular tests for CALM-AF10 rearrangement would be necessary to detect minimal residual
disease
during follow-up.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ genetics. Monomeric Clathrin Assembly Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor T-
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics. Transcription Factors / genetics
[MeSH-minor]
Adolescent. Adult. Bone Marrow / pathology. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 11. Cord Blood Stem
Cell
Transplantation. Female. Histone-Lysine N-Methyltransferase / genetics. Histone-Lysine N-Methyltransferase / metabolism. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Male. Recurrence. Translocation, Genetic
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20445327.001).
[ISSN]
1598-6535
[Journal-full-title]
The Korean journal of laboratory medicine
[ISO-abbreviation]
Korean J Lab Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Korea (South)
[Chemical-registry-number]
0 / Homeodomain Proteins; 0 / MLLT10 protein, human; 0 / Monomeric Clathrin Assembly Proteins; 0 / Oncogene Proteins, Fusion; 0 / PICALM protein, human; 0 / Transcription Factors; EC 2.1.1.- / histone methyltransferase; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
[Number-of-references]
14
38.
Gujral S, Badrinath Y, Kumar A, Subramanian PG, Raje G, Jain H, Pais A, Amre Kadam PS, Banavali SD, Arora B, Kumar P, Hari Menon VG, Kurkure PA, Parikh PM, Mahadik S, Chogule AB, Shinde SC, Nair CN:
Immunophenotypic profile of acute leukemia: critical analysis and insights gained at a tertiary care center in India.
Cytometry B Clin Cytom
; 2009 May;76(3):199-205
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunophenotypic profile of
acute leukemia
: critical analysis and insights gained at a tertiary care center in India.
BACKGROUND: To analyze the spectrum of various types and subtypes of
acute leukemia
.
METHODS: Two thousand five hundred and eleven consecutive new referral cases of
acute leukemia
(AL) were evaluated based on WHO classification.
RESULTS: It included 1,471 cases (58%) of
acute
lymphoblastic
leukemia
(ALL), 964 cases (38%) of
acute
myeloid
leukemia
(AML), 45 cases (1.8%) of chronic myelogenous
leukemia
in blast crisis (CMLBC), 37 cases (1.5%) of
biphenotypic acute leukemia
(BAL), 1 case of Triphenotypic AL, and 2 cases of
acute
undifferentiated
leukemia
(AUL).
Common subtypes of ALL were B-
cell
ALL (76%), which comprised of intermediate stage/CALLA positive (73%), early precursor/proBALL (3%).
T-
cell
ALL constituted 24% (351 cases) of ALL.
CMLBC was commonly of
myeloid
blast crisis subtype (40 cases).
CONCLUSION: B-
cell
ALL was the commonest subtype in children and AML in adults.
CD13 was most sensitive and CD117 most specific for determining
myeloid lineage
.
A minimal primary panel of nine antibodies consisting of three
myeloid
markers (CD13, CD33, and CD117), B-
cell lymphoid
marker (CD19), T-
cell
marker (CD7), with CD45, CD10, CD34, and HLADR could assign
lineage
to 92% of AL.
Cytogenetics findings lead to a change in the diagnostic subtype of
myeloid
malignancy in 38 (1.5%) cases.
[MeSH-major]
Immunophenotyping.
Leukemia
/ immunology.
Leukemia
/ pathology
[MeSH-minor]
Acute
Disease
. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cytogenetic Analysis. Female. Histocytochemistry. Humans. In Situ Hybridization. India. Infant. Infant, Newborn. Male. Middle Aged. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Young Adult
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 Clinical Cytometry Society.
(PMID = 18803279.001).
[ISSN]
1552-4957
[Journal-full-title]
Cytometry. Part B, Clinical cytometry
[ISO-abbreviation]
Cytometry B Clin Cytom
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
39.
Mulloy JC, Wunderlich M, Zheng Y, Wei J:
Transforming human blood stem and progenitor cells: a new way forward in leukemia modeling.
Cell Cycle
; 2008 Nov 1;7(21):3314-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transforming human blood stem and progenitor cells: a new way forward in
leukemia
modeling.
MLL-AF9 (MA9) is a
leukemia
fusion gene formed upon translocation of the AF9 gene on chromosome 9 and the MLL gene on chromosome 11.
MA9 is commonly found in
acute
myeloid
leukemia
(AML) and occasionally in
acute
lymphoid
leukemia
and is associated with intermediate to poor outcome.
We have recently described a model system whereby we expressed the MA9 fusion gene in human CD34(+) Umbilical Cord Blood (UCB) cells and showed that these cells transformed to
acute
myeloid
or
lymphoid
leukemia
when injected into immunodeficient mice.
The
Mixed Lineage
Leukemia
(MLL) oncogenes are unique in this model system in that they promote full transformation of primary human blood cells, while all other
leukemia
-associated oncogenes tested thus far have induced only partial phenotypes.
Here we provide an update on the use of this system for modeling human
leukemia
and its potential application for therapeutic testing of novel compounds to treat the
disease
.
MedlinePlus Health Information.
consumer health - Leukemia
.
MedlinePlus Health Information.
consumer health - Stem Cells
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 2002 Sep;16(9):1818-26
[
12200698.001
]
[Cites]
Leukemia. 2008 Nov;22(11):2029-40
[
18685615.001
]
[Cites]
Genes Dev. 2003 Dec 15;17(24):3029-35
[
14701873.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23
[
15128949.001
]
[Cites]
Nature. 1994 Feb 17;367(6464):645-8
[
7509044.001
]
[Cites]
EMBO J. 1994 Feb 15;13(4):928-33
[
8112307.001
]
[Cites]
Nat Med. 1997 Jul;3(7):730-7
[
9212098.001
]
[Cites]
Nature. 1999 Jul 29;400(6743):464-8
[
10440377.001
]
[Cites]
Blood. 2006 Feb 1;107(3):1166-73
[
16234360.001
]
[Cites]
Nature. 2006 Aug 17;442(7104):818-22
[
16862118.001
]
[Cites]
Cancer Cell. 2006 Oct;10(4):257-68
[
17045204.001
]
[Cites]
Science. 2007 Apr 27;316(5824):600-4
[
17463288.001
]
[Cites]
Exp Hematol. 2007 May;35(5):782-92
[
17577927.001
]
[Cites]
Exp Hematol. 2007 Oct;35(10):1538-49
[
17889721.001
]
[Cites]
Cancer Cell. 2007 Nov;12(5):467-78
[
17996650.001
]
[Cites]
Methods Enzymol. 2008;439:365-93
[
18374178.001
]
[Cites]
Cancer Cell. 2008 May;13(5):432-40
[
18455126.001
]
[Cites]
Leukemia. 2008 May;22(5):898-904
[
18354486.001
]
[Cites]
Cancer Cell. 2008 Jun;13(6):483-95
[
18538732.001
]
[Cites]
Leukemia. 2008 Sep;22(9):1803-6
[
18668135.001
]
[Cites]
Leukemia. 2003 Apr;17(4):760-3
[
12682634.001
]
(PMID = 18948748.001).
[ISSN]
1551-4005
[Journal-full-title]
Cell cycle (Georgetown, Tex.)
[ISO-abbreviation]
Cell Cycle
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA118319; United States / NCI NIH HHS / CA / K01 CA090370; United States / NCRR NIH HHS / RR / M01 RR 08084; United States / NCRR NIH HHS / RR / M01 RR008084; United States / NCI NIH HHS / CA / CA118319-04; United States / NCI NIH HHS / CA / R01 CA118319-04; United States / NCI NIH HHS / CA / CA118319; United States / NCI NIH HHS / CA / CA90370
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / MLL-AF9 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 3.6.5.2 / rac GTP-Binding Proteins
[Other-IDs]
NLM/ NIHMS169825; NLM/ PMC2812025
40.
Lee JC, Yang S, Zou Y, Joseph L:
Erythroid/B-cell biphenotypic acute leukemia first case report.
Leukemia
; 2009 Oct;23(10):1920-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Erythroid/B-
cell
biphenotypic acute leukemia
first case report.
[MeSH-major]
B-Lymphocytes / pathology. Erythroid Cells / pathology.
Leukemia
,
Biphenotypic
,
Acute
/ pathology
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19458630.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD
41.
Papenhausen PR, Griffin S, Tepperberg J:
Oncogene amplification in transforming myelodysplasia.
Exp Mol Pathol
; 2005 Oct;79(2):168-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The MLL gene, located within band 11q23, has been shown to be involved in translocations with a large variety of reciprocal sites in both
lymphoid and myeloid
leukemia
and has also been shown to undergo submicroscopic self-fusion/partial duplication.
The frequency and clinical correlations of MLL gene amplification in
leukemia
will need careful follow-up, since the frequently cryptic amplification described in these cases may not generally provoke confirmatory FISH studies.
A common cytogenetic profile of 5 q-, -17/17 p-, -18/18 q-,
and a
missing or abnormal chromosome 11, may help direct appropriate follow-up studies.
Both genes also show a high degree of diversity of pathogenic mechanisms of
leukemia
evolution, including numerous reciprocal fusion genes in transformation to either AML or ALL and gain of function amplification.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Core Binding Factor Alpha 2 Subunit. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged.
Myeloid
-
Lymphoid
Leukemia
Protein. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics. Proto-Oncogene Proteins / genetics
MedlinePlus Health Information.
consumer health - Neural Tube Defects
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16026782.001).
[ISSN]
0014-4800
[Journal-full-title]
Experimental and molecular pathology
[ISO-abbreviation]
Exp. Mol. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Proto-Oncogene Proteins; 0 / RUNX1 protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
42.
Zhang J, Mi YC, Wang Y, Lin D, Li W, Sun XM, Zhou K, Bian SG, Wang JX:
[Study on the clinical characteristics of adult biphenotypic acute leukaemia].
Zhonghua Xue Ye Xue Za Zhi
; 2009 Jan;30(1):18-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Study on the clinical characteristics of adult
biphenotypic acute
leukaemia
].
OBJECTIVE: To analyze the clinical and biological characteristics and prognosis of adult
biphenotypic acute
leukaemia
(BAL).
The chemotherapy regimens were accordingly for
acute
lymphoblastic leukaemia
(ALL),
acute
myeloid leukaemia
(AML) or for both ALL and AML.
(1) The incidence of BAL in
acute
leukaemias
was 6.7%, with a male predominance and 52.3% of BAL patients had WBC > or = 30 x 10(9)/L and 16.9% WBC > or = 100 x 10(9)/L. (2) Percentages of coexpression of
myeloid and B lymphoid
antigens were 81.5%, of
myeloid and T lymphoid
antigens 10.8%, of
myeloid
, B-
and T lymphoid
antigens 4.6%, and of
B and T lymphoid
antigens 3.1%. (3) Normal and abnormal karyotypes accounted for 41.5% and 58.5%, respectively in 53 BAL patients with karyotype analysis.
(1) High white blood
cell
count and coexpression of
myeloid
/
B lymphoid
antigens are common in BAL. (2) Abnormal karyotypes and Ph (+) or bcr-abl( +) often happen. (3) The treatment outcome of BAL is poor.
[MeSH-major]
Leukemia
,
Biphenotypic
,
Acute
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19563029.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
43.
Kakihana K, Ohashi K, Sakai F, Kamata N, Hosomi Y, Nishiwaki M, Yokoyama R, Kobayashi T, Yamashita T, Akiyama H, Sakamaki H:
Leukemic infiltration of the lung following allogeneic hematopoietic stem cell transplantation.
Int J Hematol
; 2009 Jan;89(1):118-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Leukemic infiltration of the lung following allogeneic hematopoietic stem
cell
transplantation.
Pulmonary leukemic infiltration (PLI) is more common than generally recognized, but accurate antemortem
diagnosis
with pathological proof is rarely achieved.
We describe herein the clinical courses of two patients with PLI following hematopoietic stem
cell
transplantation (HSCT).
One case is a male patient with
acute biphenotypic leukemia
, and the other is a female patient with myelodysplastic syndrome.
Moreover, the former case presented PLI as the initial manifestation of relapsed
leukemia
and the latter was accompanied with the fungal pneumonia.
High-resolution computed tomography (HRCT) of the chest at onset of PLI showed diffuse small nodular lesions along peribronchovascular bundle,
and diagnosis
of leukemic infiltration was made based on pathological findings obtained from transbronchial lung biopsy.
Thus, radiological and pathological corroborating assessment was important to reach the correct
diagnosis
.
[MeSH-major]
Hematopoietic Stem
Cell
Transplantation / adverse effects. Leukemic Infiltration /
diagnosis
. Lung Neoplasms / etiology
[MeSH-minor]
Adult. Female. Humans.
Leukemia
/ pathology. Lung / pathology. Male. Middle Aged. Myelodysplastic Syndromes /
diagnosis
. Myelodysplastic Syndromes / etiology. Opportunistic Infections. Transplantation, Homologous
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Haematol. 1998 Mar;100(4):680-7
[
9531334.001
]
[Cites]
Chest. 1990 Mar;97(3):674-8
[
2407452.001
]
[Cites]
Br J Haematol. 2003 Mar;120(6):1058-61
[
12648078.001
]
[Cites]
Bone Marrow Transplant. 1994;14 Suppl 4:S19-28
[
7728120.001
]
[Cites]
AJR Am J Roentgenol. 2000 Feb;174(2):517-21
[
10658733.001
]
[Cites]
Radiat Med. 2003 Jan-Feb;21(1):7-15
[
12801138.001
]
[Cites]
Clin Chest Med. 1990 Jun;11(2):323-32
[
2189666.001
]
[Cites]
Bone Marrow Transplant. 2001 Sep;28(5):425-34
[
11593314.001
]
[Cites]
Eur Radiol. 2002 Jan;12 (1):166-74
[
11868094.001
]
[Cites]
Semin Respir Crit Care Med. 2005 Oct;26(5):514-9
[
16267702.001
]
[Cites]
Bone Marrow Transplant. 2000 Jun;25(12):1263-8
[
10871731.001
]
[Cites]
Annu Rev Med. 1992;43:425-35
[
1580600.001
]
[Cites]
Bone Marrow Transplant. 2007 Sep;40(5):465-72
[
17618318.001
]
[Cites]
Chest. 1990 Nov;98(5):1233-9
[
2225971.001
]
[Cites]
Chest. 1996 Apr;109(4):1066-77
[
8635332.001
]
(PMID = 19093164.001).
[ISSN]
1865-3774
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
44.
Xu XQ, Wang JM, Lü SQ, Chen L, Yang JM, Zhang WP, Song XM, Hou J, Ni X, Qiu HY:
Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population.
Haematologica
; 2009 Jul;94(7):919-27
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical and biological characteristics of adult
biphenotypic acute leukemia
in comparison with that of
acute
myeloid
leukemia
and
acute
lymphoblastic
leukemia
: a case series of a Chinese population.
BACKGROUND:
Biphenotypic acute leukemia
is a rare
disorder
that is difficult to diagnose.
It displays features of both
myeloid and lymphoid lineage
.
There is still a lack of studies in
biphenotypic acute leukemia
in a Chinese population.
We present here a comprehensive investigation of the clinical and biological characteristics, and outcome of
biphenotypic acute leukemia
in our hospital in over a seven year period.
DESIGN AND METHODS: We retrospectively analyzed 452 adult
acute leukemia
patients diagnosed according to French-American-British (FAB) classification and
biphenotypic acute leukemia
diagnosed according to European Group for the Immunological Characterization of
Leukemias
(EGIL) classification, respectively.
Biological characteristics, response to treatment, and outcome were examined in
biphenotypic acute leukemia
patients and compared with that in
acute
myeloid
leukemia
and
acute
lymphoblastic
leukemia
patients with complete follow-up profiles diagnosed in the same period.
RESULTS: Of 452
acute leukemia
patients, 21 cases (4.6%) were diagnosed as
biphenotypic acute leukemia
.
Among them, 14 (66.7%) were
B lymphoid and myeloid
, 5 (23.8%) were
T lymphoid and myeloid
, one (4.8%) was T/
B lymphoid
and one (4.8%) was trilineage differentiation.
When compared with
acute
myeloid
leukemia
and
acute
lymphoblastic
leukemia
, patients with
biphenotypic acute leukemia
showed significantly higher incidence of CD34 antigen expression, unfavorable karyotypes, and extramedullary infiltration (p<0.05).
In this cohort of patients with
biphenotypic acute leukemia
, t(9;22) was the most common
abnormality
in chromosome structure.
The median
disease
-free survival and overall survival in
biphenotypic acute leukemia
patients was five months and ten months, respectively, significantly shorter than those in
acute
myeloid
leukemia
and
acute
lymphoblastic
leukemia
patients (p<0.05).
CONCLUSIONS: The prognosis of
biphenotypic acute leukemia
patients is poor when compared with
de
novo
acute
myeloid
leukemia
or
acute
lymphoblastic
leukemia
.
Biphenotypic acute leukemia
patients showed a much higher incidence of CD34 antigen expression, complex abnormal karyotype, extramedullary infiltration, relapse, and resistance to therapy after relapse.
[MeSH-major]
Leukemia
,
Biphenotypic
,
Acute
/
diagnosis
.
Leukemia
,
Myeloid
,
Acute
/
diagnosis
. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma /
diagnosis
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6
[
10861016.001
]
[Cites]
Zhonghua Xue Ye Xue Za Zhi. 2000 Jul;21(7):352-4
[
11877003.001
]
[Cites]
Nature. 2008 Apr 10;452(7188):768-72
[
18401412.001
]
[Cites]
Nat Rev Immunol. 2002 Feb;2(2):127-32
[
11910894.001
]
[Cites]
Blood. 2002 Sep 15;100(6):1965-71
[
12200353.001
]
[Cites]
Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):375-7
[
12408768.001
]
[Cites]
Ann Intern Med. 1985 Oct;103(4):620-5
[
3862359.001
]
[Cites]
Blood. 1990 Aug 15;76(4):808-13
[
2166608.001
]
[Cites]
Ann Hematol. 1991 Feb;62(1):16-21
[
2031964.001
]
[Cites]
N Engl J Med. 1993 Sep 23;329(13):909-14
[
8361504.001
]
[Cites]
Leukemia. 1995 Oct;9(10):1783-6
[
7564526.001
]
[Cites]
Leukemia. 1996 Aug;10(8):1283-7
[
8709632.001
]
[Cites]
Haematologica. 1997 Jan-Feb;82(1):64-6
[
9107085.001
]
[Cites]
Blood. 1997 Oct 15;90(8):2863-92
[
9376567.001
]
[Cites]
Br J Haematol. 1998 Jan;100(1):147-55
[
9450804.001
]
[Cites]
Haematologica. 1999 Aug;84(8):699-706
[
10457405.001
]
[Cites]
Am J Hematol. 2005 Mar;78(3):173-80
[
15726601.001
]
[Cites]
Leukemia. 2006 Apr;20(4):620-6
[
16437134.001
]
[Cites]
Br J Haematol. 2007 Jul;138(2):213-6
[
17593028.001
]
[Cites]
Leukemia. 2007 Nov;21(11):2264-70
[
17611554.001
]
[Cites]
Int J Hematol. 2008 Mar;87(2):132-6
[
18288568.001
]
[Cites]
Leuk Lymphoma. 2008 Apr;49(4):700-9
[
18398737.001
]
[Cites]
Nature. 2008 Apr 10;452(7188):764-7
[
18401411.001
]
[CommentIn]
Haematologica. 2009 Dec;94(12):1778-80; author reply 1780
[
19996120.001
]
[CommentIn]
Haematologica. 2009 Jul;94(7):891-3
[
19570749.001
]
(PMID = 19454497.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
0 / Antigens, CD34
[Other-IDs]
NLM/ PMC2704302
45.
Liu Z, Liu XL, Du QF, Xu N, Zhong M, Song LL, Yi ZS, Liu QF, Meng FY, Zhou SY:
[Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].
Nan Fang Yi Ke Da Xue Xue Bao
; 2009 Mar;29(3):512-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinical characteristics and outcomes of 59 patients with
acute
lymphoblastic
leukemia
positive for BCR/ABL].
OBJECTIVE: To study the clinical characteristics and outcomes of BCR/ABL-positive
acute
lymphoblastic
leukemia
(BCR/ABL360888725-ALL) and screen the prognostic factors for BCR/ABL360888725-ALL.
METHODS: From January 2001 to May 2008, 59 patients (median age of 32 years ranging from 3 to 69 years) with the
diagnosis
of BCR/ABL360888725-ALL by fluorescence in situ hybridization received induction chemotherapy with VDLP-/+Ara-C regimen.
The patients who failed to respond to the chemotherapy received subsequent consolidation chemotherapy with imatinib (400-800 mg/day) (17 cases) or allogeneic hematopoietic stem
cell
transplantation (allo-HSCT) (16 cases).
In patients with peripheral white blood
cell
(WBC) count <30=10(9)/L, 30-99.9(9)/L and > or =100(9)/L, the CR rates were 75.0% (18/24), 56.3% (9/15) and 26.3% (5/19) (P=0.006), and the overall survival probability of 2 years ( OSs of 2-yrs) was 24.7%, 22.5% and 21.1%, respectively (P=0.180).
According to the FAB classification, 56 cases were divided into L1, L2 and
biphenotypic acute leukemia
(BAL) subgroups, and their CR rates were 66.7% (6/9), 63.2% (24/38) and 22.2% (2/9) (P=0.029), with OSs of 2-yrs of 22.2%, 27.0% and 22.0%, respectively (P=0.623).
In terms of immunophenotype grouping by EGIL, the patients with ALL,
myeloid
antigen-positive ALL and BAL had CR rates of 61.1% (11/18), 60.6% (20/33) and 12.5% (1/8) (P=0.039), and the OSs of 2-yrs of 22.7%, 21.0% and 18.8%, respectively (P=0.643).
In 55 patients with known karyotype, the CR rates were 71.4%(5/7), 70.8% (17/24) and 37.5% (9/24) in normal, sole t(9;22)
abnormality
, t(9;22) with additional abnormalities groups (P=0.046), with the OSs of 2-yrs of 42.9%, 34.0% and 7.3%, respectively (P=0.000).
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genes, abl / genetics. Hematopoietic Stem
Cell
Transplantation. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / therapy
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19304540.001).
[ISSN]
1673-4254
[Journal-full-title]
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
[ISO-abbreviation]
Nan Fang Yi Ke Da Xue Xue Bao
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
46.
Nakada S, Katsuki Y, Imoto I, Yokoyama T, Nagasawa M, Inazawa J, Mizutani S:
Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations.
J Clin Invest
; 2006 Jan;116(1):80-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Topoisomerase II (Topo II) inhibitors are
cell
cycle-specific DNA-damaging agents and often correlate with secondary
leukemia
with chromosomal translocations involving the
mixed
-
lineage
leukemia
/
myeloid lymphoid
leukemia
(MLL) gene on chromosome 11 band q23 (11q23).
[MeSH-major]
Cell
Cycle / physiology. Chromosome Aberrations / chemically induced. Etoposide / pharmacology.
Myeloid
-
Lymphoid
Leukemia
Protein / genetics. Translocation, Genetic
[MeSH-minor]
Bone Neoplasms.
Cell
Division.
Cell
Line.
Cell
Line, Tumor. Chromosome Banding. Chromosomes, Human, Pair 11. Cloning, Molecular. G2 Phase. Gene Expression Regulation. Gene Expression Regulation, Neoplastic. Histone-Lysine N-Methyltransferase. Humans. Osteosarcoma
Coriell Cell Repositories.
culture/stock collections - Coriell Cell Repositories
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mutat Res. 2000 Mar 3;466(1):9-15
[
10751720.001
]
[Cites]
J Biol Chem. 1996 Nov 15;271(46):29238-44
[
8910583.001
]
[Cites]
Br J Haematol. 2000 Apr;109(1):13-23
[
10848777.001
]
[Cites]
Leukemia. 2000 Jun;14(6):1014-7
[
10865966.001
]
[Cites]
Blood. 2000 Jul 1;96(1):24-33
[
10891426.001
]
[Cites]
Cancer Res. 2001 Mar 15;61(6):2542-6
[
11289128.001
]
[Cites]
Med Pediatr Oncol. 2001 May;36(5):525-35
[
11340607.001
]
[Cites]
Annu Rev Genet. 2001;35:673-745
[
11700297.001
]
[Cites]
Carcinogenesis. 2002 Jan;23(1):19-24
[
11756219.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):925-30
[
11805335.001
]
[Cites]
Mol Cell Biol. 2002 Feb;22(4):1049-59
[
11809797.001
]
[Cites]
Blood. 2002 Mar 15;99(6):1909-12
[
11877259.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Apr;33(4):331-45
[
11921269.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Apr;33(4):395-400
[
11921273.001
]
[Cites]
Lancet Oncol. 2002 Apr;3(4):235-43
[
12067686.001
]
[Cites]
Nat Genet. 2002 Sep;32(1):185-90
[
12195425.001
]
[Cites]
Nat Rev Cancer. 2003 Mar;3(3):155-68
[
12612651.001
]
[Cites]
Blood. 2003 May 1;101(9):3622-7
[
12511424.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62
[
12679524.001
]
[Cites]
Curr Med Chem Anticancer Agents. 2003 Jul;3(4):271-90
[
12769773.001
]
[Cites]
J Clin Oncol. 2003 Jun 1;21(11):2123-37
[
12775738.001
]
[Cites]
Cancer Cell. 2003 May;3(5):449-58
[
12781363.001
]
[Cites]
Cancer Causes Control. 1996 Nov;7(6):581-90
[
8932918.001
]
[Cites]
Curr Opin Struct Biol. 1998 Feb;8(1):26-32
[
9519293.001
]
[Cites]
Leukemia. 1998 Mar;12(3):346-52
[
9529129.001
]
[Cites]
J Clin Oncol. 1999 Feb;17(2):569-77
[
10080601.001
]
[Cites]
EMBO J. 1999 Jul 1;18(13):3564-74
[
10393173.001
]
[Cites]
Oncologist. 1999;4(3):225-40
[
10394590.001
]
[Cites]
Nature. 2004 Nov 18;432(7015):316-23
[
15549093.001
]
[Cites]
Nature. 2004 Nov 18;432(7015):338-41
[
15549096.001
]
[Cites]
Mol Cell. 2004 Dec 22;16(6):991-1002
[
15610741.001
]
[Cites]
Mol Cell. 2004 Dec 22;16(6):1003-15
[
15610742.001
]
[Cites]
N Engl J Med. 2005 Apr 14;352(15):1529-38
[
15829534.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4790-5
[
10758153.001
]
[Cites]
Cancer Cell. 2003 Aug;4(2):99-110
[
12957285.001
]
[Cites]
Blood. 2004 Jan 1;103(1):283-90
[
12969974.001
]
[Cites]
Science. 2004 Jan 2;303(5654):92-5
[
14704429.001
]
[Cites]
Nat Genet. 2004 Apr;36(4):331-4
[
15054488.001
]
[Cites]
Cancer Res. 1974 Aug;34(8):1788-93
[
4210356.001
]
[Cites]
J Cell Biol. 1975 Sep;66(3):521-30
[
1057547.001
]
[Cites]
J Biol Chem. 1984 Nov 10;259(21):13560-6
[
6092381.001
]
[Cites]
Mol Cell Biol. 1987 Sep;7(9):3119-23
[
2823120.001
]
[Cites]
Proc Natl Acad Sci U S A. 1988 Feb;85(4):1086-90
[
2829215.001
]
[Cites]
N Engl J Med. 1989 Jul 20;321(3):136-42
[
2787477.001
]
[Cites]
Cancer Res. 1993 Jul 1;53(13):2954-6
[
8319201.001
]
[Cites]
Lancet. 1993 Oct 2;342(8875):819-20
[
8104269.001
]
[Cites]
Blood. 1996 Mar 1;87(5):1912-22
[
8634439.001
]
[Cites]
Blood. 1996 Apr 1;87(7):2649-58
[
8639880.001
]
[Cites]
Cell. 1996 Jun 14;85(6):853-61
[
8681380.001
]
[ErratumIn]
J Clin Invest. 2006 Aug;116(8):2306-7
(PMID = 16357944.001).
[ISSN]
0021-9738
[Journal-full-title]
The Journal of clinical investigation
[ISO-abbreviation]
J. Clin. Invest.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 6PLQ3CP4P3 / Etoposide; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
[Other-IDs]
NLM/ PMC1312016
47.
Nishiuchi T, Ohnishi H, Kamada R, Kikuchi F, Shintani T, Waki F, Kitanaka A, Kubota Y, Tanaka T, Ishida T:
Acute leukemia of ambiguous lineage, biphenotype, without CD34, TdT or TCR-rearrangement.
Intern Med
; 2009;48(16):1437-41
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acute leukemia
of ambiguous
lineage
, biphenotype, without CD34, TdT or TCR-rearrangement.
Biphenotypic acute leukemia
(BAL) is a rare entity that comprises 0.5-3% of all
acute
leukemias and
probably arises from multipotent progenitor cells.
We report the case of a 41-year-old man with BAL having
myeloid and
T-
lymphoid lineage
phenotypes.
This pattern is rarely encountered and suggests that the blast cells were possibly considered immature with aspects of differentiation indicating
myeloid lineage
, rather than T-
lymphoid lineage
.
[MeSH-major]
Antigens, CD34 / genetics.
Cell Lineage
/ genetics. DNA Nucleotidylexotransferase / genetics. Gene Rearrangement / genetics.
Leukemia
,
Biphenotypic
,
Acute
/ genetics. Receptors, Antigen, T-
Cell
. Receptors, Antigen, T-
Cell
, alpha-beta / genetics. Receptors, Antigen, T-
Cell
, gamma-delta / genetics
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19687594.001).
[ISSN]
1349-7235
[Journal-full-title]
Internal medicine (Tokyo, Japan)
[ISO-abbreviation]
Intern. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antigens, CD34; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; EC 2.7.7.31 / DNA Nucleotidylexotransferase
48.
Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, Largaespada DA:
A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.
Blood
; 2009 Jan 29;113(5):1075-85
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
NF1 inactivation occurs in specific human cancers, including juvenile myelomonocytic
leukemia
, an aggressive myeloproliferative
disorder
of childhood.
However, evidence suggests that Nf1 loss alone does not cause
leukemia
.
We therefore hypothesized that inactivation of the Nf1 tumor suppressor gene requires cooperating mutations to cause
acute leukemia
.
One of these genes, Bcl11a, confers a growth advantage in cultured Nf1 mutant hematopoietic cells and causes early onset of
leukemia
of either
myeloid
or
lymphoid lineage
in mice when expressed in Nf1-deficient bone marrow.
Importantly, Bcl11a is expressed in human chronic myelomonocytic
leukemia
and juvenile myelomonocytic
leukemia
samples.
These findings suggest that deregulated Bcl11a cooperates with Nf1 in leukemogenesis,
and a
therapeutic strategy targeting the BCL11A pathway may prove beneficial in the treatment of
leukemia
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Addgene Non-profit plasmid repository.
clones/clone libraries - Get Article's Plasmids - Addgene
(subscription/membership/fee required).
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 2007 May;21(5):1093-7
[
17301810.001
]
[Cites]
Blood. 2007 May 15;109(10):4392-8
[
17284535.001
]
[Cites]
Science. 2000 Mar 10;287(5459):1804-8
[
10710306.001
]
[Cites]
Exp Hematol. 2007 Jun;35(6):908-19
[
17533045.001
]
[Cites]
Bioinformatics. 2007 Jul 1;23(13):i133-41
[
17646289.001
]
[Cites]
Biotechniques. 2007 Jul;43(1):79-84
[
17695256.001
]
[Cites]
Oncogene. 2007 Aug 30;26(40):5840-50
[
17369851.001
]
[Cites]
Mol Cell Biol. 2000 May;20(9):3178-86
[
10757802.001
]
[Cites]
Leuk Res. 2000 Jul;24(7):601-10
[
10867136.001
]
[Cites]
Genomics. 2000 Dec 15;70(3):387-91
[
11161790.001
]
[Cites]
Exp Hematol. 2001 Mar;29(3):278-85
[
11274754.001
]
[Cites]
Genes Dev. 2001 Apr 1;15(7):859-76
[
11297510.001
]
[Cites]
Semin Cancer Biol. 2001 Jun;11(3):191-200
[
11407944.001
]
[Cites]
Nature. 2001 Aug 9;412(6847):647-51
[
11493923.001
]
[Cites]
J Virol. 2001 Oct;75(19):9427-34
[
11533205.001
]
[Cites]
J Clin Invest. 2001 Sep;108(5):709-15
[
11544276.001
]
[Cites]
Cell. 2001 Oct 19;107(2):137-48
[
11672522.001
]
[Cites]
Blood. 2001 Dec 1;98(12):3274-82
[
11719364.001
]
[Cites]
Blood. 2001 Dec 1;98(12):3413-20
[
11719382.001
]
[Cites]
Blood. 2002 Jan 15;99(2):627-33
[
11781247.001
]
[Cites]
Blood. 2002 Feb 15;99(4):1474-7
[
11830502.001
]
[Cites]
EMBO J. 2002 May 15;21(10):2383-96
[
12006491.001
]
[Cites]
Oncogene. 2002 Jul 25;21(32):4978-82
[
12118376.001
]
[Cites]
Exp Hematol. 2002 Nov;30(11):1263-72
[
12423679.001
]
[Cites]
Oncogene. 2002 Dec 5;21(55):8486-97
[
12466968.001
]
[Cites]
J Virol. 2003 Jan;77(2):1059-68
[
12502821.001
]
[Cites]
Mol Cell Biol. 2003 Apr;23(8):2859-70
[
12665584.001
]
[Cites]
Blood. 2003 Apr 15;101(8):3188-97
[
12515727.001
]
[Cites]
Nat Immunol. 2003 Jun;4(6):525-32
[
12717432.001
]
[Cites]
Oncogene. 2003 Jul 17;22(29):4581-5
[
12881715.001
]
[Cites]
Curr Opin Neurol. 2004 Apr;17(2):101-5
[
15021234.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1617-28
[
15084694.001
]
[Cites]
Blood. 2004 Jun 1;103(11):4243-50
[
14982883.001
]
[Cites]
J Virol. 1982 May;42(2):379-88
[
6283161.001
]
[Cites]
Nature. 1990 Mar 15;344(6263):251-3
[
2179728.001
]
[Cites]
Mol Cell Biol. 1990 Sep;10(9):4658-66
[
2167436.001
]
[Cites]
Cell. 1990 Nov 16;63(4):843-9
[
2121370.001
]
[Cites]
Cell. 1992 Apr 17;69(2):265-73
[
1568246.001
]
[Cites]
Nature. 1992 Apr 23;356(6371):713-5
[
1570015.001
]
[Cites]
Mol Cell Biol. 1993 Jan;13(1):351-7
[
8093327.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5539-43
[
8516298.001
]
[Cites]
Cell. 1993 Sep 10;74(5):833-43
[
8104101.001
]
[Cites]
Genes Dev. 1994 May 1;8(9):1019-29
[
7926784.001
]
[Cites]
Br J Cancer. 1994 Nov;70(5):969-72
[
7947106.001
]
[Cites]
J Virol. 1995 Aug;69(8):5095-102
[
7609078.001
]
[Cites]
Blood. 1995 Dec 15;86(12):4603-11
[
8541551.001
]
[Cites]
Nat Genet. 1996 Feb;12(2):137-43
[
8563750.001
]
[Cites]
Nat Genet. 1996 Feb;12(2):149-53
[
8563752.001
]
[Cites]
Blood. 1996 Nov 15;88(10):3710-9
[
8916935.001
]
[Cites]
Cell. 1997 Mar 7;88(5):593-602
[
9054499.001
]
[Cites]
Science. 1997 May 2;276(5313):795-8
[
9115204.001
]
[Cites]
Brain Res. 1997 Jun 6;759(1):149-52
[
9219873.001
]
[Cites]
Nucleic Acids Res. 1997 Sep 1;25(17):3389-402
[
9254694.001
]
[Cites]
Nature. 2004 Dec 2;432(7017):635-9
[
15577913.001
]
[Cites]
Arch Biochem Biophys. 2005 Feb 15;434(2):316-25
[
15639232.001
]
[Cites]
Int J Cancer. 2005 May 1;114(5):683-95
[
15609309.001
]
[Cites]
Fam Cancer. 2005;4(4):323-33
[
16341812.001
]
[Cites]
Leukemia. 2006 Jan;20(1):151-4
[
16307021.001
]
[Cites]
Exp Hematol. 2006 May;34(5):631-41
[
16647569.001
]
[Cites]
Genes Dev. 2006 Aug 1;20(15):2024-9
[
16882980.001
]
[Cites]
Nat Rev Cancer. 2006 Sep;6(9):663-73
[
16915296.001
]
[Cites]
Leukemia. 2006 Oct;20(10):1880-2
[
16871282.001
]
[Cites]
J Immunol. 2007 Feb 15;178(4):2527-34
[
17277161.001
]
[Cites]
Blood. 2007 Feb 15;109(4):1687-91
[
17090653.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Apr 6;355(2):538-42
[
17306224.001
]
[Cites]
Nat Genet. 2007 Apr;39(4):476-85
[
17369827.001
]
[Cites]
Br J Haematol. 2007 May;137(3):252-61
[
17408467.001
]
(PMID = 18948576.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U01 CA084221; United States / NCI NIH HHS / CA / CA84221
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / BCL11A protein, human; 0 / Bcl11a protein, mouse; 0 / CDKN1A protein, human; 0 / Carrier Proteins; 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neurofibromin 1; 0 / Nuclear Proteins
[Other-IDs]
NLM/ PMC2635073
49.
Saitoh T, Matsushima T, Iriuchishima H, Yamane A, Irisawa H, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H:
Presentation of extramedullary Philadelphia chromosome-positive biphenotypic acute leukemia as testicular mass: Response to imatinib-combined chemotherapy.
Leuk Lymphoma
; 2006 Dec;47(12):2667-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Presentation of extramedullary Philadelphia chromosome-positive
biphenotypic acute leukemia
as testicular mass: Response to imatinib-combined chemotherapy.
[MeSH-major]
Antineoplastic Agents / therapeutic use.
Leukemia
, Myelogenous, Chronic, BCR-ABL Positive /
diagnosis
. Piperazines / pharmacology. Pyrimidines / pharmacology. Testicular Neoplasms /
diagnosis
[MeSH-minor]
Benzamides. Bone Marrow Cells / cytology. Flow Cytometry. Humans. Imatinib Mesylate. Male. Middle Aged. Philadelphia Chromosome. Stem
Cell
Transplantation. Transplantation, Homologous
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Testicular Cancer
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17169818.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
50.
Yin H, Glass J, Blanchard KL:
MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.
Mol Cancer
; 2007;6:51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Fusion of the MOZ and TIF2 genes by an inv (8) (p11q13) translocation has been identified in patients with
acute
mixed
-
lineage
leukemia
.
Stable expression of MOZ-TIF2 inhibited retinoic acid (RA) inducible endogenous CD11b
and C
/EBPbeta gene response.
[MeSH-minor]
Acute
Disease
. Blotting, Western. Carrier Proteins / genetics. Carrier Proteins / metabolism. Corticosterone. Genes, Reporter. Humans.
Leukemia
,
Myeloid
/ genetics. Receptors, Androgen / genetics. Receptors, Estrogen / genetics
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Genes Dev. 2000 May 15;14(10):1209-28
[
10817756.001
]
[Cites]
Genes Chromosomes Cancer. 2000 Jun;28(2):138-44
[
10824998.001
]
[Cites]
Genes Chromosomes Cancer. 2000 Aug;28(4):415-24
[
10862050.001
]
[Cites]
Genes Dev. 2000 Jul 1;14(13):1553-77
[
10887150.001
]
[Cites]
J Cell Biol. 2000 Jul 10;150(1):265-73
[
10893273.001
]
[Cites]
J Mol Biol. 2000 Oct 20;303(2):243-53
[
11023789.001
]
[Cites]
Cancer Cell. 2004 Dec;6(6):587-96
[
15607963.001
]
[Cites]
Mol Cell Biol. 2005 Feb;25(3):988-1002
[
15657427.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3611-6
[
15731352.001
]
[Cites]
Genes Dev. 2006 May 1;20(9):1175-86
[
16651658.001
]
[Cites]
Genes Dev. 2006 May 15;20(10):1321-30
[
16702405.001
]
[Cites]
J Biol Chem. 2006 Jun 23;281(25):17124-33
[
16613851.001
]
[Cites]
Mol Endocrinol. 1997 Feb;11(2):148-61
[
9013762.001
]
[Cites]
Nature. 1997 Jun 12;387(6634):733-6
[
9192902.001
]
[Cites]
Cell. 1997 Jun 27;89(7):1175-84
[
9215639.001
]
[Cites]
Recent Prog Horm Res. 1997;52:103-19; discussion 119-20
[
9238849.001
]
[Cites]
EMBO J. 1998 Jan 15;17(2):507-19
[
9430642.001
]
[Cites]
Mol Endocrinol. 1998 Feb;12(2):302-13
[
9482670.001
]
[Cites]
Blood. 1998 May 1;91(9):3127-33
[
9558366.001
]
[Cites]
Recept Signal Transduct. 1997;7(4):241-56
[
9633825.001
]
[Cites]
Mol Endocrinol. 1998 Aug;12(8):1172-83
[
9717843.001
]
[Cites]
Blood. 1998 Sep 15;92(6):2118-22
[
9731070.001
]
[Cites]
Mol Endocrinol. 1998 Oct;12(10):1605-18
[
9773983.001
]
[Cites]
Genes Dev. 1998 Nov 1;12(21):3357-68
[
9808623.001
]
[Cites]
J Virol. 1999 May;73(5):3574-81
[
10196247.001
]
[Cites]
Science. 1999 Jun 25;284(5423):2174-7
[
10381882.001
]
[Cites]
Mol Cell Biol. 1999 Sep;19(9):6085-97
[
10454556.001
]
[Cites]
Mol Cell Biol. 1999 Sep;19(9):6164-73
[
10454563.001
]
[Cites]
Cancer Genet Cytogenet. 1999 Aug;113(1):70-2
[
10459350.001
]
[Cites]
J Biol Chem. 1999 Sep 3;274(36):25756-68
[
10464314.001
]
[Cites]
Mol Cell Biol. 1999 Dec;19(12):8383-92
[
10567563.001
]
[Cites]
Gene. 2000 Mar 7;245(1):1-11
[
10713439.001
]
[Cites]
Mol Cell Biol. 2001 Jan;21(1):39-50
[
11113179.001
]
[Cites]
J Biol Chem. 2000 Dec 29;275(52):40810-6
[
11010967.001
]
[Cites]
Hum Mol Genet. 2001 Feb 15;10(4):395-404
[
11157802.001
]
[Cites]
J Biol Chem. 2001 Mar 2;276(9):6695-702
[
11078741.001
]
[Cites]
Leukemia. 2001 Jan;15(1):89-94
[
11243405.001
]
[Cites]
EMBO Rep. 2000 Aug;1(2):151-7
[
11265755.001
]
[Cites]
J Biol Chem. 2001 Apr 27;276(17):13505-8
[
11279224.001
]
[Cites]
J Biol Chem. 2001 May 25;276(21):18375-83
[
11279135.001
]
[Cites]
J Biol Chem. 2001 Mar 9;276(10):7493-9
[
11102454.001
]
[Cites]
Oncogene. 2001 May 28;20(24):3047-54
[
11420720.001
]
[Cites]
J Biol Chem. 2001 Oct 5;276(40):36865-8
[
11459854.001
]
[Cites]
EMBO J. 2001 Nov 1;20(21):6084-94
[
11689448.001
]
[Cites]
EMBO J. 2001 Dec 17;20(24):7184-96
[
11742995.001
]
[Cites]
Cell Growth Differ. 2002 Feb;13(2):69-75
[
11864910.001
]
[Cites]
J Biol Chem. 2002 Mar 22;277(12):10226-35
[
11779876.001
]
[Cites]
Cell. 2002 Feb 22;108(4):465-74
[
11909518.001
]
[Cites]
Mol Cell Biol. 2002 Aug;22(16):5923-37
[
12138202.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14789-94
[
12397173.001
]
[Cites]
J Biol Chem. 2002 Nov 29;277(48):46066-72
[
12351636.001
]
[Cites]
Cell. 2002 Dec 27;111(7):931-41
[
12507421.001
]
[Cites]
Br J Haematol. 2003 Jan;120(2):271-3
[
12542485.001
]
[Cites]
Genes Chromosomes Cancer. 2003 Apr;36(4):402-5
[
12619164.001
]
[Cites]
Genes Chromosomes Cancer. 2003 Apr;36(4):413-9
[
12619166.001
]
[Cites]
Cancer Cell. 2003 Mar;3(3):259-71
[
12676584.001
]
[Cites]
Nucleic Acids Res. 2003 Jun 1;31(11):2735-44
[
12771199.001
]
[Cites]
Mol Endocrinol. 2003 Sep;17(9):1681-92
[
12805412.001
]
[Cites]
Nucleic Acids Res. 2004;32(3):959-76
[
14960713.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4453-8
[
15070739.001
]
[Cites]
Development. 2004 May;131(10):2443-61
[
15128673.001
]
[Cites]
Oncogene. 2004 May 24;23(24):4225-31
[
15156177.001
]
[Cites]
Genes Dev. 2004 Jul 15;18(14):1753-65
[
15256502.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4948-52
[
8643509.001
]
[Cites]
Nature. 1996 Jul 25;382(6589):319-24
[
8684459.001
]
[Cites]
EMBO J. 1996 Jul 15;15(14):3667-75
[
8670870.001
]
[Cites]
Nat Genet. 1996 Sep;14(1):33-41
[
8782817.001
]
[Cites]
Cell. 1996 Nov 29;87(5):953-9
[
8945521.001
]
[Cites]
Nature. 1996 Dec 19-26;384(6610):641-3
[
8967953.001
]
[Cites]
J Biol Chem. 1999 Oct 1;274(40):28528-36
[
10497217.001
]
(PMID = 17697320.001).
[ISSN]
1476-4598
[Journal-full-title]
Molecular cancer
[ISO-abbreviation]
Mol. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Carrier Proteins; 0 / NCOA2 protein, human; 0 / Nuclear Receptor Coactivator 2; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Androgen; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Estrogen; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human; W980KJ009P / Corticosterone
[Other-IDs]
NLM/ PMC2048977
51.
Kozlov I, Beason K, Yu C, Hughson M:
CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.
Cancer Genet Cytogenet
; 2005 Nov;163(1):62-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CD79a expression in
acute
myeloid
leukemia
t(8;21) and the importance of cytogenetics in the
diagnosis
of
leukemias
with immunophenotypic ambiguity.
Acute
leukemias
that express antigens associated with more than one
lineage
have been classified as
acute
lymphocytic
leukemia
with
myeloid
markers,
acute
myeloid
leukemia
with
lymphoid
markers, or
biphenotypic acute leukemia
(BAL).
CD79a functions in and has a high degree of specificity for B-
cell
differentiation.
It has only recently begun to be reported in
biphenotypic acute
leukemias
.
Cases of
acute leukemia
submitted to the flow cytometry laboratory were retrospectively reviewed beginning from the time analysis for cytoplasmic CD79a was added to
leukemia
and lymphoma panels.
The immunophenotyping met proposed scoring criteria for
a diagnosis
of BAL.
Nevertheless, the cytogenetic and FISH findings indicate that CD79a, despite its specificity for B-
cell
differentiation, represented the aberrant presence of
a B
-
cell
antigen in
leukemias
of distinct
myeloid
linage.
It is doubtful that, in this setting, CD79a expression should be considered a manifestation of
lineage
ambiguity.
[MeSH-major]
Antigens, CD79 / genetics. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8.
Leukemia
,
Myeloid
/ genetics. Translocation, Genetic
[MeSH-minor]
Acute
Disease
. Adult. Antigens, CD / genetics. Antigens, CD / immunology. B-Lymphocytes / immunology. Blast Crisis. Bone Marrow Cells / pathology. Cytarabine / therapeutic use. Flow Cytometry. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. T-Lymphocytes / immunology
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Cancer Genet Cytogenet. 2007 Apr 1;174(1):76-7
[
17350472.001
]
(PMID = 16271957.001).
[ISSN]
0165-4608
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, CD79; 04079A1RDZ / Cytarabine
52.
Georgy M, Yonescu R, Griffin CA, Batista DA:
Acute mixed lineage leukemia and a t(6;14)(q25;q32) in two adults.
Cancer Genet Cytogenet
; 2008 Aug;185(1):28-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acute
mixed lineage
leukemia
and a
t(6;14)(q25;q32) in two adults.
Acute
mixed lineage
leukemia
(AMLL) is a rare form of
leukemia
in which both
myeloid and lymphoid
markers are present.
Few chromosome abnormalities have been identified associated with this form of
leukemia
.
A translocation involving the long arms of chromosomes 6 and 14 was previously described in four young individuals with
acute leukemia
and in three of these cases the
diagnosis
was
mixed lineage
.
[MeSH-major]
Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 6.
Leukemia
,
Biphenotypic
,
Acute
/ genetics. Translocation, Genetic
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18656690.001).
[ISSN]
1873-4456
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
53.
Bursen A, Schwabe K, Rüster B, Henschler R, Ruthardt M, Dingermann T, Marschalek R:
The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Blood
; 2010 Apr 29;115(17):3570-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The chromosomal translocation t(4;11)(q21;q23) is the most frequent genetic aberration of the human MLL gene, resulting in high-risk
acute
lymphoblastic
leukemia
(ALL).
Recipients of AF4.MLL- or double-transduced LSPCs developed pro-B ALL, B/T
biphenotypic acute leukemia
, or
mixed lineage
leukemia
.
Transplantation of MLL.AF4- or mock-transduced LSPCs did not result in
disease
development during an observation period of 13 months.
These findings indicate that the expression of the AF4.MLL fusion protein is capable of inducing
acute
lymphoblastic
leukemia
even in the absence of the MLL.AF4 fusion protein.
In view of recent findings, these results may imply that t(4;11)
leukemia
is based on 2 oncoproteins, providing an explanation for the very early onset of
disease
in humans.
[MeSH-major]
Cell
Transformation, Neoplastic / metabolism. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Leukemic.
Myeloid
-
Lymphoid
Leukemia
Protein / metabolism. Nuclear Proteins / metabolism. Oncogene Proteins, Fusion / metabolism. Precursor B-
Cell Lymphoblastic
Leukemia
-Lymphoma / metabolism
SciCrunch.
ArrayExpress: Data: Microarray
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20194896.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Aff1 protein, mouse; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Mll protein, mouse
54.
Alvarado Y, Welch MA, Swords R, Bruzzi J, Schlette E, Giles FJ:
Nelarabine activity in acute biphenotypic leukemia.
Leuk Res
; 2007 Nov;31(11):1600-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nelarabine activity in
acute biphenotypic leukemia
.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use.
Leukemia
/ drug therapy
[MeSH-minor]
Acute
Disease
. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Flow Cytometry. Humans. Middle Aged. Phenotype. Vincristine / administration & dosage
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17512588.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Arabinonucleosides; 5J49Q6B70F / Vincristine; 60158CV180 / nelarabine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
55.
Suh B, Song J, Kim J, Park TS, Choi JR:
Constitutional pericentric inversion 9 in Korean patients with chronic myelogenous leukemia.
Korean J Lab Med
; 2010 Jun;30(3):218-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Constitutional pericentric inversion 9 in Korean patients with chronic myelogenous
leukemia
.
BACKGROUND: Although the pericentric inversion of chromosome 9, inv(9)(p11q13), is generally considered a normal variation, it is also associated with solid tumors and several hematologic malignancies such as
biphenotypic acute leukemia
, ALL, AML, and myeloproliferative neoplasms.
The purpose of this retrospective study was to investigate the frequency and clinical features of CML patients with concomitant inv(9)
and t
(9;22)(q34;q11.2) variation at our institution.
METHODS: We reviewed the bone marrow chromosome database entries between October 2006 and December 2008 to identify patients with concomitant inv(9)
and t
(9;22) variations.
RESULTS: Among the 51 CML patients, 4 (7.8%) had concomitant inv(9)
and t
(9;22) variations.
[MeSH-major]
Asian Continental Ancestry Group / genetics. Chromosome Inversion. Chromosomes, Human, Pair 9.
Leukemia
,
Myeloid
,
Acute
/ genetics
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20603579.001).
[ISSN]
1598-6535
[Journal-full-title]
The Korean journal of laboratory medicine
[ISO-abbreviation]
Korean J Lab Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Korea (South)
56.
Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA, Erfurth F, Diaz MO, Zeleznik-Le NJ:
The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.
Proc Natl Acad Sci U S A
; 2005 Sep 27;102(39):14028-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
MLL, involved in many chromosomal translocations associated with
acute
myeloid and lymphoid
leukemia
, has >50 known partner genes with which it is able to form in-frame fusions.
Characterizing important downstream target genes of MLL and of MLL fusion proteins may provide rational therapeutic strategies for the treatment of MLL-associated
leukemia
.
To this end, we developed inducible MLL-AF4 fusion
cell
lines in different backgrounds.
Overexpression of MLL-AF4 does not lead to increased proliferation in either
cell
line, but rather,
cell
growth was slowed compared with similar
cell
lines inducibly expressing truncated MLL.
We found that in the MLL-AF4-induced
cell
lines, the expression of the cyclin-dependent kinase inhibitor gene CDKN1B was dramatically changed at both the RNA and protein (p27kip1) levels.
Further, we confirmed CDKN1B promoter binding by ChIP in MLL-AF4 as well as in MLL-AF9
leukemia
cell
lines.
Our results suggest that CDKN1B is a downstream target of MLL and of MLL-AF4, and that, depending on the background
cell
type, MLL-AF4 inhibits or activates CDKN1B expression.
This
finding
may have implications in terms of
leukemia
stem
cell
resistance to chemotherapy in MLL-AF4
leukemias
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell. 1994 Jul 15;78(1):67-74
[
8033213.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54
[
15640349.001
]
[Cites]
J Biol Chem. 1995 Mar 10;270(10):4971-4
[
7890601.001
]
[Cites]
Mol Carcinog. 1999 Nov;26(3):172-9
[
10559792.001
]
[Cites]
Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72
[
10595755.001
]
[Cites]
Curr Opin Oncol. 2000 Jan;12(1):3-12
[
10687723.001
]
[Cites]
Oncogene. 2000 Jul 6;19(29):3290-8
[
10918585.001
]
[Cites]
EMBO J. 2000 Sep 1;19(17):4655-64
[
10970858.001
]
[Cites]
Am J Physiol Cell Physiol. 2000 Oct;279(4):C1045-57
[
11003585.001
]
[Cites]
Blood. 2000 Oct 15;96(8):2746-54
[
11023508.001
]
[Cites]
Nat Med. 2000 Nov;6(11):1235-40
[
11062534.001
]
[Cites]
J Immunol. 2001 Jan 1;166(1):304-12
[
11123306.001
]
[Cites]
Oncogene. 2001 Oct 4;20(45):6524-30
[
11641776.001
]
[Cites]
Nucleic Acids Res. 2002 Feb 15;30(4):958-65
[
11842107.001
]
[Cites]
Mol Cell Biol. 2002 May;22(9):3014-23
[
11940659.001
]
[Cites]
Oncogene. 2002 May 13;21(21):3403-13
[
12032778.001
]
[Cites]
Blood. 2002 Jun 15;99(12):4629-31
[
12036898.001
]
[Cites]
Curr Opin Hematol. 2002 Jul;9(4):282-7
[
12042701.001
]
[Cites]
Oncogene. 2002 May 9;21(20):3199-206
[
12082635.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8342-7
[
12829790.001
]
[Cites]
Cancer Cell. 2003 Aug;4(2):99-110
[
12957285.001
]
[Cites]
Leukemia. 2004 Jan;18(1):92-102
[
14603337.001
]
[Cites]
Mol Cell Biol. 2004 Jan;24(2):617-28
[
14701735.001
]
[Cites]
Cell. 2004 Jan 23;116(2):221-34
[
14744433.001
]
[Cites]
Leukemia. 2004 Jun;18(6):1064-71
[
14990976.001
]
[Cites]
Oncogene. 2004 Sep 20;23(43):7178-87
[
15378078.001
]
[Cites]
Blood. 1987 Jul;70(1):192-9
[
3496132.001
]
[Cites]
Cell. 1994 Jul 15;78(1):59-66
[
8033212.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11293-8
[
12151601.001
]
[Cites]
Blood. 2002 Nov 15;100(10):3710-8
[
12393701.001
]
[Cites]
Mol Cell. 2002 Nov;10(5):1107-17
[
12453418.001
]
[Cites]
Mol Cell. 2002 Nov;10(5):1119-28
[
12453419.001
]
[Cites]
Oncogene. 2003 Jun 5;22(23):3655-68
[
12789274.001
]
[Cites]
Nature. 1995 Nov 30;378(6556):505-8
[
7477409.001
]
[Cites]
Blood. 1996 Apr 1;87(7):2870-7
[
8639906.001
]
[Cites]
Cell. 1996 May 31;85(5):721-32
[
8646780.001
]
[Cites]
Cell. 1996 May 31;85(5):733-44
[
8646781.001
]
[Cites]
Nat Med. 1997 Feb;3(2):227-30
[
9018244.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6380-5
[
9177226.001
]
[Cites]
FEBS Lett. 1997 Jul 7;411(1):1-6
[
9247132.001
]
[Cites]
EMBO J. 1997 Jul 16;16(14):4226-37
[
9250666.001
]
[Cites]
Cancer Res. 1998 Jan 1;58(1):114-22
[
9426067.001
]
[Cites]
Leukemia. 1998 May;12(5):779-87
[
9593281.001
]
[Cites]
Leukemia. 1998 Jul;12(7):1119-27
[
9665199.001
]
[Cites]
Blood. 1999 Sep 15;94(6):2056-64
[
10477735.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10610-4
[
7938000.001
]
(PMID = 16169901.001).
[ISSN]
0027-8424
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA40046; United States / NCI NIH HHS / CA / CA104300; United States / NCI NIH HHS / CA / P01 CA040046; United States / NCI NIH HHS / CA / CA78438; United States / NCI NIH HHS / CA / R01 CA104300; United States / NCI NIH HHS / CA / CA81269
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
[Other-IDs]
NLM/ PMC1236570
57.
Costantini AS, Benvenuti A, Vineis P, Kriebel D, Tumino R, Ramazzotti V, Rodella S, Stagnaro E, Crosignani P, Amadori D, Mirabelli D, Sommani L, Belletti I, Troschel L, Romeo L, Miceli G, Tozzi GA, Mendico I, Maltoni SA, Miligi L:
Risk of leukemia and multiple myeloma associated with exposure to benzene and other organic solvents: evidence from the Italian Multicenter Case-control study.
Am J Ind Med
; 2008 Nov;51(11):803-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Risk of
leukemia
and multiple myeloma associated with exposure to benzene and other organic solvents: evidence from the Italian Multicenter Case-control study.
BACKGROUND: While there is a general consensus about the ability of benzene to induce
acute
myeloid
leukemia
(AML), its effects on chronic
lymphoid
leukemia
and multiple myeloma (MM) are still under debate.
We conducted a population-based case-control study to evaluate the association between exposure to organic solvents and risk of
myeloid and lymphoid
leukemia
and MM.
METHODS: Five hundred eighty-six cases of
leukemia
(and 1,278 population controls), 263 cases of MM (and 1,100 population controls) were collected.
There were elevated point estimates for the associations between medium/high benzene exposure and chronic lymphatic
leukemia
(OR = 1.8, 95% CI = 0.9-3.9) and MM (OR = 1.9, 95% CI = 0.9-3.9).
Risks of chronic lymphatic
leukemia
were somewhat elevated, albeit with wide confidence intervals, from medium/high exposure to xylene and toluene as well.
Our results support the association between benzene, xylene, and toluene and chronic lymphatic
leukemia
and between benzene and MM with longer latencies than have been observed for AML in other studies.
[MeSH-major]
Benzene / adverse effects.
Leukemia
,
Lymphoid
/ chemically induced. Multiple Myeloma / chemically induced. Occupational Exposure / adverse effects. Solvents / adverse effects
Genetic Alliance.
consumer health - Multiple myeloma
.
MedlinePlus Health Information.
consumer health - Acute Lymphocytic Leukemia
.
MedlinePlus Health Information.
consumer health - Chronic Lymphocytic Leukemia
.
MedlinePlus Health Information.
consumer health - Multiple Myeloma
.
MedlinePlus Health Information.
consumer health - Occupational Health
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
TOLUENE
.
Hazardous Substances Data Bank.
BENZENE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2008 Wiley-Liss, Inc.
(PMID = 18651579.001).
[ISSN]
1097-0274
[Journal-full-title]
American journal of industrial medicine
[ISO-abbreviation]
Am. J. Ind. Med.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA51086
[Publication-type]
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Solvents; 0 / Xylenes; 3FPU23BG52 / Toluene; J64922108F / Benzene
58.
Schwartz CM, Cheng A, Mughal MR, Mattson MP, Yao PJ:
Clathrin assembly proteins AP180 and CALM in the embryonic rat brain.
J Comp Neurol
; 2010 Sep 15;518(18):3803-18
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In this study, we focus on two closely related clathrin assembly proteins, AP180 and CALM (clathrin assembly
lymphoid myeloid
leukemia
protein), in the developing embryonic rat brain.
[MeSH-minor]
Animals.
Cell
Line. Clathrin / metabolism. Clathrin-Coated Vesicles / metabolism. Female. Neurons / cytology. Neurons / metabolism. Pregnancy. Rats. Stem Cells / cytology. Stem Cells / metabolism
COS Scholar Universe.
author profiles
.
SciCrunch.
The Antibody Registry: Reagent: Antibodies
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosci. 2008 Oct 8;28(41):10257-71
[
18842885.001
]
[Cites]
J Neurosci. 2009 Jun 10;29(23):7404-12
[
19515908.001
]
[Cites]
J Neurosci. 1995 Nov;15(11):7238-49
[
7472478.001
]
[Cites]
Genes Dev. 1995 Nov 1;9(21):2635-45
[
7590241.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4804-9
[
8643484.001
]
[Cites]
J Biol Chem. 1997 Mar 7;272(10):6393-8
[
9045662.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13305-10
[
9371841.001
]
[Cites]
Science. 1998 Nov 6;282(5391):1145-7
[
9804556.001
]
[Cites]
Neuron. 1998 Dec;21(6):1465-75
[
9883738.001
]
[Cites]
Protein Sci. 1999 Feb;8(2):435-8
[
10048338.001
]
[Cites]
Mol Biol Cell. 1999 Jul;10(7):2343-60
[
10397769.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8907-12
[
10430869.001
]
[Cites]
Mol Biol Cell. 1999 Aug;10(8):2687-702
[
10436022.001
]
[Cites]
J Comp Neurol. 2005 Jan 3;481(1):58-69
[
15558718.001
]
[Cites]
Dev Biol. 2005 Jun 15;282(2):467-79
[
15950611.001
]
[Cites]
Eur J Neurosci. 2005 Oct;22(8):1928-41
[
16262632.001
]
[Cites]
Traffic. 2005 Dec;6(12):1225-34
[
16262731.001
]
[Cites]
Stem Cells Dev. 2005 Oct;14(5):517-34
[
16305337.001
]
[Cites]
J Comp Neurol. 2006 Jan 10;494(2):368-79
[
16320245.001
]
[Cites]
Stem Cells. 2006 Apr;24(4):865-75
[
16357341.001
]
[Cites]
Neuroscience. 2006 Jul 7;140(3):1003-10
[
16600520.001
]
[Cites]
Curr Opin Cell Biol. 2006 Aug;18(4):416-21
[
16806881.001
]
[Cites]
Curr Opin Cell Biol. 2006 Aug;18(4):395-406
[
16806884.001
]
[Cites]
Nat Neurosci. 2009 Jun;12(6):735-44
[
19448628.001
]
[Cites]
J Comp Neurol. 2007 Jan 1;500(1):20-46
[
17099894.001
]
[Cites]
J Comp Neurol. 2007 Jun 10;502(5):673-82
[
17436285.001
]
[Cites]
J Comp Neurol. 2007 Sep 20;504(3):314-27
[
17640037.001
]
[Cites]
Neuron. 2003 Aug 28;39(5):749-65
[
12948443.001
]
[Cites]
Annu Rev Neurosci. 2003;26:701-28
[
14527272.001
]
[Cites]
Trends Cell Biol. 2004 Apr;14(4):167-74
[
15066634.001
]
[Cites]
J Biol Chem. 2004 Oct 29;279(44):46191-203
[
15292237.001
]
[Cites]
J Comp Neurol. 1981 Jun 1;198(4):677-716
[
7251936.001
]
[Cites]
Differentiation. 1983;25(2):193-203
[
6198232.001
]
[Cites]
J Neurosci. 1999 Dec 1;19(23):10201-12
[
10575017.001
]
[Cites]
Biotechniques. 2000 Feb;28(2):216-8
[
10683726.001
]
[Cites]
J Biol Chem. 2000 Mar 3;275(9):6479-89
[
10692452.001
]
[Cites]
Science. 2001 Feb 9;291(5506):1051-5
[
11161218.001
]
[Cites]
Cell. 2001 Feb 9;104(3):433-40
[
11239400.001
]
[Cites]
Science. 2002 Apr 19;296(5567):550-3
[
11910072.001
]
[Cites]
J Comp Neurol. 2002 May 27;447(2):152-62
[
11977118.001
]
[Cites]
Traffic. 2002 Aug;3(8):513-20
[
12121414.001
]
[Cites]
Neuromolecular Med. 2002;2(2):101-14
[
12428806.001
]
[Cites]
Cancer Res. 2003 May 1;63(9):2244-50
[
12727846.001
]
[Cites]
Cell. 2003 May 30;113(5):643-55
[
12787505.001
]
[Cites]
EMBO J. 2003 Jul 1;22(13):3254-66
[
12839988.001
]
[Cites]
Neuroscience. 2003;121(1):25-37
[
12946697.001
]
[Cites]
EMBO J. 1983;2(12):2355-61
[
6141938.001
]
[Cites]
Eur J Cell Biol. 1984 May;34(1):137-43
[
6428888.001
]
[Cites]
J Immunol. 1984 Oct;133(4):1710-5
[
6206131.001
]
[Cites]
Neurochem Pathol. 1985 Summer;3(2):119-38
[
2413405.001
]
[Cites]
J Neuropathol Exp Neurol. 1986 Nov;45(6):692-703
[
3534145.001
]
[Cites]
EMBO J. 1986 Dec 1;5(12):3143-9
[
3816757.001
]
[Cites]
Cell Motil Cytoskeleton. 1988;10(3):349-62
[
2460261.001
]
[Cites]
J Neurosci. 1989 Apr;9(4):1223-32
[
2564886.001
]
[Cites]
J Biol Chem. 1991 Mar 5;266(7):4401-8
[
1999423.001
]
[Cites]
J Neurosci. 1992 Jun;12(6):2130-43
[
1607932.001
]
[Cites]
Development. 1992 Sep;116(1):201-11
[
1483388.001
]
[Cites]
Mol Endocrinol. 1992 Dec;6(12):2129-35
[
1491694.001
]
[Cites]
EMBO J. 1993 Feb;12(2):667-75
[
8440257.001
]
[Cites]
J Biol Chem. 1993 Jun 15;268(17):12655-62
[
7685348.001
]
[Cites]
J Neurosci. 1994 Sep;14(9):5399-416
[
8083744.001
]
[Cites]
Nature. 2007 Aug 23;448(7156):883-8
[
17713526.001
]
[Cites]
Curr Opin Cell Biol. 2007 Aug;19(4):417-25
[
17631994.001
]
[Cites]
J Comp Neurol. 2008 Jan 1;506(1):16-29
[
17990269.001
]
[Cites]
Traffic. 2008 Mar;9(3):417-29
[
18182011.001
]
[Cites]
Stem Cells. 2008 Feb;26(2):412-21
[
18024420.001
]
(PMID = 20653035.001).
[ISSN]
1096-9861
[Journal-full-title]
The Journal of comparative neurology
[ISO-abbreviation]
J. Comp. Neurol.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / / Z99 AG999999
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Clathrin; 0 / Monomeric Clathrin Assembly Proteins; 0 / Picalm protein, rat; 0 / clathrin assembly protein AP180
[Other-IDs]
NLM/ NIHMS215726; NLM/ PMC2909614
59.
Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Ozcebe OI:
Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
J Natl Med Assoc
; 2009 Mar;101(3):270-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biphenotypic acute leukemia
treated with
acute
myeloid
leukemia
regimens: a case series.
This study retrospectively analyzed 8 cases of
biphenotypic acute leukemia
(BAL) in respect of morphology, immune phenotype, karyotype, and clinical manifestations.
Six patients had
myeloid
plus
T lymphoid
, and 2 cases had
myeloid
plus B-
lymphoid
immune phenotypic markers.
Because selection of an antileukemic chemotherapy regimen for
acute leukemia
is largely based on whether a case is classified as
myeloid
or
lymphoid
, the presence of markers for both lineages may have important implications for treatment.
All of our patients were treated with regimens designed for
acute
myeloid
leukemia
(AML).
[MeSH-major]
Leukemia
,
Biphenotypic
,
Acute
/ drug therapy
[MeSH-minor]
Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers. Case-Control Studies. Cytarabine / therapeutic use. Female. Humans. Idarubicin / therapeutic use. Immunophenotyping.
Leukemia
,
Myeloid
,
Acute
/ drug therapy.
Leukemia
,
Myeloid
,
Acute
/ physiopathology. Male. Middle Aged. Mitoxantrone / therapeutic use. Retrospective Studies
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19331261.001).
[ISSN]
1943-4693
[Journal-full-title]
Journal of the National Medical Association
[ISO-abbreviation]
J Natl Med Assoc
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
60.
Guo Y, Chen YM, Zou Y, Chen XJ, Zhang L, Wang SC, Zhu XF:
[Biologic features of 688 cases of childhood acute leukemia-a single centre retrospective study].
Zhongguo Dang Dai Er Ke Za Zhi
; 2009 Oct;11(10):793-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Biologic features of 688 cases of childhood
acute leukemia
-a single centre retrospective study].
OBJECTIVE: To investigate the biologic features of childhood
acute leukemia
in the northern region of China through a small cohort study in a single center.
METHODS: The medical records of 688 children with
acute leukemia
(age< or =15 years) who were initially diagnosed at Blood
Disease
Hospital of Chinese Academy of Medical Sciences from October 2003 to June 2006 were retrospectively studied.
RESULTS: Four hundred children were diagnosed as
acute
lymphoblastic
leukemia
(ALL), with a peak incidence at ages of 1-4 years.
Two hundred and eighteen children were classified into B-
cell
ALL, and 34 into T-
cell
ALL.
E2A-PBX1 fusion gene was expressed in 3.9% of children with B-
cell
ALL.
Two hundred and twenty-two children were diagnosed as
acute
myeloid
leukemia
(AML), with a peak incidence at ages of 10-15 years.
Acute
hybrid
leukemia
(AHL) was confirmed in 24 children (4.2%), with a median age of 9 years.
Seventy-four percent of the children with (AHL) had mainly CD13 and CD33 expression in
myeloid
antigen integral.
CONCLUSIONS: There are differences in the biologic features of childhood
acute leukemia
between the northern region of China and other regions and races, which suggests that there might be differences in the pathogenesis of childhood
acute leukemia
in different environmental exposures.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ genetics. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19849934.001).
[ISSN]
1008-8830
[Journal-full-title]
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
[ISO-abbreviation]
Zhongguo Dang Dai Er Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
61.
Xu B, Li L, Tang JH, Zhou SY:
Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia.
Di Yi Jun Yi Da Xue Xue Bao
; 2005 Oct;25(10):1207-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with
acute
lymphoblastic
leukemia
.
OBJECTIVE: To analyze Fms-like tyrosine kinase 3 (FLT3) gene and FLT3 internal tandem duplication (ITD) mutation in
acute
lymphoblastic
leukemia
(ALL) patients of different immunological subtypes.
The positivity rate of FLT3 gene in pre-pre B-
lineage
ALL, pre-B-ALL, B-
lineage
ALL
and T
-
lineage
ALL cases were 93.3% (14/15), 77.8% (14/18), 41.7% (5/12) and 28.6% (4/14), respectively.
Two cases (3.2%) were found to have FLT3/ITD mutation, which were also positive for
myeloid
antigen expression and diagnosed as
acute
mixed
-
lineage
leukemia
, showing leukocytosis and high percentage of bone marrow blast cells with poor prognosis.
CONCLUSIONS: FLT3 gene can be detected in both B-
and T
-
lineage
ALL patients, but more frequently in the former.
In B-
lineage
ALL patients, FLT3 gene is more frequent in cases with undifferentiated than those with differentiated blast cells.
FLT3/ITD is rarely detected in ALL patients and FLT3/ITD mutation detection might be helpful to identify the genotypes and evaluate the prognosis of
acute leukemia
.
[MeSH-major]
Mutation. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics. Receptor Protein-Tyrosine Kinases / genetics. Tandem Repeat Sequences / genetics. fms-Like Tyrosine Kinase 3 / genetics
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16234090.001).
[ISSN]
1000-2588
[Journal-full-title]
Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
[ISO-abbreviation]
Di Yi Jun Yi Da Xue Xue Bao
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
62.
Zheng C, Wu J, Liu X, Ding K, Cai X, Zhu W:
What is the optimal treatment for biphenotypic acute leukemia?
Haematologica
; 2009 Dec;94(12):1778-80; author reply 1780
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
What is the optimal treatment for
biphenotypic acute leukemia
?
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Biphenotypic
,
Acute
/ drug therapy
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 1992 Oct 15;80(8):2066-73
[
1327288.001
]
[Cites]
Leukemia. 2003 Aug;17(8):1538-43
[
12886240.001
]
[Cites]
Blood. 1989 Nov 1;74(6):2096-102
[
2553160.001
]
[Cites]
Haematologica. 2009 Jul;94(7):919-27
[
19454497.001
]
[Cites]
Leukemia. 1995 Oct;9(10):1783-6
[
7564526.001
]
[Cites]
Leukemia. 2007 Nov;21(11):2264-70
[
17611554.001
]
[Cites]
Blood. 2009 May 21;113(21):5083-9
[
19131545.001
]
[CommentOn]
Haematologica. 2009 Jul;94(7):919-27
[
19454497.001
]
(PMID = 19996120.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
Italy
[Chemical-registry-number]
0 / Antigens, CD34; EC 1.11.1.7 / Peroxidase
[Other-IDs]
NLM/ PMC2791943
63.
Verheyden S, Demanet C:
Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions.
Leukemia
; 2006 Aug;20(8):1437-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Susceptibility to
myeloid and lymphoid
leukemia
is mediated by distinct inhibitory KIR-HLA ligand interactions.
[MeSH-major]
HLA-B Antigens / physiology. HLA-C Antigens / physiology. Killer Cells, Natural / immunology.
Leukemia
,
Lymphoid
/ immunology.
Leukemia
,
Myeloid
/ immunology. Receptors, Immunologic / physiology. Tumor Escape
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Chronic Lymphocytic Leukemia
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16761016.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Letter; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / HLA-B Antigens; 0 / HLA-C Antigens; 0 / Receptors, Immunologic; 0 / Receptors, KIR
64.
Slany RK:
The molecular biology of mixed lineage leukemia.
Haematologica
; 2009 Jul;94(7):984-93
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The molecular biology of
mixed lineage
leukemia
.
Mixed lineage
leukemia
is a very aggressive blood cancer that predominantly occurs in pediatric patients.
In contrast to other types of childhood
acute
leukemias
,
mixed lineage
leukemia
presents with a dismal prognosis and despite the availability of advanced treatment methods cure rates have stagnated over the last years.
Mixed lineage
leukemia
is characterized by the presence of MLL fusion proteins that are the result of chromosomal translocations affecting the MLL gene at 11q23.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ genetics.
Leukemia
,
Myeloid
,
Acute
/ therapy. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / therapy
[MeSH-minor]
Child. Chromatin / chemistry. Chromatin / metabolism. DNA Methylation. Dimerization. Genes, Homeobox. Histone-Lysine N-Methyltransferase. Humans. Models, Biological.
Myeloid
-
Lymphoid
Leukemia
Protein / genetics. Protein Structure, Tertiary. RNA Polymerase II / metabolism. Recombinant Fusion Proteins / chemistry. Time Factors. Transcription, Genetic
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2005 Jul 1;280(26):24315-21
[
15851483.001
]
[Cites]
Oncogene. 2005 Aug 18;24(35):5525-32
[
15856011.001
]
[Cites]
J Clin Oncol. 2005 Sep 10;23(26):6306-15
[
16155013.001
]
[Cites]
Blood. 2005 Oct 1;106(7):2484-90
[
15956279.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14765-70
[
16199523.001
]
[Cites]
Cancer Res. 2005 Oct 15;65(20):9245-52
[
16230385.001
]
[Cites]
Cell. 2005 Oct 21;123(2):207-18
[
16239140.001
]
[Cites]
Nat Med. 2005 Dec;11(12):1287-9
[
16311605.001
]
[Cites]
Cancer Res. 2005 Dec 15;65(24):11367-74
[
16357144.001
]
[Cites]
J Clin Invest. 2006 Jan;116(1):80-9
[
16357944.001
]
[Cites]
Genes Dev. 2006 Mar 1;20(5):586-600
[
16510874.001
]
[Cites]
PLoS Genet. 2006 Apr;2(4):e51
[
16604156.001
]
[Cites]
Genes Chromosomes Cancer. 2006 Aug;45(8):754-60
[
16688745.001
]
[Cites]
Blood. 2006 Jul 1;108(1):297-304
[
16507773.001
]
[Cites]
Blood. 2006 Jul 15;108(2):441-51
[
16556894.001
]
[Cites]
Mol Cell. 2006 Aug 4;23(3):297-305
[
16885020.001
]
[Cites]
Nat Struct Mol Biol. 2006 Aug;13(8):704-12
[
16829959.001
]
[Cites]
Nat Struct Mol Biol. 2006 Aug;13(8):713-9
[
16878130.001
]
[Cites]
Genes Dev. 2006 Sep 1;20(17):2397-409
[
16951254.001
]
[Cites]
Cancer Res. 2006 Sep 15;66(18):8975-9
[
16982737.001
]
[Cites]
EMBO J. 2006 Sep 20;25(18):4245-52
[
16946699.001
]
[Cites]
EMBO J. 2006 Oct 4;25(19):4503-12
[
16990798.001
]
[Cites]
Br J Haematol. 2006 Nov;135(4):438-49
[
16965385.001
]
[Cites]
Hum Mol Genet. 2007 Jan 1;16(1):92-106
[
17135274.001
]
[Cites]
Blood. 2007 May 1;109(9):4020-2
[
17202314.001
]
[Cites]
Cancer Res. 2007 Aug 1;67(15):7275-83
[
17671196.001
]
[Cites]
J Cell Physiol. 2007 Nov;213(2):306-15
[
17708529.001
]
[Cites]
Blood. 2007 Oct 1;110(7):2774-5
[
17881645.001
]
[Cites]
Nat Cell Biol. 2007 Oct;9(10):1208-15
[
17891136.001
]
[Cites]
Leukemia. 2007 Nov;21(11):2258-63
[
17690691.001
]
[Cites]
Genes Dev. 2007 Nov 1;21(21):2762-74
[
17942707.001
]
[Cites]
Mol Cell Biol. 2007 Dec;27(24):8466-79
[
17923682.001
]
[Cites]
Blood. 2007 Dec 15;110(13):4445-54
[
17855633.001
]
[Cites]
Leuk Res. 2008 Apr;32(4):633-42
[
17875318.001
]
[Cites]
Mol Cell Biol. 2008 Apr;28(8):2825-39
[
18285465.001
]
[Cites]
Cell Stem Cell. 2007 Sep 13;1(3):338-45
[
18371367.001
]
[Cites]
Mol Cell. 2008 Apr 11;30(1):7-10
[
18406322.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7517-22
[
18483194.001
]
[Cites]
Cancer Cell. 2008 Jul 8;14(1):36-46
[
18598942.001
]
[Cites]
Cancer Res. 2008 Aug 1;68(15):6199-207
[
18676843.001
]
[Cites]
Nature. 2008 Oct 30;455(7217):1205-9
[
18806775.001
]
[Cites]
Cancer Cell. 2008 Nov 4;14(5):355-68
[
18977325.001
]
[Cites]
Blood. 2008 Dec 1;112(12):4690-3
[
18796627.001
]
[Cites]
Genes Dev. 2008 Dec 15;22(24):3403-8
[
19141473.001
]
[Cites]
Cancer Res. 2009 Feb 1;69(3):1109-16
[
19155294.001
]
[Cites]
Mol Cell. 2009 Jan 30;33(2):181-91
[
19187761.001
]
[Cites]
Cell Stem Cell. 2009 Feb 6;4(2):129-40
[
19200802.001
]
[Cites]
Oncogene. 2009 Feb 12;28(6):815-23
[
19060922.001
]
[Cites]
EMBO J. 2009 Apr 8;28(7):980-91
[
19229293.001
]
[Cites]
Blood. 2009 Apr 23;113(17):4011-5
[
19144982.001
]
[Cites]
Leuk Res. 2009 Jul;33(7):937-47
[
19232721.001
]
[Cites]
Blood. 2009 May 14;113(20):4922-9
[
19029444.001
]
[Cites]
Leukemia. 2009 Aug;23(8):1490-9
[
19262598.001
]
[Cites]
Cancer Res. 2001 Jun 1;61(11):4550-5
[
11389089.001
]
[Cites]
Blood. 2001 Jul 1;98(1):201-9
[
11418481.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8756-61
[
11438682.001
]
[Cites]
Mol Cell Biol. 2001 Aug;21(16):5678-87
[
11463848.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12902-7
[
11687631.001
]
[Cites]
Nat Genet. 2002 Jan;30(1):41-7
[
11731795.001
]
[Cites]
Nucleic Acids Res. 2002 Feb 15;30(4):958-65
[
11842107.001
]
[Cites]
J Biol Chem. 2002 Mar 29;277(13):10753-5
[
11805083.001
]
[Cites]
Cancer Cell. 2002 Mar;1(2):133-43
[
12086872.001
]
[Cites]
Blood. 2002 Nov 15;100(10):3710-8
[
12393701.001
]
[Cites]
Mol Cell. 2002 Nov;10(5):1107-17
[
12453418.001
]
[Cites]
Mol Cell. 2002 Nov;10(5):1119-28
[
12453419.001
]
[Cites]
Mol Cell Biol. 2003 Jan;23(1):186-94
[
12482972.001
]
[Cites]
Oncogene. 2003 Jan 9;22(1):157-60
[
12527918.001
]
[Cites]
Blood. 2003 Mar 15;101(6):2355-62
[
12446457.001
]
[Cites]
Cancer Cell. 2003 Feb;3(2):173-83
[
12620411.001
]
[Cites]
Mol Cell Biol. 2003 Jun;23(12):4230-46
[
12773566.001
]
[Cites]
Blood. 2003 Jul 1;102(1):262-8
[
12637319.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8342-7
[
12829790.001
]
[Cites]
Cancer Cell. 2003 Aug;4(2):99-110
[
12957285.001
]
[Cites]
Blood. 2003 Oct 1;102(7):2395-402
[
12805060.001
]
[Cites]
Cancer Cell. 2003 Sep;4(3):197-207
[
14522254.001
]
[Cites]
Blood. 2003 Oct 15;102(8):2951-9
[
12730115.001
]
[Cites]
Cell. 2003 Oct 31;115(3):293-303
[
14636557.001
]
[Cites]
Mol Cell Biol. 2004 Jan;24(2):617-28
[
14701735.001
]
[Cites]
Mol Cell Biol. 2004 Jul;24(13):5639-49
[
15199122.001
]
[Cites]
Leukemia. 2004 Aug;18(8):1364-72
[
15269783.001
]
[Cites]
Blood. 2004 Nov 1;104(9):2690-6
[
15251979.001
]
[Cites]
Hum Genet. 1979 Jan 25;46(2):173-80
[
283972.001
]
[Cites]
Hum Genet. 1979;53(1):5-16
[
295044.001
]
[Cites]
Cancer Genet Cytogenet. 1982 Oct;7(2):165-72
[
6959693.001
]
[Cites]
Blood. 1984 Sep;64(3):701-6
[
6590097.001
]
[Cites]
Blood. 1985 Nov;66(5):1115-23
[
3931724.001
]
[Cites]
Blood. 1986 Mar;67(3):689-97
[
3947743.001
]
[Cites]
Blood. 1986 Aug;68(2):597-9
[
3730620.001
]
[Cites]
Proc Natl Acad Sci U S A. 1988 Nov;85(21):8136-40
[
3141923.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 Mar;87(6):2112-6
[
2107543.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9
[
1720549.001
]
[Cites]
Mech Dev. 1991 Sep;35(2):113-27
[
1684714.001
]
[Cites]
Cell. 1992 Nov 13;71(4):691-700
[
1423624.001
]
[Cites]
Cell. 1992 Nov 13;71(4):701-8
[
1423625.001
]
[Cites]
Nat Genet. 1992 Oct;2(2):113-8
[
1303259.001
]
[Cites]
Development. 1993 Jan;117(1):119-34
[
7900984.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10610-4
[
7938000.001
]
[Cites]
Nature. 1995 Nov 30;378(6556):505-8
[
7477409.001
]
[Cites]
Science. 1996 Mar 29;271(5257):1873-6
[
8596958.001
]
[Cites]
Blood. 1997 Jul 15;90(2):535-41
[
9226152.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8732-7
[
9238046.001
]
[Cites]
EMBO J. 1997 Jul 16;16(14):4226-37
[
9250666.001
]
[Cites]
Mol Cell Biol. 1998 Jan;18(1):122-9
[
9418860.001
]
[Cites]
Oncogene. 1998 Mar 12;16(10):1351-6
[
9546437.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4152-7
[
9539705.001
]
[Cites]
Blood. 1998 Jul 1;92(1):108-17
[
9639506.001
]
[Cites]
Oncogene. 1999 Aug 19;18(33):4663-71
[
10467413.001
]
[Cites]
Leukemia. 1999 Oct;13(10):1525-33
[
10516753.001
]
[Cites]
Mol Cell Biol. 2004 Dec;24(23):10470-8
[
15542854.001
]
[Cites]
Blood. 2004 Dec 1;104(12):3527-34
[
15297313.001
]
[Cites]
Curr Biol. 2004 Nov 23;14(22):2063-9
[
15556871.001
]
[Cites]
Blood. 2005 Jan 15;105(2):812-20
[
15374878.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54
[
15640349.001
]
[Cites]
Blood. 2005 Mar 1;105(5):2124-31
[
15528316.001
]
[Cites]
Cell. 2005 Apr 22;121(2):167-78
[
15851025.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8603-8
[
15941828.001
]
[Cites]
Cell. 2005 Jun 17;121(6):873-85
[
15960975.001
]
[Cites]
Oncogene. 2000 Mar 30;19(14):1744-51
[
10777208.001
]
[Cites]
Br J Haematol. 2000 Apr;109(1):13-23
[
10848777.001
]
[Cites]
EMBO J. 2000 Sep 1;19(17):4655-64
[
10970858.001
]
[Cites]
Leukemia. 2000 Nov;14(11):1898-908
[
11069025.001
]
[Cites]
Mol Cell Biol. 2001 Apr;21(7):2249-58
[
11259575.001
]
(PMID = 19535349.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Italy
[Chemical-registry-number]
0 / Chromatin; 0 / MLL protein, human; 0 / Recombinant Fusion Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.7.- / RNA Polymerase II
[Number-of-references]
122
[Other-IDs]
NLM/ PMC2704309
65.
Jeha S, Kantarjian H:
Clofarabine for the treatment of acute lymphoblastic leukemia.
Expert Rev Anticancer Ther
; 2007 Feb;7(2):113-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clofarabine for the treatment of
acute
lymphoblastic
leukemia
.
A marked improvement in the outcome of patients with
acute
lymphoblastic
leukemia
has been achieved with chemotherapeutic agents developed between the 1950s and 1970s.
As the limits of optimizing the use of old drugs are reached, most adults with
acute
lymphoblastic
leukemia
still succumb to their
disease and
leukemia
remains the leading cause of nonaccidental death in children.
Clofarabine, a next-generation deoxyadenosine analog, has demonstrated significant activity in children and adults with refractory
lymphoid and myeloid
leukemia
in early clinical trials and was granted approval for use in children with
acute
lymphoblastic
leukemia
in second or higher relapse.
[MeSH-major]
Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / drug therapy
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17288522.001).
[ISSN]
1744-8328
[Journal-full-title]
Expert review of anticancer therapy
[ISO-abbreviation]
Expert Rev Anticancer Ther
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
[Number-of-references]
36
66.
Kinjo K, Sandoval S, Sakamoto KM, Shankar DB:
The role of CREB as a proto-oncogene in hematopoiesis.
Cell Cycle
; 2005 Sep;4(9):1134-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cyclic-AMP response element binding protein (CREB) is a transcription factor that functions in glucose homeostasis, growth-factor- dependent
cell
survival, proliferation and memory.
Data from our laboratory shows that a majority of patients with
acute
lymphoid and myeloid
leukemia
overexpress CREB in the bone marrow.
CREB overexpression is associated with poor initial outcome of clinical
disease
in AML patients.
To study its role in hematopoiesis, we overexpressed CREB in
leukemia
cell
lines and in mice.
CREB overexpression resulted in increased survival and proliferation of
myeloid
cells and blast-transformation of bone marrow progenitor cells from transgenic mice expressing CREB in the
myeloid lineage
.
CREB transgenic mice also develop myeloproliferative
disease
after one year.
Thus, CREB acts as a proto-oncogene to regulate hematopoiesis and contributes to the
leukemia
phenotype.
Our results suggest that CREB-dependent pathways may serve as targets for directed therapies in
leukemia
in the future.
[MeSH-minor]
Animals. Bone Marrow Cells / metabolism.
Cell
Line, Tumor.
Cell
Proliferation.
Cell
Survival.
Cell
Transformation, Neoplastic. Gene Expression Regulation, Neoplastic. Glucose / metabolism. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Humans.
Leukemia
,
Myeloid
,
Acute
/ metabolism. Mice. Mice, Transgenic. Neoplasms / metabolism. Phenotype. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / metabolism. Proto-Oncogene Proteins / chemistry. Signal Transduction. Up-Regulation
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
GLUCOSE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16096372.001).
[ISSN]
1551-4005
[Journal-full-title]
Cell cycle (Georgetown, Tex.)
[ISO-abbreviation]
Cell Cycle
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Cyclic AMP Response Element-Binding Protein; 0 / Proto-Oncogene Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; IY9XDZ35W2 / Glucose
[Number-of-references]
18
67.
Tsutsumi Y, Tanaka J, Minami H, Musashi M, Fukushima A, Ehira N, Kanamori H, Yamato H, Sasaki J, Funaki C, Hasegawa S, Obara S, Ogura N, Asaka M, Imamura M, Masauzi N:
Acute biphenotypic leukemia and an acquired X chromosome.
Cancer Genet Cytogenet
; 2005 Feb;157(1):94-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acute biphenotypic leukemia
and an acquired X chromosome.
[MeSH-major]
Chromosomes, Human, X.
Leukemia
/ genetics. Sex Chromosome Aberrations
[MeSH-minor]
Acute
Disease
. Aged. Humans. Male
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15676158.001).
[ISSN]
0165-4608
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
United States
68.
Hatoum HA, Mahfouz RA, Otrock ZK, Hudaib AR, Taher AT, Shamseddine AI:
Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
Am J Hematol
; 2007 Jan;82(1):69-72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acute
myeloid
leukemia
with T-
cell
receptor gamma gene rearrangement occurring in a patient with chronic
lymphocytic
leukemia
: a case report.
The association of chronic
lymphocytic
leukemia
(CLL) and
acute leukemia
, either
lymphoid
or
myeloid
is a rare event.
Our review of the medical literature revealed only 6 cases of CLL transformation to
acute
myeloid
leukemia
(AML) (M0, M1 and M2) with no other associated malignancy.
We report a similar case but with occurrence of AML-M4 associated with normal cytogenetic analysis and molecular testing but with positive T-
cell
receptor gamma gene rearrangement rather than the usual Vbeta rearrangement.
[MeSH-major]
Gene Rearrangement, gamma-Chain T-
Cell
Antigen Receptor.
Leukemia
,
Lymphocytic
, Chronic, B-
Cell
/ genetics.
Leukemia
,
Myeloid
,
Acute
/ genetics. Neoplasms, Second Primary / genetics
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Leukemia, T-cell, chronic
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16947317.001).
[ISSN]
0361-8609
[Journal-full-title]
American journal of hematology
[ISO-abbreviation]
Am. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
[Number-of-references]
22
69.
Oka S, Yokote T, Akioka T, Hara S, Kobayashi K, Hirata Y, Hiraoka N, Tsuji M, Hanafusa T:
Trisomy 21 as the sole acquired karyotypic abnormality in biphenotypic acute leukemia.
Int J Hematol
; 2007 Apr;85(3):270-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Trisomy 21 as the sole acquired karyotypic
abnormality
in
biphenotypic acute leukemia
.
[MeSH-major]
Chromosome Aberrations. Down Syndrome / blood. Down Syndrome / pathology.
Leukemia
/ genetics
[MeSH-minor]
Acute
Disease
/ classification.
Acute
Disease
/ therapy. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Treatment Outcome. Vincristine / therapeutic use
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Down Syndrome
.
MedlinePlus Health Information.
consumer health - Leukemia
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 1998 Jul 15;92(2):596-9
[
9657760.001
]
[Cites]
Br J Haematol. 2005 Feb;128(4):548-51
[
15686466.001
]
[Cites]
Ann Hematol. 2003 Apr;82(4):236-40
[
12707727.001
]
[Cites]
Blood. 1986 Jan;67(1):1-11
[
3079640.001
]
[Cites]
Leukemia. 1992 Mar;6(3):171-5
[
1533007.001
]
[Cites]
Blood. 1990 Aug 15;76(4):808-13
[
2166608.001
]
[Cites]
Leuk Res. 1999 Nov;23(11):1079-83
[
10576514.001
]
[Cites]
Am J Med Genet Suppl. 1990;7:262-6
[
2149959.001
]
[Cites]
Blood. 1983 Jun;61(6):1138-45
[
6404327.001
]
[Cites]
J Clin Oncol. 1998 Dec;16(12):3803-9
[
9850025.001
]
(PMID = 17483067.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
Japan
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
70.
Mandal C, Dutta A, Mallick A, Chandra S, Misra L, Sangwan RS, Mandal C:
Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade.
Apoptosis
; 2008 Dec;13(12):1450-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of
lymphoid and myeloid
origin through mitochondrial death cascade.
Here we demonstrate how WA exhibits a strong growth-inhibitory effect on several human leukemic
cell
lines and on primary cells from patients with
lymphoblastic and myeloid
leukemia
in a dose-dependent manner, showing no toxicity on normal human lymphocytes and primitive hematopoietic progenitor cells.
WA-mediated decrease in
cell
viability was observed through apoptosis as demonstrated by externalization of phosphatidylserine, a time-dependent increase in Bax/Bcl-2 ratio; loss of mitochondrial transmembrane potential, cytochrome c release, caspases 9 and 3 activation; and accumulation of cells in sub-G0 region based on DNA fragmentation.
WA caused increased levels of Bax in response to MAPK signaling, which resulted in the initiation of mitochondrial death cascade, and therefore it holds promise as a new, alternative, inexpensive chemotherapeutic agent for the treatment of patients with
leukemia
of both
lymphoid and myeloid
origin.
[MeSH-major]
Apoptosis / drug effects. Ergosterol / analogs & derivatives.
Leukemia
. MAP Kinase Signaling System / physiology. Mitochondria. Tumor Cells, Cultured / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism
[MeSH-minor]
Animals. Caspase Inhibitors. Caspases / metabolism.
Cell
Survival / drug effects. Dose-Response Relationship, Drug. Enzyme Activation. Humans. Medicine, Traditional. Membrane Potential, Mitochondrial / drug effects. Mice. Molecular Structure. Plants, Medicinal / chemistry. Poly(ADP-ribose) Polymerases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Withanolides. bcl-2-Associated X Protein / metabolism
MedlinePlus Health Information.
consumer health - Leukemia
.
Hazardous Substances Data Bank.
ERGOSTEROL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18987975.001).
[ISSN]
1573-675X
[Journal-full-title]
Apoptosis : an international journal on programmed cell death
[ISO-abbreviation]
Apoptosis
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Caspase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 0 / Withanolides; 0 / bcl-2-Associated X Protein; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases; L6DO3QW4K5 / withaferin A; Z30RAY509F / Ergosterol
71.
Hinrichsen L, Meyerholz A, Groos S, Ungewickell EJ:
Bending a membrane: how clathrin affects budding.
Proc Natl Acad Sci U S A
; 2006 Jun 6;103(23):8715-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We have found that domains containing the adapter complex 2 (AP2)-coated vesicle adapter and the endocytic accessory proteins CALM (clathrin assembly
lymphoid myeloid
leukemia
protein), epsin, and eps15/eps15R (EGF receptor pathway substrate 15-related) nevertheless persist at the plasma membrane.
[MeSH-major]
Cell
Membrane / metabolism.
Cell
Surface Extensions / metabolism. Clathrin / metabolism
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Rev Mol Cell Biol. 2002 Aug;3(8):555-65
[
12154367.001
]
[Cites]
Nature. 2002 Sep 26;419(6905):361-6
[
12353027.001
]
[Cites]
Biophys J. 2003 Feb;84(2 Pt 1):842-53
[
12547768.001
]
[Cites]
Mol Biol Cell. 2003 Feb;14(2):516-28
[
12589051.001
]
[Cites]
J Cell Biol. 2003 Jul 7;162(1):113-24
[
12847086.001
]
[Cites]
J Cell Biol. 2003 Aug 18;162(4):693-701
[
12913109.001
]
[Cites]
J Cell Biol. 2003 Sep 1;162(5):909-18
[
12952941.001
]
[Cites]
EMBO J. 2003 Oct 1;22(19):4980-90
[
14517237.001
]
[Cites]
Annu Rev Cell Dev Biol. 2003;19:287-332
[
14570572.001
]
[Cites]
J Biol Chem. 2003 Nov 14;278(46):45160-70
[
12960147.001
]
[Cites]
Dev Cell. 2004 Jan;6(1):29-41
[
14723845.001
]
[Cites]
Science. 2004 Jan 23;303(5657):495-9
[
14645856.001
]
[Cites]
Curr Biol. 2004 Mar 23;14(6):R250-2
[
15043839.001
]
[Cites]
Mamm Genome. 2000 Nov;11(11):1006-15
[
11063258.001
]
[Cites]
Science. 2001 Feb 9;291(5506):1051-5
[
11161218.001
]
[Cites]
Traffic. 2000 Jul;1(7):545-52
[
11208142.001
]
[Cites]
Traffic. 2000 Jan;1(1):19-28
[
11208055.001
]
[Cites]
Traffic. 2001 Feb;2(2):138-47
[
11247304.001
]
[Cites]
J Cell Biol. 2001 Sep 17;154(6):1209-23
[
11564758.001
]
[Cites]
J Cell Biol. 2001 Oct 15;155(2):193-200
[
11604418.001
]
[Cites]
J Cell Biol. 2001 Oct 15;155(2):291-300
[
11604424.001
]
[Cites]
J Biol Chem. 2001 Dec 7;276(49):46230-6
[
11577110.001
]
[Cites]
J Biol Chem. 2002 Mar 8;277(10):8209-16
[
11756460.001
]
[Cites]
Nature. 2002 Mar 28;416(6879):451-5
[
11919637.001
]
[Cites]
J Biol Chem. 2002 May 31;277(22):19897-904
[
11889126.001
]
[Cites]
J Biol Chem. 2002 Jul 26;277(30):27433-41
[
12021271.001
]
[Cites]
Nat Rev Mol Cell Biol. 2006 Jan;7(1):9-19
[
16365634.001
]
[Cites]
Traffic. 2006 Mar;7(3):262-81
[
16497222.001
]
[Cites]
Dev Cell. 2006 Mar;10(3):329-42
[
16516836.001
]
[Cites]
EMBO J. 1988 Apr;7(4):919-29
[
3402440.001
]
[Cites]
J Biol Chem. 2004 Apr 16;279(16):16657-61
[
14985334.001
]
[Cites]
Trends Cell Biol. 2004 Jul;14(7):352-8
[
15246428.001
]
[Cites]
Cell. 2004 Sep 3;118(5):591-605
[
15339664.001
]
[Cites]
J Cell Biol. 1969 Jul;42(1):202-20
[
4182372.001
]
[Cites]
Cell. 1979 Feb;16(2):303-12
[
455437.001
]
[Cites]
J Cell Biol. 1980 Mar;84(3):560-83
[
6987244.001
]
[Cites]
J Cell Biol. 1981 Dec;91(3 Pt 1):790-7
[
7328122.001
]
[Cites]
J Cell Biol. 1985 Dec;101(6):2055-62
[
4066749.001
]
[Cites]
Eur J Cell Biol. 1986 Oct;42(1):35-44
[
3792341.001
]
[Cites]
EMBO J. 1986 Dec 1;5(12):3143-9
[
3816757.001
]
[Cites]
J Cell Biol. 1988 Sep;107(3):877-86
[
3417785.001
]
[Cites]
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9289-93
[
2574457.001
]
[Cites]
J Biol Chem. 1991 Mar 5;266(7):4437-41
[
1900294.001
]
[Cites]
J Cell Biol. 1992 Nov;119(4):787-96
[
1358896.001
]
[Cites]
Biophys J. 1993 Jul;65(1):316-24
[
8369439.001
]
[Cites]
J Biol Chem. 1995 Mar 3;270(9):4933-42
[
7876268.001
]
[Cites]
J Biol Chem. 1995 Apr 28;270(17):10079-83
[
7730311.001
]
[Cites]
Biophys J. 1997 Feb;72(2 Pt 1):953-7
[
9017220.001
]
[Cites]
J Biol Chem. 1998 Jan 30;273(5):3003-12
[
9446614.001
]
[Cites]
Biophys J. 1998 Jun;74(6):2862-75
[
9635740.001
]
[Cites]
Curr Biol. 1998 Dec 17-31;8(25):1399-402
[
9889104.001
]
[Cites]
Mol Biol Cell. 1999 Apr;10(4):961-74
[
10198050.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6775-80
[
10359788.001
]
[Cites]
EMBO J. 2004 Nov 10;23(22):4371-83
[
15496985.001
]
[Cites]
Mol Biol Cell. 2005 Feb;16(2):964-75
[
15601897.001
]
[Cites]
J Biol Chem. 2005 Feb 18;280(7):6109-17
[
15533940.001
]
[Cites]
J Biol Chem. 2005 Feb 18;280(7):6101-8
[
15533941.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2760-5
[
15701692.001
]
[Cites]
Mol Biol Cell. 2005 Apr;16(4):1769-76
[
15689492.001
]
[Cites]
Biochim Biophys Acta. 2005 Jul 10;1744(3):415-37
[
15922462.001
]
[Cites]
Traffic. 2005 Dec;6(12):1225-34
[
16262731.001
]
[Cites]
Nature. 2005 Dec 1;438(7068):590-6
[
16319878.001
]
[Cites]
Dev Cell. 2005 Dec;9(6):791-804
[
16326391.001
]
[Cites]
Nat Cell Biol. 1999 May;1(1):33-9
[
10559861.001
]
(PMID = 16735469.001).
[ISSN]
0027-8424
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adaptor Protein Complex 2; 0 / Adaptor Proteins, Vesicular Transport; 0 / Clathrin; 0 / epsin
[Other-IDs]
NLM/ PMC1482644
72.
Kim HR, Hong JH, Yoon CH, Lee SH, Park SH, Kim HY:
Arthritis preceding acute biphenotypic leukemia.
Clin Rheumatol
; 2006 May;25(3):380-1
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Arthritis preceding
acute biphenotypic leukemia
.
[MeSH-major]
Arthritis / etiology.
Leukemia
/ complications
[MeSH-minor]
Acute
Disease
. Adult. Ankle / pathology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Pain / drug therapy. Phenotype
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
Genetic Alliance.
consumer health - Arthritis
.
MedlinePlus Health Information.
consumer health - Arthritis
.
MedlinePlus Health Information.
consumer health - Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Acta Haematol. 1999 Mar;101(1):1-6
[
10085431.001
]
[Cites]
Wiad Lek. 1998;51 Suppl 4:296-9
[
10731987.001
]
[Cites]
Semin Arthritis Rheum. 1994 Aug;24(1):48-56
[
7985037.001
]
(PMID = 16220224.001).
[ISSN]
0770-3198
[Journal-full-title]
Clinical rheumatology
[ISO-abbreviation]
Clin. Rheumatol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents
73.
Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Barón AE, Drabkin HA:
HOX expression patterns identify a common signature for favorable AML.
Leukemia
; 2008 Nov;22(11):2041-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Deregulated HOX expression, by chromosomal translocations
and myeloid
-
lymphoid
leukemia
(MLL) rearrangements, is causal in some types of
leukemia
.
Using real-time reverse transcription-PCR, we examined the expression of 43 clustered HOX, polycomb, MLL and FLT3 genes in 119 newly diagnosed adult
acute
myeloid leukemias
(AMLs) selected from all major cytogenetic groups.
We also observed that HOXA9 levels were significantly inversely correlated with survival and that BMI-1 was overexpressed in cases with 11q23 rearrangements, suggesting that p19(ARF) suppression may be involved in MLL-associated
leukemia
.
These results underscore the close relationship between HOX expression patterns and certain forms of AML and emphasize the need to determine whether these differences play a role in the
disease
process.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Exp Hematol. 2001 Sep;29(9):1125-34
[
11532354.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8961-5
[
11470909.001
]
[Cites]
Oncogene. 2001 Feb 15;20(7):874-8
[
11314021.001
]
[Cites]
Blood. 2001 Apr 15;97(8):2434-9
[
11290608.001
]
[Cites]
Nat Med. 2001 Apr;7(4):444-51
[
11283671.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14372-7
[
10588712.001
]
[Cites]
Br J Haematol. 1999 Jun;105(4):894-900
[
10554798.001
]
[Cites]
Cancer Cell. 2008 Apr;13(4):299-310
[
18394553.001
]
[Cites]
Cell. 2008 Feb 22;132(4):681-96
[
18295583.001
]
[Cites]
Exp Hematol. 2007 Aug;35(8):1249-55
[
17560011.001
]
[Cites]
Biostatistics. 2007 Jan;8(1):101-17
[
16613833.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6560-4
[
16611732.001
]
[Cites]
Cancer Cell. 2006 Jan;9(1):57-68
[
16413472.001
]
[Cites]
Blood. 2002 Oct 15;100(8):2717-23
[
12351377.001
]
[Cites]
Genes Chromosomes Cancer. 2003 Jun;37(2):149-58
[
12696063.001
]
[Cites]
Blood. 2003 Oct 1;102(7):2395-402
[
12805060.001
]
[Cites]
Mol Cell Biol. 2004 Jan;24(2):617-28
[
14701735.001
]
[Cites]
Blood Rev. 2004 Jun;18(2):115-36
[
15010150.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1605-16
[
15084693.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1617-28
[
15084694.001
]
[Cites]
Leukemia. 2004 Jun;18(6):1059-63
[
15085154.001
]
[Cites]
Nat Genet. 1996 Feb;12(2):149-53
[
8563752.001
]
[Cites]
Leukemia. 2002 Feb;16(2):186-95
[
11840284.001
]
[Cites]
Cell. 2002 Apr 5;109(1):29-37
[
11955444.001
]
[Cites]
Blood. 2002 Jul 1;100(1):59-66
[
12070009.001
]
[Cites]
Nat Genet. 1996 Feb;12(2):159-67
[
8563754.001
]
[Cites]
Mol Cell. 2005 Dec 22;20(6):845-54
[
16359901.001
]
[Cites]
Blood. 2005 Dec 1;106(12):3747-54
[
16109776.001
]
[Cites]
Blood. 2005 Nov 15;106(10):3618-20
[
16046528.001
]
[Cites]
Leukemia. 2005 Nov;19(11):1948-57
[
16107895.001
]
[Cites]
Blood. 2001 Sep 15;98(6):1752-9
[
11535508.001
]
[Cites]
Leukemia. 2005 Sep;19(9):1536-42
[
16015387.001
]
[Cites]
N Engl J Med. 2005 Jan 20;352(3):254-66
[
15659725.001
]
[Cites]
Blood. 2005 Jan 1;105(1):292-300
[
15331439.001
]
[Cites]
Science. 1999 Oct 15;286(5439):531-7
[
10521349.001
]
[Cites]
Blood. 1999 Jul 15;94(2):519-28
[
10397719.001
]
[Cites]
Blood. 1999 May 1;93(9):3074-80
[
10216104.001
]
[Cites]
Mol Cell Biol. 1999 Apr;19(4):3051-61
[
10082572.001
]
[Cites]
Blood. 1998 Oct 1;92(7):2322-33
[
9746770.001
]
[Cites]
Immunity. 1997 Jan;6(1):13-22
[
9052833.001
]
[Cites]
Mol Cell Biol. 1998 Jan;18(1):322-33
[
9418879.001
]
(PMID = 18668134.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA97710; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA097710-04; United States / NCI NIH HHS / CA / R21 CA097710; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA55164; United States / NCI NIH HHS / CA / R33 CA097710-04; United States / NCI NIH HHS / CA / R33 CA097710; United States / NCI NIH HHS / CA / P01 CA055164
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / BMI1 protein, human; 0 / Homeodomain Proteins; 0 / MLL protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Polycomb-Group Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / myeloid ecotropic viral integration site 1 protein; 117896-08-9 / nucleophosmin; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 6.3.2.19 / Polycomb Repressive Complex 1
[Other-IDs]
NLM/ NIHMS104075; NLM/ PMC2676170
74.
Miyazawa Y, Irisawa H, Matsushima T, Mitsui T, Uchiumi H, Saitohi T, Handa H, Karasawa M, Murakami H, Tsukamoto N, Nojima Y:
[Reversible posterior leukoencephalopathy syndrome probably caused by L-asparaginase].
Rinsho Ketsueki
; 2006 Jun;47(6):531-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A 46-year-old male with refractory
biphenotypic acute leukemia
was treated with doxorubicin (days 1-3, 15-17), vincristine (days 1, 8, 15, 22), prednisolone (days 1-28), and L-asparaginase (L-ASP: days 15-28) as reinduction therapy.
[MeSH-major]
Asparaginase / adverse effects. Brain / pathology. Brain Diseases / chemically induced. Brain Diseases /
diagnosis
[MeSH-minor]
Acute
Disease
. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Humans. Hypertension / chemically induced.
Leukemia
/ drug therapy. Male. Middle Aged. Prednisolone / administration & dosage. Seizures / chemically induced. Vincristine / administration & dosage
MedlinePlus Health Information.
consumer health - Brain Diseases
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
PREDNISOLONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16862982.001).
[ISSN]
0485-1439
[Journal-full-title]
[Rinshō ketsueki] The Japanese journal of clinical hematology
[ISO-abbreviation]
Rinsho Ketsueki
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
75.
Owaidah TM, Al Beihany A, Iqbal MA, Elkum N, Roberts GT:
Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system.
Leukemia
; 2006 Apr;20(4):620-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytogenetics, molecular and ultrastructural characteristics of
biphenotypic acute leukemia
identified by the EGIL scoring system.
Biphenotypic acute leukemia
(BAL) is a rare, difficult to diagnose entity.
Its identification is important for risk stratification in
acute leukemia
(AL).
The scoring proposal of the European Group for the Classification of
Acute Leukemia
(EGIL) is useful for this purpose, but its performance against objective benchmarks is unclear.
Mixed
, small and large blast cells predominated, with FAB M2 and L1 constituting the majority.
All patients were positive for
myeloid
(M) markers and either
B cell
(B) (17 or 74%) or
T cell
(T) (8 or 34%) markers with two exceptional patients demonstrating trilineage phenotype.
In six (26%) patients
myeloid lineage
commitment was also demonstrable by electron cytochemistry.
Abnormal findings were present in 19 (83%) patients by cytogenetics/FISH/molecular analysis as follows: t(9;22) (17%); MLL gene rearrangement (26%); deletion(6q) (13%); 12p11.2 (9%); numerical abnormalities (13%), and three (13%) new, previously unreported translocations t(X;6)(p22.3;q21); t(2;6)(q37;p21.3);
and t
(8;14)(p21;q32).
[MeSH-major]
Chromosome Aberrations. Chromosomes, Human / genetics. Cytogenetic Analysis / methods.
Leukemia
/
diagnosis
.
Leukemia
/ genetics
[MeSH-minor]
Acute
Disease
. Adolescent. Adult. Aged.
Cell Lineage
. Child. Child, Preschool. Cohort Studies. DNA Mutational Analysis. Female. Gene Rearrangement. Guidelines as Topic. Humans. In Situ Hybridization, Fluorescence / methods. In Vitro Techniques. Infant. Male.
Myeloid
-
Lymphoid
Leukemia
Protein / genetics. Phenotype. Risk Factors. Sensitivity and Specificity
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16437134.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article
[Publication-country]
England
[Chemical-registry-number]
149025-06-9 / Myeloid-Lymphoid Leukemia Protein
76.
Lee HR, Kang SH, Kang HJ, Shin HY, Ahn HS, Kim HK, Park MH, Cho HI, Lee DS:
Lineage switch from acute myeloid leukemia to biphenotypic acute leukemia with acquisition of Philadelphia chromosome.
Cancer Genet Cytogenet
; 2008 Jul 15;184(2):124-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lineage
switch from
acute
myeloid
leukemia
to
biphenotypic acute leukemia
with acquisition of Philadelphia chromosome.
[MeSH-major]
Cell Lineage
/ genetics.
Leukemia
, Myelogenous, Chronic, BCR-ABL Positive / pathology.
Leukemia
,
Myeloid
,
Acute
/ genetics. Philadelphia Chromosome
[MeSH-minor]
Cell
Transdifferentiation / genetics. Child.
Disease
Progression. Humans. Male. Phenotype
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18617064.001).
[ISSN]
1873-4456
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
United States
77.
Michaud J, Simpson KM, Escher R, Buchet-Poyau K, Beissbarth T, Carmichael C, Ritchie ME, Schütz F, Cannon P, Liu M, Shen X, Ito Y, Raskind WH, Horwitz MS, Osato M, Turner DR, Speed TP, Kavallaris M, Smyth GK, Scott HS:
Integrative analysis of RUNX1 downstream pathways and target genes.
BMC Genomics
; 2008 Jul 31;9:363
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: The RUNX1 transcription factor gene is frequently mutated in sporadic
myeloid and lymphoid
leukemia
through translocation, point mutation or amplification.
It is also responsible for a familial platelet
disorder
with predisposition to
acute
myeloid
leukemia
(FPD-AML).
The disruption of the largely unknown biological pathways controlled by RUNX1 is likely to be responsible for the development of
leukemia
.
We have used multiple microarray platforms and bioinformatic techniques to help identify these biological pathways to aid in the understanding of why RUNX1 mutations lead to
leukemia
.
1)
cell
lines with RUNX1 mutations from FPD-AML patients, 2) over-expression of RUNX1 and CBFbeta, and 3) Runx1 knockout mouse embryos using either cDNA or Affymetrix microarrays.
A number of biological processes were identified among the differentially expressed genes and functional assays suggest that heterozygous RUNX1 point mutations in patients with FPD-AML impair
cell
proliferation, microtubule dynamics and possibly genetic stability.
CONCLUSION: This work is the first large-scale study attempting to identify the genetic networks regulated by RUNX1, a master regulator in the development of the hematopoietic system and
leukemia
.
The biological pathways and target genes controlled by RUNX1 will have considerable importance in
disease
progression in both familial and sporadic
leukemia
as well as therapeutic implications.
COS Scholar Universe.
author profiles
.
Bern Open Repository and Information System.
Free Full text from BORIS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Genome Res. 2003 Aug;13(8):1828-37
[
12902378.001
]
[Cites]
Chem Biol. 2003 Jul;10(7):597-607
[
12890533.001
]
[Cites]
Methods. 2003 Dec;31(4):265-73
[
14597310.001
]
[Cites]
J Clin Invest. 2003 Dec;112(11):1751-61
[
14660751.001
]
[Cites]
Mol Endocrinol. 2003 Dec;17(12):2448-60
[
14500759.001
]
[Cites]
Nat Rev Cancer. 2004 Apr;4(4):253-65
[
15057285.001
]
[Cites]
J Biol Chem. 2004 Apr 9;279(15):15678-87
[
14747476.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1617-28
[
15084694.001
]
[Cites]
Oncogene. 2004 May 24;23(24):4211-9
[
15156175.001
]
[Cites]
Oncogene. 2004 May 24;23(24):4284-96
[
15156185.001
]
[Cites]
Nat Rev Mol Cell Biol. 2004 Jun;5(6):481-92
[
15173827.001
]
[Cites]
Bioinformatics. 2004 Jun 12;20(9):1464-5
[
14962934.001
]
[Cites]
J Virol. 1990 Oct;64(10):4808-19
[
2168969.001
]
[Cites]
Mol Cell Biol. 1993 Jun;13(6):3324-39
[
8497254.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6859-63
[
8341710.001
]
[Cites]
J Immunol. 1993 Oct 15;151(8):4306-14
[
8409403.001
]
[Cites]
Cell. 1994 Aug 26;78(4):635-44
[
8069912.001
]
[Cites]
IARC Sci Publ. 1997;(142):159-84
[
9354918.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4584-8
[
9539781.001
]
[Cites]
Oncogene. 1998 Nov 5;17(18):2287-93
[
9811459.001
]
[Cites]
Blood. 1999 Mar 15;93(6):1817-24
[
10068652.001
]
[Cites]
Development. 1999 Jun;126(11):2563-75
[
10226014.001
]
[Cites]
Nat Genet. 1999 Oct;23(2):144-6
[
10508507.001
]
[Cites]
Nat Genet. 1999 Oct;23(2):166-75
[
10508512.001
]
[Cites]
Int J Cancer. 2005 Jan 10;113(2):221-8
[
15386419.001
]
[Cites]
Bull Cancer. 2004 May;91(5):E81-112
[
15568225.001
]
[Cites]
Cancer Res. 2004 Dec 15;64(24):8846-53
[
15604243.001
]
[Cites]
Br J Haematol. 2005 Feb;128(3):318-23
[
15667533.001
]
[Cites]
Oncogene. 2005 Feb 10;24(7):1129-37
[
15592512.001
]
[Cites]
J Biol Chem. 2000 Feb 4;275(5):3438-45
[
10652337.001
]
[Cites]
Gene. 2000 Mar 21;245(2):223-35
[
10717473.001
]
[Cites]
Oncogene. 2000 Jul 13;19(30):3434-8
[
10918600.001
]
[Cites]
Blood. 2000 Aug 15;96(4):1366-73
[
10942379.001
]
[Cites]
Genomics. 2000 Aug 15;68(1):71-9
[
10950928.001
]
[Cites]
Nat Genet. 2000 Sep;26(1):103-5
[
10973259.001
]
[Cites]
Blood. 2000 Sep 15;96(6):2108-15
[
10979955.001
]
[Cites]
EMBO J. 2001 Feb 15;20(4):723-33
[
11179217.001
]
[Cites]
Gene. 2001 Jan 10;262(1-2):23-33
[
11179664.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403
[
11526243.001
]
[Cites]
Mech Dev. 2001 Dec;109(2):413-7
[
11731260.001
]
[Cites]
Blood. 2002 Feb 15;99(4):1364-72
[
11830488.001
]
[Cites]
Leukemia. 2002 Apr;16(4):658-68
[
11960347.001
]
[Cites]
Cell Mol Life Sci. 2002 Aug;59(8):1406-12
[
12363043.001
]
[Cites]
Leukemia. 2003 Jan;17(1):9-16
[
12529654.001
]
[Cites]
Nucleic Acids Res. 2003 Feb 15;31(4):e15
[
12582260.001
]
[Cites]
Cancer Invest. 2003;21(1):105-36
[
12643014.001
]
[Cites]
J Cell Physiol. 2003 Aug;196(2):301-11
[
12811823.001
]
[Cites]
Cell. 1996 Jan 26;84(2):321-30
[
8565077.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9
[
8622955.001
]
[Cites]
Oncogene. 1997 Aug 7;15(6):677-83
[
9264408.001
]
[Cites]
Oncogene. 1997 Sep;15(11):1315-27
[
9315100.001
]
[Cites]
Curr Opin Drug Discov Devel. 2005 Mar;8(2):262-9
[
15782549.001
]
[Cites]
Bioinformatics. 2005 May 1;21(9):2067-75
[
15657102.001
]
[Cites]
Nucleic Acids Res. 2005;33(10):3154-64
[
15933209.001
]
[Cites]
BMC Bioinformatics. 2005;6:144
[
15941488.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9
[
16174746.001
]
[Cites]
Mutat Res. 2005 Oct 15;578(1-2):333-70
[
16084534.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
[
16199517.001
]
[Cites]
BMC Bioinformatics. 2007;8:242
[
17612399.001
]
[Cites]
Exp Cell Res. 2003 Oct 15;290(1):93-107
[
14516791.001
]
(PMID = 18671852.001).
[ISSN]
1471-2164
[Journal-full-title]
BMC genomics
[ISO-abbreviation]
BMC Genomics
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / R01 DK058161; United States / NHLBI NIH HHS / HL / R01 HL079507; United States / NIDDK NIH HHS / DK / DK58161; United States / NHLBI NIH HHS / HL / HL079507
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / CBFB protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor beta Subunit; 0 / RUNX1 protein, human; 0 / Runx1 protein, mouse
[Other-IDs]
NLM/ PMC2529319
78.
He G, Wu D, Sun A, Xue Y, Jin Z, Qiu H, Tang X, Miao M, Fu Z, Ma X, Wang X, Chen Z, Ruan C:
B-Lymphoid and myeloid lineages biphenotypic acute leukemia with t(8;21)(q22;q22).
Int J Hematol
; 2008 Mar;87(2):132-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
B-
Lymphoid and myeloid
lineages
biphenotypic acute leukemia
with t(8;21)(q22;q22).
By analyzing the characteristics of morphology, immune phenotype, chromosome karyotype and clinical manifestations of six cases of B-
lymphoid and myeloid
lineages
biphenotypic acute leukemia
(BAL) with t(8;21)(q22;q22), a new subgroup of BAL was reported.
Immunophenotype revealed B-
lymphoid and myeloid
lineages positive, together with frequent and high expression of CD34 and CD33, and weak expression of HLA-DR.
Chemotherapy for
myeloid and lymphoid
leukemia
simultaneously produced good response in the patients.
q22) might be a new subgroup of BAL, and it was suggested that the
leukemia
clone with t(8;21)(q22;q22) might have originated from an early phase of hematopoiesis, and AML1/ETO fusion gene might be related to differentiation of B lymphocyte.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ genetics.
Leukemia
,
Myeloid
,
Acute
/ pathology. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / genetics. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / pathology. Translocation, Genetic
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 1994 May 27;269(21):15310-7
[
8195169.001
]
[Cites]
Genes Dev. 1996 Sep 1;10 (17 ):2198-211
[
8804314.001
]
[Cites]
Cell Cycle. 2005 Dec;4(12):1716-8
[
16294039.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6
[
10861016.001
]
[Cites]
Ann Intern Med. 1985 Oct;103(4):620-5
[
3862359.001
]
[Cites]
Br J Haematol. 1998 Jan;100(1):147-55
[
9450804.001
]
[Cites]
Haematologica. 2002 Mar;87(3):306-19
[
11869944.001
]
[Cites]
Leukemia. 1995 Oct;9(10):1783-6
[
7564526.001
]
[Cites]
J Biol Chem. 1999 Aug 27;274(35):24671-6
[
10455134.001
]
[Cites]
Mol Cell Biol. 1992 Jun;12 (6):2662-72
[
1375324.001
]
[Cites]
Blood. 2000 Jun 15;95(12 ):3845-52
[
10845919.001
]
[Cites]
EMBO J. 1998 Apr 15;17 (8):2319-33
[
9545244.001
]
[Cites]
Leukemia. 1996 Aug;10(8):1283-7
[
8709632.001
]
[Cites]
Nature. 1999 Oct 7;401(6753):556-62
[
10524622.001
]
[Cites]
Cancer Genet Cytogenet. 2005 Nov;163(1):62-7
[
16271957.001
]
[Cites]
Br J Haematol. 1996 Mar;92(4):855-65
[
8616078.001
]
(PMID = 18288568.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, CD79; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / CD79A protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3
79.
Gujral S, Polampalli S, Badrinath Y, Kumar A, Subramanian PG, Raje G, Amare P, Arora B, Banavali SD, Nair CN:
Clinico-hematological profile in biphenotypic acute leukemia.
Indian J Cancer
; 2009 Apr-Jun;46(2):160-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinico-hematological profile in
biphenotypic acute leukemia
.
BACKGROUND: We present a clinico-hematological profile and treatment outcome of
Biphenotypic Acute Leukemia
(BAL).
MATERIAL AND METHODS:
Diagnosis
was based on WHO classification, including clinical details, morphology, cytochemistry, immunophenotyping, and molecular genetics.
We included those cases, which fulfilled the European Group for the Immunological Characterization of
Acute Leukemia
's (EGIL's) scoring system criteria for the
diagnosis
of BAL, as per recommendation of the WHO classification.
B-
Myeloid
(14 cases) followed by T-
Myeloid
BAL (13 cases) were the commonest subtypes.
Polymorphous population of blasts (16 cases) was commonly associated with T-
Myeloid
BAL (10 cases).
BCR ABL fusion positivity was a common cytogenetic
abnormality
(seven cases).
CONCLUSIONS: Pediatric BAL
and T
-
B lymphoid
BAL have a better prognosis.
BCR-ABL expression is an important prognostic factor, as these cases will be labeled as Chronic
myeloid
leukemia
(CML) in blast crisis with
biphenotypic
expression and treated accordingly.
[MeSH-major]
Immunophenotyping.
Leukemia
,
Biphenotypic
,
Acute
/ blood.
Leukemia
,
Biphenotypic
,
Acute
/
diagnosis
[MeSH-minor]
Adolescent. Adult. Case-Control Studies. Child. Child, Preschool.
Disease
Progression. Female. Hematologic Tests. Humans. Incidence. Male. Middle Aged. Phenotype. Retrospective Studies. Young Adult
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19346652.001).
[ISSN]
0019-509X
[Journal-full-title]
Indian journal of cancer
[ISO-abbreviation]
Indian J Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
80.
Van Etten RA:
Aberrant cytokine signaling in leukemia.
Oncogene
; 2007 Oct 15;26(47):6738-49
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aberrant cytokine signaling in
leukemia
.
Abnormalities of cytokine and growth factor signaling pathways are characteristic of all forms of
leukemia
:
lymphoid and myeloid
,
acute
and chronic.
In this review, our current knowledge of leukemic
cell
cytokine signaling will be summarized, and some speculations on the significance and implications of these insights will be advanced.
A better understanding of aberrant cytokine signaling in
leukemia
should provide additional targets for the rational therapy of these diseases.
MedlinePlus Health Information.
consumer health - Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17934482.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA090576; United States / NCI NIH HHS / CA / R01 CA105043; United States / NCI NIH HHS / CA / CA090576; United States / NCI NIH HHS / CA / CA105043
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Cytokines
[Number-of-references]
139
[Other-IDs]
NLM/ NIHMS579951; NLM/ PMC4344827
81.
Han X, Bueso-Ramos CE:
Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias.
Am J Clin Pathol
; 2007 Apr;127(4):528-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Precursor T-
cell
acute
lymphoblastic
leukemia
/
lymphoblastic
lymphoma and
acute biphenotypic
leukemias
.
Session 4 of the 2005 Society of Hematopathology/European Association for Haematopathology Workshop focused on case presentations of precursor T-
cell
acute
lymphoblastic
leukemia
/
lymphoblastic
lymphoma (pre-T ALL/LBL) and
acute biphenotypic leukemia
.
Acute biphenotypic
leukemias
are characterized by a single population of blasts that express
myeloid
, T- or B-
lineage
antigens in various combinations and account for fewer than 4% of all
acute
leukemias
.
An accurate
diagnosis
of pre-T ALL/LBL and
acute biphenotypic leukemia
requires a multiparametric approach, including examination of
morphologic
features, immunophenotype, clinical characteristics, and cytogenetic and molecular findings.
[MeSH-major]
Biomarkers, Tumor / analysis.
Leukemia
,
Lymphoid
/
diagnosis
. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma /
diagnosis
[MeSH-minor]
Chromosome Aberrations.
Diagnosis
, Differential. Gene Expression Profiling. Humans. Immunohistochemistry
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Lymphoblastic lymphoma
.
MedlinePlus Health Information.
consumer health - Chronic Lymphocytic Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17369128.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Congresses
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
82.
Xavier MO, Oliveira Fde M, Almeida Vd, Prolla G, Severo LC:
Invasive Aspergillus flavus sinusitis: case report in a patient with biphenotypic acute leukemia.
Rev Inst Med Trop Sao Paulo
; 2009 Jan-Feb;51(1):57-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Invasive Aspergillus flavus sinusitis: case report in a patient with
biphenotypic acute leukemia
.
Here we report a case of invasive pansinusitis with proptosis of the right eye caused by Aspergillus flavus in an immunocompromised patient with
acute biphenotypic leukemia
without aggressive therapy response.
[MeSH-major]
Aspergillosis /
diagnosis
. Aspergillus flavus / isolation & purification. Immunocompromised Host.
Leukemia
,
Biphenotypic
,
Acute
/ immunology. Sinusitis / microbiology
Genetic Alliance.
consumer health - Acute Biphenotypic Leukemia
.
MedlinePlus Health Information.
consumer health - Aspergillosis
.
MedlinePlus Health Information.
consumer health - Sinusitis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19229393.001).
[ISSN]
1678-9946
[Journal-full-title]
Revista do Instituto de Medicina Tropical de São Paulo
[ISO-abbreviation]
Rev. Inst. Med. Trop. Sao Paulo
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Brazil
83.
Hu XX, Gong SL, Song XM, Chen L, Qiu HY, Gao L, Wang JM:
[Report of a case of hybrid acute leukemia with t (12; 22) and literature review].
Zhonghua Xue Ye Xue Za Zhi
; 2006 May;27(5):331-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Report of a case of
hybrid
acute leukemia
with t (12; 22) and literature review].
OBJECTIVE: To report
a hybrid
acute leukemia
(HAL) patient with t (12;.
Leukemia
surface markers were detected by anti-biotin-biotin complex and monoclonal antibodies.
RESULTS: The clinical and hematological findings were compatible with the
diagnosis
of HAL.
Lymphoid and myeloid
markers were positive on the
leukemia
cells.
22) translocation is a rare chromosome
abnormality
in
leukemia
.
This translocation as a cytogenetic marker for poor-prognosis in
leukemia
needs to be further studied.
[MeSH-major]
Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 22 / genetics.
Leukemia
,
Biphenotypic
,
Acute
/ genetics. Translocation, Genetic
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16875585.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
Case Reports; English Abstract; Journal Article; Review
[Publication-country]
China
[Number-of-references]
20
84.
Liu B, Li R, Wu HJ, Chen Y:
[Clinical study on prognosis of acute leukemia subtypes Ly + AML and My + ALL].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 2007 Apr;15(2):421-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinical study on prognosis of
acute leukemia
subtypes Ly + AML and My + ALL].
The purpose of this study was to investigate the prognosis of
acute
myelogenous
leukemia
(AML),
acute
lymphoblastic
leukemia
(ALL),
lymphoid
antigen-positive
acute
myeloid
leukemia
(Ly + AML),
myeloid
antigen-positive
acute leukemia
(My + ALL) and
biphenotypic acute leukemia
(BAL).
Immunophenotyping was performed on medullary specimens of 197
acute leukemia
(AL) patients by using three-color flow cytometry analysis and CD45/SSC gating.
The results showed that in Ly + AML, CD7 was the most common (53.8%) as compared to other
lymphoid
markers, however, in My + ALL CD13 was the most common (47.2%) as compared to other
myeloid
markers.
It is concluded that since Ly + AML has
lymphoid
markers, and the prognosis of Ly + AML is worse than AML, the clinical therapy for Ly + AML should contain both AML and ALL.
Though My + ALL had
myeloid
markers, no significant difference was found between My + ALL and ALL, it might be supposed that their therapy could be the same.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17493361.001).
[ISSN]
1009-2137
[Journal-full-title]
Zhongguo shi yan xue ye xue za zhi
[ISO-abbreviation]
Zhongguo Shi Yan Xue Ye Xue Za Zhi
[Language]
CHI
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Antigens, CD34; 0 / Antigens, CD7; EC 3.4.11.2 / Antigens, CD13
85.
Rosenbluth MJ, Lam WA, Fletcher DA:
Force microscopy of nonadherent cells: a comparison of leukemia cell deformability.
Biophys J
; 2006 Apr 15;90(8):2994-3003
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Force microscopy of nonadherent cells: a comparison of
leukemia
cell
deformability.
We apply this technique to compare the deformability of human
myeloid and lymphoid
leukemia
cells and neutrophils at low deformation rates, and we find that the cells are well described by an elastic model based on Hertzian mechanics.
Myeloid
(HL60) cells were measured to be a factor of 18 times stiffer than
lymphoid
(Jurkat) cells and six times stiffer than human neutrophils on average (E(infinity) = 855 +/- 670 Pa for HL60 cells, E(infinity) = 48 +/- 35 Pa for Jurkat cells, E(infinity) = 156 +/- 87 for neutrophils, mean +/- SD).
This work demonstrates a simple method for extending AFM mechanical property measurements to nonadherent cells and characterizes properties of human
leukemia
cells that may contribute to leukostasis, a complication associated with
acute leukemia
.
[MeSH-major]
Leukemia
,
Myeloid
/ pathology. Neutrophils / pathology. Precursor
Cell Lymphoblastic
Leukemia
-Lymphoma / pathology
[MeSH-minor]
Acute
Disease
.
Cell
Adhesion.
Cell
Line, Tumor. Cells, Cultured. Elasticity. Humans. Micromanipulation. Microscopy, Atomic Force. Models, Biological. Viscosity
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
SciCrunch.
BioNumbers: The Database of Useful Biological Numbers: Data: Value observation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Baillieres Clin Haematol. 1987 Sep;1(3):725-46
[
3327563.001
]
[Cites]
Biophys J. 2005 Nov;89(5):3203-13
[
16113121.001
]
[Cites]
Biophys J. 1989 Jul;56(1):151-60
[
2752085.001
]
[Cites]
J Biomech Eng. 1990 Aug;112(3):269-76
[
2214708.001
]
[Cites]
J Biomech Eng. 1990 Aug;112(3):295-302
[
2214711.001
]
[Cites]
Blood. 1990 Dec 15;76(12):2606-12
[
2265253.001
]
[Cites]
Biophys J. 1991 Oct;60(4):856-66
[
1742456.001
]
[Cites]
Biorheology. 1991;28(6):557-67
[